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Foreword  
The UNAIDS 2016–2021 Strategy, which the UNAIDS Programme Coordinating Board adopted 
in 2015, was a bold call to accelerate the HIV response and reach the people being left behind. 
It called for frontloading investments in that response so a range of ambitious targets for 2020 
could be reached. It was also one of the first United Nations strategies to be aligned with the 
Sustainable Development Goals and was aimed at guiding and supporting locally tailored 
responses while fostering new forms of leadership and accountability at the regional, country 
and community levels. 
Since 2015, the global context has changed dramatically. Even before the COVID-19 pandemic, 
progress in the global AIDS response was not on-track to reach the 2020 HIV targets.  
The most recent data (for 2019) show that dramatic rapid progress is necessary––and possible. 
UNAIDS’ 2020 global AIDS update, Seizing the moment, highlights the gains made along the 
HIV testing and treatment cascade: an estimated 81% of people living with HIV knew their HIV 
status in 2019 and more than two thirds (67%) of all people living with HIV were on antiretroviral 
therapy. The number of people living with HIV on treatment has tripled since 2010 (1). However, 
only a small number of countries will reach the 90–90–90 targets by the end of 2020. As a 
result, in more than a quarter (28%) of countries, less than half of all people living with HIV had 
suppressed viral loads in 2019.  
The barriers and disparities in the global AIDS response are increasingly evident between 
regions, countries, and populations and communities. Unequal access to health and social 
services often mirrors, exacerbates and overlaps with other inequalities, including gender 
inequalities and inequalities resulting from discrimination based on income, race, age, ethnicity, 
disability, immigration status or sexual orientation. These inequalities shape a global epidemic in 
which a majority of new HIV infections are among key populations and their partners. The 
inequalities underpin the HIV epidemics in sub-Saharan Africa, the epicentre of the global 
pandemic and where girls account for 5 in 6 new HIV infections among adolescents aged 15–19 
years.  
At the same time, we cannot forget that we have the science, tools and commitment to prevent 
each new HIV infection and to avoid each AIDS-related death. We must have the courage to 
ask ourselves why we are failing and what we must do to get back on-track. 
This evidence review is one component of the Strategy review process. It asks critical questions 
as we prepare to develop the next UNAIDS Strategy. What is working and how does it need to 
be sustained or scaled-up? Where and in what respects are we falling behind, and why? How 
do we overcome the gaps and obstacles that stand in the way of consistent progress across all 
communities, countries and regions? How do we highlight the importance of fighting stigma and 
discrimination, changing harmful laws, supporting access to legal redress and confronting 
gender inequality in order to achieve the next Strategy's targets among all populations and in 
every community in a country? 
The review highlights approaches that we can build on, especially in areas where the evidence-
informed approaches of the current UNAIDS Strategy remain sound but have not been 
implemented with sufficient speed, quality or scale. The review also provides a sobering 
analysis of where the global HIV response is falling short. It sets the scene for a deeper 
discussion about the steps that are needed to support countries and communities as they strive 
to leave no one behind and end AIDS as a public health threat.  
Together with several other inputs, the review will inform the development of the next UNAIDS 
Strategy and it will guide the future direction of the global HIV response.  
In the months ahead, we will continue to consult widely. We will convene a multistakeholder 
consultation in September 2020 to review the current Strategy and discuss strategic priorities for 
the next Strategy. We will also agree on an approach for developing the next Strategy. We will 
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then continue to engage the Programme Coordinating Board and a wide range of stakeholders 
through focus group discussions, interviews and other consultations.  
We count on your continued, active engagement in this process to ensure that the next UNAIDS 
Strategy remains ambitious, visionary and evidence-informed, and that it gets us back on-track 
to AIDS by 2030. 
In the coming months we will continue to consult widely. We will convene a multi-stakeholder 
consultation in September 2020 to review the current UNAIDS strategy and to discuss strategic 
priorities for the next strategy. We will also agree on an approach for developing the next 
strategy. We will then continue to engage the Programme Coordinating Board and a wide range 
of stakeholders through focus group discussions, interviews and other consultations. We count 
on your continued active engagement in this process to ensure that the next UNAIDS strategy 
remains ambitious, visionary and evidence-informed, and that it gets us back on track to reach 
the end of AIDS by 2030. 
Winnie Byanyima  
UNAIDS Executive Director 
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Key themes and 2016–2020 commitments 
 
At its 45th meeting, the UNAIDS Programme Coordinating Board (PCB) requested the UNAIDS 
Executive Director to review implementation of the current UNAIDS Strategy, with a focus on 
implications for strategic priorities beyond 2021. This brief evidence review is one component of 
an overall Strategy review process that will inform a September 2020 multistakeholder 
consultation on future strategic priorities.  
This review summarizes the results of the evidence review of the current UNAIDS Strategy. 
Results are presented in seven thematic areas that align to the strategic result areas (SRAs) of 
the 2016–2021 UNAIDS Strategy and the 10 core commitments of the 2016 Political Declaration 
on Ending AIDS (Figure 1).  
 
Figure 1. Evidence review of thematic areas, UNAIDS strategy result areas and the 10 
core commitments of the United Nations 2016 Political Declaration on ending AIDS
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2016 United Nations General Assembly commitments and UNAIDS 
Strategy Result Areas 
Note: The 10 core commitments agreed at the UN General Assembly High Level Meeting on Ending 
AIDS in 2016 closely match the Strategy Result Areas and the topics within each area, as included in the 
2016–2021 strategy.  
HLM Commitment 1. Ensure that 30 million people living with HIV have access to 
treatment through meeting the 90–90–90 targets by 2020. 
SDG 3. Ensure healthy lives and promote well-being for all at all ages 
Strategy Result Area 1: 
Children, adolescents 
and adults living with 
HIV access testing, 
know their status and 
are immediately offered 
and sustained on 
affordable quality 
treatment. 
Voluntary HIV testing services accessible for people at risk of HIV 
infection. 
Early infant diagnostic services accessible to all children exposed 
to HIV, and all children under 5 years living with HIV on 
treatment. 
All adults, adolescents and children offered antiretroviral therapy 
and linked to treatment services upon HIV diagnosis. 
People on treatment supported and monitored regularly, including 
scaled-up viral load monitoring, and treatment literacy and 
nutritional support. 
Accessibility, affordability and quality of HIV treatment improved, 
including through community delivery systems. 
HIV services scaled-up and adapted to local contexts, including 
in cities, fragile communities and humanitarian emergencies. 
Adequate investments made in research and development for 
better diagnostics, antiretroviral medicines, prevention 
commodities, monitoring tools, vaccines and a cure. 
HLM Commitment 2. Eliminate new HIV infections among children by 2020 while 
ensuring that 1.6 million children have access to HIV treatment by 2018. 
SDG 3. Ensure healthy lives and promote well-being for all at all ages 
Strategy Result Area 2: 
New HIV infections 
among children 
eliminated and their 
mother’s health and 
well-being sustained. 
Immediate treatment accessible to all pregnant women living with 
HIV (Option B+). 
HIV, sexual and reproductive health, including family planning, 
TB and maternal and child health services integrated and 
accessible for women, especially women living with HIV. 
HIV prevention services for male partners promoted, including 
testing and treatment. 
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HLM Commitment 3. Ensure access to combination prevention options, including pre-
exposure prophylaxis, voluntary medical male circumcision, harm reduction and 
condoms, to at least 90% of people by 2020, especially young women and adolescent 
girls in high-prevalence countries and key populations—gay men and other men who 
have sex with men, transgender people, sex workers and their clients, people who 
inject drugs and prisoners. 
SDG 10. Reduce inequality within and among countries 
Strategy Result Area 4: 
Tailored HIV 
combination prevention 
services are accessible 
to key populations, 
including sex workers, 
men who have sex with 
men, people who inject 
drugs, transgender 
people and prisoners, 
as well as migrants.  
Combination prevention services adequately resourced and 
available, tailored to populations, locations and interventions with 
maximum impact. 
Outreach and new media inform and create demand for use of 
traditional and new prevention technologies, including condoms 
and pre-exposure prophylaxis. 
Three million people on pre-exposure prophylaxis annually, 
focused particularly on key populations and people at high risk in 
high prevalence settings. 
People who inject drugs access clean needles and syringes, as 
well as opioid substitution therapy and other evidence-informed 
drug dependence treatment. 
Migrants, refugees and crisis-affected populations have access to 
HIV-related services. 
People living with HIV and other key populations meaningfully 
engaged in decision-making and implementation of HIV 
prevention programmes. 
HLM Commitment 5. Ensure that 90% of young people have the skills, knowledge and 
capacity to protect themselves from HIV and have access to sexual and reproductive 
health services by 2020, in order to reduce the number of new HIV infections among 
adolescent girls and young women to below 100 000 per year.  
SDG 10. Reduce inequality within and among countries 
Strategy Result Area 3: 
Young people, 
especially young 
women and adolescent 
girls, access 
combination prevention 
services and are 
empowered to protect 
themselves from HIV. 
Youth-friendly HIV, sexual and reproductive health and harm 
reduction information and services accessed independently and 
equally by young women and men. 
All people, especially young people, reduce HIV-related risk 
behaviour and access HIV combination prevention services, 
including primary prevention and sexual and reproductive health 
services. 
Twenty billion condoms available annually in low- and middle-
income countries for people of all ages. 
Additional 27 million men in high-prevalence settings voluntarily 
medically circumcised as part of access to integrated sexual and 
reproductive health services for men. 
Quality comprehensive sexuality education accessed by all 
adolescent and young people. 
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Information accessed, awareness raised and demand created 
through traditional and new forms of communication and 
outreach. 
Young people meaningfully engaged in the response to ensure 
effectiveness and sustainability. 
HLM Commitment 4. Eliminate gender inequalities and end all forms of violence and 
discrimination against women and girls, people living with HIV and key populations 
by 2020 
SDG 5. Achieve gender equality and empower all women and girls 
Strategy Result Area 5: 
Women and men 
practice and promote 
healthy gender norms 
and work together to 
end gender-based, 
sexual and intimate 
partner violence to 
mitigate risk and impact 
of HIV. 
Women and girls and men and boys engaged and empowered to 
prevent gender-based, sexual and intimate partner violence, and 
promote healthy gender norms and behaviour. 
Laws, policies and practices enable women and girls to protect 
themselves from HIV and access HIV-related services, including 
by upholding their rights and autonomy. 
Sexual and reproductive health and rights needs fully met to 
prevent HIV transmission. 
Young women in high-prevalence settings access economic 
empowerment initiatives. 
Women meaningfully engaged in decision-making and 
implementation of the AIDS response. 
Commitment 6. Ensure that 75% of people living with, at risk of and affected by HIV 
benefit from HIV-sensitive social protection by 2020. 
SDG 17. Strengthen the means of implementation and revitalize the global partnership for 
sustainable development 
Strategy Result Area 8: 
People-centred HIV and 
health services are 
integrated in the context 
of stronger systems for 
health.  
People living with, at risk of and affected by HIV empowered 
through HIV-sensitive national social protection programmes, 
including cash transfers. 
Commitment 9. Empower people living with, at risk of and affected by HIV to know 
their rights and to access justice and legal services to prevent and challenge 
violations of human rights. 
     SDG 16. Promote peaceful and inclusive societies for sustainable development, provide 
access to justice for all and build effective, accountable and inclusive institutions at all levels 
Strategy Result Area 6: 
Punitive laws, policies, 
practices, stigma and 
discrimination that block 
Punitive laws, policies and practices removed, including overly 
broad criminalization of HIV transmission, travel restrictions, 
mandatory testing and those that block key populations’ access 
to services. 
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effective responses to 
HIV are removed. 
People living with, at risk of and affected by HIV know their rights 
and are able to access legal services and challenge violations of 
human rights. 
HIV-related stigma and discrimination eliminated among service 
providers in health-care, workplace and educational settings. 
Laws, policies and programmes to prevent and address violence 
against key populations issued and implemented. 
Commitment 7. Ensure that at least 30% of all service delivery is community-led by 
2020. 
SDG 17. Strengthen the means of implementation and revitalize the global partnership for 
sustainable development 
Strategy Result Area 7: 
AIDS response is fully 
funded and efficiently 
implemented based on 
reliable strategic 
information.  
Investment and support to civil society, including networks of 
people living with, at risk of and affected by HIV, scaled up to 
enhance their essential role in the response. 
Commitment 8. Ensure that HIV investments increase to US$ 26 billion by 2020, 
including a quarter for HIV prevention and 6% for social enablers. 
SDG 17. Strengthen the means of implementation and revitalize the global partnership for 
sustainable development 
Strategy Result Area 7: 
AIDS response is fully 
funded and efficiently 
implemented based on 
reliable strategic 
information.  
Investment of at least US$ 31.1 billion available for the global 
AIDS response annually in 2020 in low- and middle-income 
countries, with one quarter invested in prevention globally. 
Low-income countries mobilize at least on average 12% of 
country resource needs, lower-middle-income mobilize 45% and 
upper-middle-income countries mobilize 95% from domestic 
sources. 
International investment for the AIDS response reaches US$ 12.7 
billion.  
Financial sustainability transition plans and country compacts 
implemented. 
Countries use timely, appropriate and reliable strategic 
information to prioritize resource allocation, evaluate responses 
and inform accountability processes. 
Allocative and productive efficiency gains fully exploited and 
commodity costs reduced in countries of all income levels, 
including by overcoming restrictive intellectual property and trade 
barriers. 
Country capacity built, including through technology transfer 
arrangements. 
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Commitment 10. Commit to taking AIDS out of isolation through people-centred 
systems to improve universal health coverage, including treatment for tuberculosis, 
cervical cancer and hepatitis B and C  
SDG 17. Strengthen the means of implementation and revitalize the global partnership for 
sustainable development 
Strategy Result Area 8: 
People-centred HIV and 
health services are 
integrated in the context 
of stronger systems for 
health.  
HIV-sensitive universal health coverage schemes implemented 
People living with, at risk of and affected by HIV access 
integrated services, including for HIV, tuberculosis (TB), sexual 
and reproductive health, maternal, newborn and child health, viral 
hepatitis, drug dependence, food and nutrition support, 
noncommunicable diseases and mental health conditions, 
especially at the community level. 
Comprehensive systems for health strengthened through 
integration of community service delivery with formal health 
systems. 
Human resources for health trained, capacitated and retained to 
deliver integrated health and HIV services. 
Stock-outs prevented through strengthened procurement and 
supply chain systems. 
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Cross-cutting issues: inequalities, 
complexities and the future of the HIV 
response 
This evidence review of progress against the current UNAIDS Strategy presents findings and 
details in seven thematic areas. In addition, important cross-cutting findings should inform 
deliberations regarding future strategic directions of the HIV response beyond 2021. HIV 
remains an epidemic of inequalities. The dramatic differences we observe in the HIV 
response—with successes and wide gaps often occurring in the same areas or issues—reflect 
multiple axes of inequality and the actions taken to overcome or eliminate the inequalities. Many 
of the inequalities that typify HIV and drive epidemics are well documented, such as the role of 
gender, the specific vulnerabilities of youth, differential impacts among and within regions and 
countries, and the marginalization of people associated with heightened HIV vulnerability. Other 
inequalities, however, are less commonly addressed, such as the role that inequalities related to 
race and ethnicity plays in many epidemics.  
Many of the disparities in progress against HIV are unexpected and counterintuitive. For 
example, the countries with the most resources are not always the ones with the strongest or 
most sustainable HIV response. Additionally, even as unequal gender norms increase the 
vulnerability of women and girls to HIV infection, men generally have poorer outcomes than 
women across the HIV testing and treatment cascade. Women generally are more likely than 
men to know their HIV status, receive antiretroviral therapy and achieve viral suppression. 
However, there are some countries, largely outside of sub-Saharan Africa, where women have 
worse testing and treatment outcomes than men.  
The majority of poorly performing HIV responses are in settings where epidemics are heavily 
concentrated among key populations who are often marginalized by mainstream society and 
denied easy access to HIV and other health services. These key populations include gay men 
and other men who have sex with men, people who inject drugs, people in prisons and other 
closed settings, sex workers and transgender people. Even in regions with encouraging recent 
gains against the HIV epidemic, such as eastern and southern Africa, there are countries and 
sub-national settings where the response is still badly off course.  
As the global HIV response approaches its fifth decade, the epidemic defies simple 
explanations and solutions. As an example, Figure 2 shows the variation in the relationship 
between prevalence of HIV and different levels of wealth in different countries at various stages 
of the epidemic. In Namibia, HIV prevalence was higher among people with lower incomes, 
while in Togo HIV prevalence was higher among people with higher incomes, and in Eswatini 
HIV prevalence was high across all income levels. Only by recognizing and addressing those 
complexities will it be possible to end the epidemic by 2030. 
Inequalities and HIV 
HIV risk, access to services and HIV outcomes are shaped by myriad, intersecting factors. 
Some differences and disparities are apparent when comparisons are made at regional and 
national levels, while others require closer examination at sub-national levels and between 
different populations.  
The dynamics of HIV transmission can be starkly different in high- and low-prevalence settings. 
In any particular setting, differences in wealth, age, education, location, and social or legal 
status, and discrimination related to gender, race or migration status all affect people's risk of 
acquiring HIV, their access to services and the benefits they draw from those services. 
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The 2030 Agenda for Sustainable Development emphasizes the importance of reaching the 
most vulnerable first and ensuring that no one is left behind. The Shared United Nations 
Framework on Equality and Non-Discrimination outlines the elements of a comprehensive and 
coherent package of policy and programme support areas to combat discrimination and 
inequalities within and among countries at the country, regional and global levels (2).  
Figure 2. Prevalence of HIV and wealth quintile in countries with higher and countries 
with lower HIV prevalence 
 
Source: Most recent Demographic and Health Survey: Namibia (2013); United Republic of Tanzania (2011–12); Zimbabwe 
(2015); Malawi (2015–16); South Africa (2016); Zambia (2018); Mozambique (2015); Eswatini (2006–07); Lesotho (2014);  
Senegal (2017); Niger (2012); Gambia (2013); Angola (2015–16); Burundi (2016–17); Ghana (2014); Democratic Republic of the 
Congo (2013–14); Guinea (2018); Burkina Faso (2010); Ethiopia (2016); Cameroon (2018); Sierra Leone (2013); Gabon (2012); 
Togo (2013–14); Liberia (2013); Chad (2014–15); Rwanda (2014–15); Côte d’Ivoire (2011). 
Women, men and HIV 
Men and women's risks of acquiring HIV, their knowledge of their HIV status, and their access to 
and use of HIV and other health services differ significantly. As in the case of HIV and wealth, 
these gender differences vary considerably, often in surprising ways. Men accounted for the 
majority of new HIV infections outside of sub-Saharan Africa (where most HIV transmission is 
associated with specific, marginalized populations), while women accounted for 59% of new HIV 
infections in sub-Saharan Africa in 2019 (where most HIV transmission occurs in the general 
population).i 
Women generally have better outcomes across the HIV testing and treatment cascade. 
Globally, for every 100 women who are living with undiagnosed HIV infection, there are 140 
men who do not know they are living with HIV. Women are also more likely to start and remain 
on HIV treatment and to achieve viral suppression, compared to men (Figures 3 and 4). 
Women’s superior testing and treatment outcomes are especially remarkable in concentrated 
epidemics where men outnumber women among people living with HIV. Despite men’s 
comparatively greater risks of acquiring HIV in these settings, services and responses in many 
settings are not reaching men, with poor testing and treatment outcomes and higher mortality 
rates among the consequences.  
While these patterns are striking, they are not universal. In western and central Africa, for 
example, women are more likely to be living with undiagnosed HIV infection than men. Among 
 
i The data in this review document are primarily from the 2020 epidemiological and financial estimates developed by 
UNAIDS in collaboration with its partners and the 2020 country reports submitted to UNAIDS through the Global AIDS 
Monitoring process. Data and analyses within the text that is taken from other sources are explicitly referenced.  
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64 countries with viral suppression data in 2019, women had lower levels of viral suppression 
than men in 12 countries. 
Figure 3. Estimated numbers of people living with HIV who were undiagnosed, by sex, 
and the ratio of undiagnosed men to women, global, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
The HIV risk of women and men also varies by age and region. Young women aged 15–24 
years make up 10% of the population in sub-Saharan Africa but account for 24% of new HIV 
infections in that region. Outside sub-Saharan Africa, men aged 25–49 years make up 18% of 
the population but comprise 48% of new HIV infections. 
Figure 4. Adults living with HIV who were virally suppressed, by sex, global in 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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Social marginalization and HIV  
Key populations disproportionately experience stigmatization, social marginalization and 
criminalization that block access to services which are readily available to other people.  
In Zimbabwe, for example, HIV testing and treatment service coverage among women in 
general is high and health outcomes are good. Transgender women in Zimbabwe, by contrast, 
are much less likely to obtain HIV treatment and achieve viral suppression, primarily because 
only 36% of transgender women living with HIV are aware of their HIV-positive status (Figure 5). 
In many countries, the heightened HIV vulnerability and diminished service access experienced 
by key populations is directly linked with discriminatory and punitive laws and policies (Figure 6). 
Persons with disabilities (15% of the world’s population) have been shown to have higher HIV 
risk than people without disabilities (3). In western and central Africa, for example, 
biobehavioural surveys conducted in six countries found low levels of knowledge compared with 
the general population; HIV prevalence was on average three times higher among people with 
disabilities than in the general population (4).  
Figure 5. Testing and treatment cascades for cis-gender and transgender women, 
Zimbabwe, 2019 
 
Source: Harris T, Parmley L, Mapingure M, Mugurungi O, Rogers JH, Apollo T et al. HIV care cascade: men who have sex with men 
& transgender women/genderqueer, Zimbabwe. Conference on Retrovirology and Opportunistic Infections (CROI), Boston (MA), 8–
11 March 2020. Abstract 1097. 
Figure 6. Countries with discriminatory and punitive laws, global 2019 
Sources: National Commitment and Policy Instrument, 2017 and 2019; supplemented by additional sources (available on request). 
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Disparities related to race and ethnicity can contribute to uneven access to quality services and 
HIV outcomes. Although black Africans account for the vast majority of the population in South 
Africa and for the large majority of people living with HIV, the public sector services on which 
black South Africans rely are typically of poorer quality than the private sector services available 
to white South Africans. In the United States of America, black people account for 13% of the 
national population but for 43% of new HIV diagnoses and AIDS-related deaths (5). 
Figure 7. HIV prevalence by race, all ages, South Africa, 2012 and 2017 
 
Source: Simbayi LC, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S et al.  South African National HIV Prevalence, Incidence, 
Behaviour and Communication Survey, 2017. Cape Town: HSRC Press; 2019 
(http://www.hsrc.ac.za/uploads/pageContent/10779/SABSSM%20V.pdf). 
Wealth inequalities and HIV 
The links between poverty and HIV are complex. In the early years of the epidemic, wealthy 
individuals were often at higher risk of acquiring HIV. Over time, however, the HIV burden on 
lower-income households has increased, in part because the wealthy are more likely than the 
poor to obtain the information and services they need. In sub-Saharan Africa, poorer women are 
consistently less likely to have accurate and comprehensive HIV knowledge than wealthier 
women (6). Insufficient access to nutritious food has also been associated with increased HIV 
risk behaviours among women, lower treatment adherence and higher rates of AIDS-related 
mortality (7–9). 
However, the link between lower income and greater HIV vulnerability does not exist in all 
settings. For example, while people living in poorer households are less likely to receive HIV 
treatment in some countries in eastern and southern Africa, this is not the case in other 
countries such as Eswatini, Namibia and Zimbabwe (Figure 8). Programmes and policies can 
be designed to specifically serve the most vulnerable and help overcome inequalities. 
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Figure 8. Antiretroviral treatment coverage by wealth quintile, by sex, selected countries 
in sub-Saharan Africa 2019 
 
Source: Population-based health impact assessment surveys, 2016–2019 (https://phia-
data.icap.columbia.edu/visualization).  
National resources and HIV responses 
The relationship between income levels and HIV outcomes are also apparent at the macro level. 
Low-income countries tend to have higher rates of new HIV infections and higher AIDS-related 
morbidity and mortality than middle-income and high-income countries. However, as coverage 
of HIV services increased in lower-income countries, this gap narrowed dramatically. Since 
2010, the decline in new HIV infections has been notably sharper for low-income countries than 
for countries in other income groups (Figure 9). A similar pattern is apparent for AIDS-related 
mortality, with low-income countries experiencing a sharper decline than for wealthier countries. 
As an example, the AIDS-related mortality rate in Haiti, a low-income country, declined by 52% 
between 2010 and 2019 and is now lower than that of Jamaica, an upper middle-income 
country where AIDS related mortality increased by 7% over the same period.  
Figure 9. Rate of new HIV infections per 1000 people, by country income level, global, 
1990–2019 
 
Source: UNAIDS estimates, 2019; World Bank Country and Lending Groups. In: The World Bank [Internet] 
(https://datahelpdesk.worldbank.org/knowledgebase/articles/906519, accessed on 10/06/2020).  
 16 
Figure 10. Rate of AIDS-related deaths per 1 000 000 people, by country income level, 
1990–2019 
 
Source: UNAIDS estimates, 2019; World Bank Country and Lending Groups. In: The World Bank [Internet] 
(https://datahelpdesk.worldbank.org/knowledgebase/articles/906519, accessed on 10/06/2020). 
 
Especially in eastern and southern Africa, several low-income countries are outperforming many 
upper-middle-income and high-income countries in outcomes along the HIV treatment cascade. 
Overall, treatment coverage has risen more rapidly in low-income than in upper middle-income 
countries, although the landscape is diverse (Figure 11).  
The BRICS countries (Brazil, Russian Federation, India, China and South Africa) remain 
critically important to the global HIV response. In 2019, these five countries accounted for 33% 
of all new infections and 35% of all people living with HIV worldwide (Figure 12 and 13)ii. Of 
note, greater national resources do not always correlate to higher HIV treatment coverage or 
lower number of new HIV infections. More complete and publicly available data would allow for 
improved ability to better recognize progress over time. 
 
ii These data come from UNAIDS estimates. Interpretations are made on the basis of these estimates. Work is ongoing 
with the Russian Federation to validate. 
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Figure 11. HIV treatment coverage levels by World Bank Income Group classification and 
per capita gross domestic product, 2015-2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). Per capita gross domestic product: World Bank, 
retrieved from Federal Reserve Bank of St. Louis (FRED) [database]. St. Louis (MO): Federal Reserve Bank of St. Louis 
(https://fred.stlouisfed.org, accessed on 30 July 2020). 
Figure 12. Distribution of new HIV infections and people living with HIV among BRICS 
and non-BRICS countries, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
Note: The data in the figure above come from UNAIDS estimates. Interpretations are made on the basis of these estimates. 
Work is ongoing with the Russian Federation to validate the figures. 
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Figure 13. HIV treatment coverage levels among the BRICS countries and per capita 
gross domestic product, 2015–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (Brazil and South Africa); UNAIDS epidemiological estimates, 2018 (the Russian 
Federation and India); 2019 China National HIV Estimation Report and Global AIDS Monitoring (for China); World Economic 
Outlook Database [database], April 2019. 
Note: The data in the figure above come from UNAIDS estimates. Interpretations are made on the basis of these estimates. 
Work is ongoing with the Russian Federation to validate the figures.  
 
Geography and HIV 
Closer analysis similarly reveals the pitfalls of comparing broad national or regional trends. For 
example, while HIV incidence has long been higher in sub-Saharan Africa than in other regions, 
a focus on regional or national trends masks the degree to which HIV burden and trends also 
vary within countries and regions (Figure 14). This is apparent in Namibia, for example, where 
there is considerable geographic variation in HIV incidence among young women.  
Figure 14. HIV incidence, women (aged 15–24 years), sub-Saharan Africa and Namibia, 
2019 
 
Source: Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 2020 
(https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
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Likewise, comparisons of regional outcomes can obscure results in specific countries. For 
example, eastern and southern Africa as a whole is steadily approaching the 90–90–90 
milestones, resulting in a 49% decline in AIDS-related deaths since 2010. However, scale-up of 
ART in Mozambique lags well behind the regional trend, and mortality has fallen by only 20%. 
The outsized influence of one or two large countries can also distort the picture for a region as a 
whole. For example, in eastern Europe and central Asia, new HIV infections would be stable if 
not for large increases in the Russian Federation. Likewise, viral load suppression levels in the 
United States of America were much lower than in the rest of western and central Europe and 
North America region in 2016, the latest year when data on viral load suppression were 
available in the United States (Figure 15).  
Figure 15. Examples of distortion of regional figures from large epidemics 
 
 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
Note: The data in the figure above come from UNAIDS estimates. Interpretations are made on the basis of these 
estimates. Work is ongoing with the Russian Federation to validate the figures.  
 
The COVID-19 pandemic is amplifying the deep inequalities that shape people’s health, 
wellbeing and life prospects. Efforts aimed at controlling the spread of COVID-19 can penalize 
the most vulnerable in society, and the poor and marginalized are also less likely to have 
access to services. This new pandemic is reminding the world of the many factors that 
undermine the HIV response and efforts to fulfil the right to health. Addressing those challenges 
is critical to global efforts to end AIDS and achieve the Sustainable Development Goals (SDGs) 
by 2030. 
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Future strategic directions: key questions for consideration 
• What are the key characteristics of policies and programmes that help overcome 
inequalities to improve HIV outcomes? 
 
• How do we overcome generalities, conventional wisdoms, and sometimes out-
dated assumptions to help drive specific interventions to overcome current or 
persistent inequalities driving poor outcomes for HIV? 
 
• What is the potential role of innovation, including artificial intelligence, to promote 
agility and refinement of programmes to better serve people and continually reach 
those left behind? 
What are the ethics and protections that need to be in place to ensure new 
technologies and approaches that include artificial intelligence are applied in a rights-
based manor and cannot be misused to further marginalize vulnerable populations? 
• How can political leadership and financial investments in middle- and high-income 
countries be better mobilized to accelerate HIV epidemic response?  
How are those current investments targeted to populations who are most at risk and 
the interventions they need? 
• How can addressing various inequalities also contribute to progress on the 
SDGs? 
 
• How do we ensure continued progress on reducing cross-cutting inequalities 
such as those related to gender, race, income, and access to health and justice? 
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Saving lives, preventing transmission: 
HIV testing and treatment 
 
Maximizing the benefits of ART remains key to hopes for ending the HIV epidemic. 
● High-Level Meeting Commitment 1. Ensure that 30 million people living with HIV have 
access to treatment through meeting the 90–90–90 targets by 2020. 
● Strategy Result Area 1. Children, adolescents and adults living with HIV access testing, 
know their status and are immediately offered and sustained on affordable quality 
treatment. 
Status report 
Expanded access to HIV treatment and improved treatment outcomes continue to generate 
historic health benefits, with AIDS-related deaths declining by 39% from 2010 to 2019. Nearly 
700 000 people are still dying from AIDS each year. AIDS-related mortality continues to decline 
but not at a pace sufficient to achieve the Fast-Track target of reducing deaths to fewer than 
500 000 by 2020.  
The decline in AIDS-related mortality since 2010 has been notably steeper among women and 
girls (46%) than among men and boys (32%) (Figure 17). However, AIDS continues to be one of 
the top causes of mortality among women of reproductive age. The reduction in AIDS-related 
deaths is more pronounced in eastern and southern Africa (49%) than in other regions; AIDS-
related deaths increased by 24% in eastern Europe and central Asia since 2010. These 
mortality trends largely stem from differences in HIV treatment coverage, which was 72% in 
eastern and southern Africa in 2019 (an increase from 25% in 2010), compared to 44% 
coverage in eastern Europe and central Asia. 
HIV treatment is also contributing to reductions in new HIV infections. In 2018-2019, results 
from four large clinical trials found that a universal test-and-treat approach achieved rapid 
reductions in population-level HIV incidence of 20-30% (10–13). 
The world continues to make progress towards the 90–90–90 targets. As of December 2019, 
81% of people living with HIV knew their HIV status, 82% of people with an HIV diagnosis were 
receiving ART and 88% of people receiving ART had achieved viral suppression.  
Figure 16. Number of AIDS-related deaths, global, 1990–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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Figure 17. Number of AIDS-related deaths by sex, global, 2010–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
Figure 18. HIV testing and treatment cascade, global, 2019 
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end 
epidemics. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
 
Achieving each of the three 90s would result in a minimum of 73% of people living with HIV 
having durably suppressed viral loads. Despite major progress, the world is unlikely to achieve 
the 73% target by December 2020. Among the estimated 38.0 million people living with HIV 
worldwide at the end of 2019, 67% were on treatment and 59% had suppressed viral loads 
(Figure 18). The gap to reaching the first 90 was 3.3 million people, the gap to reaching the first 
and second 90s was 5.4 million people, and the gap to reaching all three 90s was 5.4 million 
people. 
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A growing number of countries across regions and income levels represent 90–90–90 success 
stories. Globally in 2019, 13 countries had by 2019 attained the 73% target for viral 
suppression. Eswatini has already achieved the 86% viral suppression target for 2030. An 
additional five countries had achieved at least 68% viral suppression among people living with 
HIV. However, most countries are not on track to achieve the 90–90–90 targets, including 28 
countries where less than half of people living with HIV had suppressed viral loads in 2019. 
Table 1. Progress towards 90–90–90 targets, by country, among those with treatment 
coverage equal to or greater than the annual global average, 2019 
 
Source: UNAIDS estimates, 2020 (see https://aidsinfo.unaids.org). 
Note: Countries are eligible for inclusion in the table if HIV treatment coverage is equal to or greater than global HIV treatment 
coverage in the year they last reported data (global treatment coverage: 49% in 2015, 54% in 2016, 59% in 2017, 62% in 2018 and 
67% in 2019). In addition, countries must also have published estimates of people living with HIV to be included in the columns 
describing progress towards people living with HIV who know their status and viral load suppression among people living with HIV. 
Estimates are for 2019, except as follows: for 2015: Japan; for 2016: Denmark, Italy, Portugal and Spain; for 2017: Germany, Peru 
and Slovakia; and for 2018: Australia, Ireland, the Netherlands, Singapore and the United States. Eswatini, in bold italics, has 
reached all three of the 2030 95–95–95 target. Australia, Namibia, the Netherlands, Switzerland and Zambia, written in bold, have 
reported reaching each of the 2020 90–90–90 targets. 
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Reaching the 2020 viral suppression target of 73% at the end of the testing and treatment 
cascade indicates strong performance across all pillars of the 90–90–90 targets, and shows that 
people are fully benefiting from that treatment. In general, high-achieving countries attain 
excellent outcomes among men as well as women, compared to the global pattern in which 
women have consistently better outcomes across the HIV testing and treatment cascade than 
men. Higher treatment coverage among women is in part due to their more regular use of 
health-care services that include routine testing, such as antenatal care. Collection and 
reporting of disaggregated data on testing and treatment outcomes will need to become 
standard practice to achieve more precise monitoring of outcome trends across the HIV 
treatment cascade by age, sex, key populations and other pertinent variables. 
Eswatini’s experience offers useful lessons for accelerating gains in HIV outcomes. Eswatini 
makes intensive efforts to reach and engage men in testing and treatment services, provides 
free care and treatment for all, strategically uses data to target and adapt testing strategies, and 
uses innovative treatment delivery strategies, including same-day treatment initiation and 
differentiated service delivery.  
Table 2. Slow progress towards 90–90–90 targets, by country, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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Progress towards the 90–90–90 targets varies considerably between and within regions (Figure 
19). As a whole, eastern and southern Africa, home to more than 54% of all people living with 
HIV, is close to achieving the 90–90–90 targets, with treatment cascade outcomes comparable 
to those reported in western and central Europe and north America. Within eastern and 
southern Africa, seven countries (Botswana, Eswatini, Namibia, Rwanda, Uganda, Zambia and 
Zimbabwe) have achieved the 90–90–90 targets, and three additional countries (Kenya, Malawi 
and the United Republic of Tanzania) are on the verge of doing so. Eswatini has already 
achieved the 2030 target of 95–95–95. However, treatment coverage and rates of viral 
suppression are markedly lower in some other countries in the region, including Mozambique. 
Similarly, global aggregate progress obscures a lack of progress in the Middle East and North 
Africa and in eastern Europe and central Asia.  
Across the HIV testing and treatment cascade, the hindrances that restrict rates of viral 
suppression vary between and within regions. In western and central Africa and the Middle East 
and North Africa, low knowledge of HIV status represents the biggest barrier to treatment 
outcomes, while in eastern Europe and central Asia, low rates of treatment initiation are the 
main barriers. Failure to ensure that people diagnosed with HIV have immediate and unfettered 
access to HIV treatment initiation leads to health disparities, undermines progress towards 
ensuring that programmes are human rights-based and client-centred, and increases costs (by 
requiring repeat testing, outreach and intensive linkage efforts).  
Differences in treatment bottlenecks are apparent within regions as well. In eastern and 
southern Africa, for example, there are substantial gaps in knowledge of HIV status in 
Madagascar and South Sudan, while in Angola and Mauritius large proportions of people living 
with HIV know their status but are not accessing treatment services. Across 57 countries 
reporting on all three prongs of the 90–90–90 target, there is substantial variation with regard to 
the specific step in the HIV treatment cascade that constitutes the largest gap. Surge strategies 
may be needed for underperforming countries and regions to rapidly catch-up and aim towards 
future targets. 
Figure 19. HIV testing and treatment cascade, region, 2019 
 
Source: UNAIDS special analysis, 2020.  For methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. 
Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
Tuberculosis (TB) deaths among people living with HIV are declining but not quickly enough. 
This is primarily due to missed identification and treatment of active TB cases, and to slow 
expansion of TB preventative therapy. TB claimed the lives of an estimated 250 000 people 
living with HIV in 2018, approximately one third of all AIDS-related deaths (14). It is the leading 
cause of death among people living with HIV.  
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Treatment and prevention efforts saw TB deaths among people living with HIV decline by 52% 
from 2010 to 2018—an important achievement, but still short of the 75% target for 2020. TB 
treatment gaps are slowing progress towards global targets and are contributing to substantial 
preventable mortality among people living with HIV. Among the 135 countries that reported 
these data in 2019, less than half (48%) of the 862 000 estimated number of people living with 
HIV who developed TB disease (incident cases) received treatment for both HIV and TB. The 
TB treatment success rate for people living with HIV was 75% in 2018, compared to global TB 
treatment success of 85%.  
Reasons for comparatively poor outcomes among HIV-positive people on TB treatment include 
late detection of HIV-associated TB and delays in starting ART or TB treatment or cotrimoxazole 
prophylaxis. In 2020, only five of 30 countries with the highest TB burden provided the WHO-
recommended "one-stop shop" model for integrated HIV and TB services. Access to TB 
preventive treatment is increasing: globally in 2018, 65 countries reported initiating TB 
preventive treatment for 1.8 million people living with HIV, up from just under 1 million in 2017. 
 
 
COVID-19 and HIV testing and treatment 
 
COVID-19 is burdening health systems and lockdowns are limiting people’s movement and 
straining economies. This can lead to life-threatening disruptions to HIV and other health 
services for people living with HIV and people at higher risk of HIV infection. Those disruptions 
could reverse some of the progress made towards the 2020 targets.  
 
Recent modelling has estimated that a 6-month complete interruption of ART could lead to 
more than 500 000 [471 000–673 000] additional deaths from AIDS-related illnesses (including 
TB) in sub-Saharan Africa in 2020–2021 (15). An interruption of ART for 20% of people living 
with HIV for six months would result in more than 110 000 additional AIDS-related deaths (16). 
The emerging logistical challenges associated with ensuring stable supplies of HIV medicines 
and other essential commodities will require continuous problem-solving and mobilization. 
 
Differentiated service delivery approaches, developed by communities to respond to their 
specific needs and circumstances, are now being taken up broadly, with the COVID-19 crisis 
providing an additional impetus for expedited roll-out. Multimonth dispensing of antiretroviral 
(ARV) medicines is an example. It can prevent disruptions in treatment regimens and reduce 
the burden on congested health facilities.  
 
In every region but Latin America, a majority of countries in 2019 had policies in place for multi-
month dispensing of antiretroviral (ARV) medicines, but few were implementing those policies 
widely (17). That changed during the first months of the COVID-19 pandemic. By May 2020, 
80% of people on HIV treatment in Zimbabwe were receiving 3-month supplies of medicines, 
reducing clinic visits by 30% and increasing systemic resilience to the impact of COVID-19. In 
response to COVID-19, Malawi also relaxed its earlier restrictions on eligibility for multimonth 
prescriptions, and Thailand and Viet Nam accelerated their rollout of multimonth dispensing of 
ARV medicines (17). Other countries, including Belarus, Dominican Republic, Ethiopia, 
Mozambique, Papua New Guinea and South Africa, have adopted more liberal prescribing 
policies for HIV medicines (17).  
 
Multimonth dispensing also empowers communities and people living with HIV, and promotes 
and supports self-care by placing the power in the hands of the people themselves to continue 
treatment and care, making continuing treatment and care easier and less burdensome on 
people, families and communities. At the same time, community service delivery approaches, 
such as community ARV distribution and peer-led adherence clubs, are bringing HIV treatment 
services closer to the people who need them and facilitating the tailoring of services to 
individual and community needs.  
 
 
 
 27 
What is working and needs to be sustained 
The important momentum towards the 90–90–90 targets in most regions must be sustained. 
Globally, there have been historic gains in scaling up HIV treatment and improving HIV 
treatment outcomes (Figure 20). In 2019, 67% of people living with HIV were receiving ART—a 
marked improvement over 2010 (25% coverage) and 2015 (49%). Similar momentum is 
apparent in many regions.  
Important steps have been taken to optimize HIV testing and treatment approaches. Instead of 
standardized approaches that expect individuals to adapt themselves to pre-determined service 
approaches and platforms, the HIV response is increasingly focused on matching service 
approaches to the needs and circumstances of clients and communities. In place of the 
longstanding reliance on generalized facility-based testing, there is growing emphasis on the 
need for differentiated testing models, including diverse facility- and community-based 
approaches that can be targeted to communities at greatest risk and tailored to individual and 
community needs.  
Differentiated models of care, including community models of care help the local health system 
manage ever-increasing numbers of patients. Similarly, countries are optimizing HIV treatment 
regimens and improving HIV outcomes by transitioning to dolutegravir-based regimens for first-
line HIV treatment, in line with WHO recommendations. In Malawi, provision of dolutegravir-
based regimens in 2019 was associated with increases in rates of viral suppression among both 
men and women and in children living with HIV (18). As the COVID-19 pandemic unfolds, health 
systems that are people-centred and that make use of differentiated approaches are proving to 
be more adaptable and responsive. 
Innovations in service delivery are improving the effectiveness and efficiency of treatment 
services. People-centred and differentiated models of care, including community models of 
care, make health systems more adaptable and responsive, reduce the strain on standard 
health facilities, free up resources for other priorities, and enable local health systems to serve 
increasing numbers of patients. For example, multimonth dispensing does away with the need 
for frequent, costly and time-consuming clinic visits that are strictly to collect ARV medications 
and reduces the workload of health-care facilities. HIV self-testing and point-of-care 
technologies for virological testing and other diagnostics increase access to those services and 
provide clients with faster results.  
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Figure 20. Progress towards 90–90–90 and viral load suppression, regions, 2015–2019  
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: 
UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
 
Scientific research continues to generate important biomedical advances. HIV treatment options 
are continually improving. The recent ATLAS and FLAIR trials demonstrated that monthly or 
two-monthly injection with the drugs cabotegravir and rilpivirine are as effective as standard 
daily oral therapy (19, 20). Such long-acting options may make HIV prevention and treatment 
simpler and more convenient than daily oral dosing. Implementation science is also helping 
drive progress towards the 90–90–90 targets, with the previously mentioned universal test-and-
treat trials identifying innovative strategies for achieving rapid improvements in testing and 
treatment cascade outcomes and in improving outcomes for men and young people living with 
HIV. Continued innovation will be needed to generate newer and improved treatment options, 
especially as the demand for second- and third-line regimens grows over time.  
Delivery of integrated TB and HIV services improves outcomes of TB treatment among people 
living with HIV and reduces the number of TB-related deaths among people living with HIV. TB 
programmes that use integrated approaches have been particularly successful in ensuring that 
notified TB patients know their HIV status and that HIV-positive TB patients are receiving ART 
(14). 
 
Where the response is falling short 
Despite progress, testing and treatment programmes are leaving many people behind. Not all 
people living with HIV are benefiting equally from the overall global progress towards the 90–
90–90 targets. Worldwide and across regions, women have notably superior outcomes across 
the testing and treatment cascade compared to men (Figures 21 and 22). Globally, an 
estimated 54% of men living with HIV had suppressed viral loads in 2019, compared to 65% of 
women living with HIV. Young people living with HIV are less likely than older adults to know 
their HIV status and access treatment (Figure 23). Discriminatory gender norms, gender-based 
violence and disempowerment pose important barriers to HIV service access for many women, 
especially for women who belong to key populations.  
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Figure 21. HIV testing and treatment cascade among adults (aged 15 years and older), by 
sex, global, 2019 
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. 
Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
 
Figure 22. Coverage of antiretroviral therapy by sex, men and women (aged 15 years and 
older), regional, 2019 
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end 
epidemics. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
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Figure 23. HIV treatment coverage among adults and children, global, 2000–2018 
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: 
UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
Children living with HIV are faring even worse. Treatment coverage among children (aged 0–14 
years) was 53% in 2019, compared with 68% among adults living with HIV, rates of viral load 
suppression among children living with HIV having improved very slowly in recent years (Figure 
24). The next section of this report examines in more detail the challenges faced by children 
living with HIV. 
Evidence indicates that key populations often struggle to obtain testing and treatment services. 
In Malawi, for example, only 40% of female sex workers living with HIV were virally suppressed 
in 2018 (21). Among countries reporting population-specific data in 2016-2019, the average rate 
of testing with awareness (positive or negative) among key populations ranged from 62% 
among people who inject drugs to 67% among sex workers (22). Although not directly 
comparable, the global estimate of awareness of HIV-positive status  among people living with 
HIV was 81% in 2019. Lack of consistently available and robust population size estimates and 
data on HIV testing and treatment utilization outcomes for key populations hinder efforts to 
improve service access for these marginalized subpopulations. Populations encountering 
stigma and discrimination are doubly disadvantaged because concerns for client safety can 
make it difficult to closely monitor HIV service coverage in those populations. 
Figure 24. Proportion of viral load suppression among people on HIV treatment, by age 
and sex, global, 2015–2019 
 
Source: UNAIDS special analysis, 2020. For methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 
2020 (https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
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Although these overall gaps are deeply concerning and require immediate action, numerous 
programmes have shown that it is possible to achieve robust access and equitable results for 
marginalized groups. Community-centred and multi-disease service models such as SEARCH 
and PopART have succeeded in rapidly narrowing service gaps among men and young people 
by using a data-driven approach to identify service gaps and develop remedies (23). In 
Zimbabwe, a large-scale programme serving female sex workers rapidly increased knowledge 
of HIV-positive status (from 48% to 78%) and ART coverage (from 29% to 67%) between 2011 
and 2016 (24). 
Preventing and addressing loss-to-follow-up dramatically improves outcomes for people living 
with HIV and strengthens progress towards national and subnational goals. While the 
overwhelming majority of people who remain on ART achieve excellent outcomes, many people 
living with HIV struggle to remain engaged in care. Low retention on HIV treatment leads to 
increased mortality and morbidity, as well as increased HIV transmission, and it undermines 
progress towards the 90–90–90 targets. A meta-analysis of HIV treatment programmes in sub-
Saharan Africa found that 22% of patients who were lost to follow-up had died (25).  
In some programmes and countries, attrition represents the single-biggest gap along the testing 
and treatment cascade. Among PEPFAR programmes, loss-to-follow-up as a percentage of HIV 
treatment clients is especially high in Côte d’Ivoire, Malawi, Nigeria and South Sudan (26). 
When services are not delivered in ways that meet people's needs for life-long continuation, 
treatment benefits are lost and programmes become less efficient.  
As evidence from low- and high-income countries shows, active adherence and other support, 
community and provider monitoring of loss-to-follow-up and context-specific and people-centred 
strategies for re-engagement can reduce programme attrition and accelerate progress towards 
high levels of viral suppression (27–30). Initiatives to reduce attrition and re-engage people who 
have dropped out of care must address pertinent social and individual factors, including poverty, 
poor health, long distances to health facilities, perception of wellness, community HIV literacy, 
stigmatization, lack of social support, competing work or child care demands, and health system 
weaknesses that contribute to discontinuity of care.  
Figure 25. Absolute number of people lost to treatment, October-December 2019 
 
Source: PEPFAR Presentation 2020 COP meeting 
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Policy gaps remain. Although dozens of countries have acted to align their testing and treatment 
programmes with international guidelines, many others have failed to do so, thereby 
undermining their progress towards the 90–90–90 targets. In early 2020, at least 32 countries 
had yet to recommend dolutegravir-based regimens as first-line therapy, and 20 countries 
required ARV prescriptions to be refilled monthly (22, 31). In the first six months of 2020, the 
number of countries having policies in place for HIV self-testing rose from 77 to 87. 
Substantial implementation gaps persist. In many settings, adoption of recommended policies 
has not led to effective implementation and scale-up of evidence-based approaches. For 
example, although nearly all (184 of 193) countries have adopted the treat-all approach, only 69 
countries have implemented the policy in at least 95% of treatment sites. In mid-2020, 20 
countries had endorsed dolutegravir-based regimens in national guidelines but were yet to 
procure the regimens. While 87 countries in 2020 had formalized policies for HIV self-testing, 
actual roll-out of self-testing had begun in only 43 countries.  
Implementation gaps are especially evident for integrated services for HIV and TB. Less than 
half of the estimated incident TB cases among people living with HIV are currently diagnosed 
and treated appropriately (14). Scale-up of the first line molecular diagnostics tests is 
insufficient, as is the use of the LAM urine assay that is recommended for TB diagnosis in 
children living with HIV and seriously ill adults living with HIV (22, 32–34). 
Countries need to adjust strategies to reach the people who are being left behind. Even high-
performing countries appear to have difficulty “going the last mile” towards the 95–95–95 
targets. The same strategies that bring countries to the brink of success are often inadequate to 
reach the people who are most vulnerable or marginalized.  
 
Audits of national treatment programmes in eastern and southern Africa have identified factors 
that may account for slowdowns in progress, including difficulties in reaching and retaining men 
and young people, lack of robust uptake of innovative testing and treatment approaches, 
inadequate treatment initiation, substantial loss-to-follow-up and poor treatment adherence. 
Countries need to adjust approaches and implement strategies that are tailored to reach the 
people who are not effectively engaged by mainstream service systems and approaches.  
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Figure 26. Progress in roll-out of dolutegravir as HIV treatment, 137 low- and middle-
income countries, 2020 
 
 
Countries where progress towards the 90–90–90 targets is lagging urgently need to reinvigorate 
national testing and treatment efforts and adopt lessons learned from high-performing 
programmes. Notwithstanding the growing number of 90–90–90 “success stories,” most 
countries are not on-track to achieve those targets. In 13 countries (Albania, Fiji, Ghana, Islamic 
Republic of Iran, Jamaica, Kyrgyzstan, Lithuania, Mauritius, Mongolia, Republic of Moldova, 
Somalia, South Sudan and Tajikistan) less than 40% of people living with HIV have achieved 
viral suppression. Testing gaps are particularly large in Madagascar and South Sudan, while 
large percentages of people in Angola and Mauritius who know they are HIV-positive are not 
accessing treatment. It is vital to further disaggregate HIV data by age, population and location 
in order to guide differentiated testing, treatment care and support strategies to reach the people 
being left behind. In western and central Africa (45% of people living with HIV virally suppressed 
in 2019), the Caribbean (50%), eastern Europe and central Asia (41%) and the Middle East and 
North Africa (32%), levels of viral suppression among people living with HIV are substantially 
lower than the global average (59%). 
While strategic information has improved in some respects, the lack of robust data, especially 
among key populations, undermines the ability to monitor progress towards the 90–90–90 
targets and towards assuring equitable access. A surprising number of countries have yet to 
report estimates across the testing and treatment cascade, often because they lack the health 
information systems to do so. While countries in eastern and southern Africa have improved 
their capacities to monitor viral suppression, data systems in western and central Africa are 
comparatively weaker. Countries also often lack reliable estimates for national cascade 
outcomes for key populations. Reliable estimates for undiagnosed children living with HIV are 
not available in most settings. In addition to national cascade estimates, subnational analyses 
are needed to identify specific locations where interventions are needed. Disaggregated data 
(particularly by sex, age, and subpopulation) can help improve the effectiveness of treatment 
programmes, but those data are too seldom available or used effectively. For example, 
available information suggests that the largest diagnostic gap is among men aged 35–49 years, 
an insight that should inform decisions regarding programmatic targeting and resource 
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allocations (17). Programmes urgently need to invest in strategic information systems that can 
guide more effective approaches for identifying and reaching specific subpopulations.  
Social and structural factors that affect treatment uptake and outcomes are insufficiently 
addressed. HIV remains highly stigmatizing. Negative attitudes of health-care providers, 
including overt acts of discrimination, deter many people living with HIV from seeking testing 
and treatment services. According to results from People Living with HIV Stigma Index surveys, 
substantial percentages of people living with HIV (more than 30% in Congo and Tajikistan, for 
example) report avoiding health services due to their HIV status. 
There is increasing evidence that 
appropriate strategies can reduce 
stigma and discrimination in health-
care settings (35). For example, 
programmes that complement 
knowledge transfer with 
opportunities to meet and hear from 
people living with HIV appear to be 
more effective in changing health-
care workers’ attitudes and cultural 
competence than trainings alone 
(36). 
Disparities in treatment access and 
outcomes also stem from laws and 
policies that violate international 
human rights and conflict with 
gender equality norms. Robust 
treatment scale-up and optimal HIV 
outcomes are incompatible with 
laws and policies that criminalize 
people who are at high risk of HIV 
infection, such as sex workers, 
people who inject drugs and gay 
men and other men who have sex 
with men. Unequal gender norms, 
stigma, discrimination and punitive 
laws prevent or deter many people 
living with HIV from seeking the 
testing and treatment services they 
need. Some countries have acted in recent years to remove discriminatory and scientifically 
unsound laws and policies towards people living with HIV and key populations (see section on 
stigma, discrimination and justice). 
The negative impact of punitive laws and policies on efforts to maximize access to HIV testing 
and treatment is especially apparent with respect to people who inject drugs. In Uganda, for 
example, mandatory drug testing protocols deter people from accessing ART, while in 
Kazakhstan and Kyrgyzstan registration requirements for people using narcotic drugs 
discourages many of them from seeking health services (37). Similarly, in Nigeria and South 
Africa, TB treatment programmes' emphasis on abstinence from using narcotics discourage 
uptake (38, 39). 
 
 
 
 
Figure 27. Percentage of people living with HIV who 
avoided going to a local clinic or hospital when they 
needed it in the last 12 months because of their HIV 
status, countries with available data, 2013‒2018 
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Future strategic directions: key questions for consideration 
● How do we build robust and sustained political support and take specific strategic 
actions to close testing and treatment gaps for: 
o Men? 
o Members of key populations 
Gay men and other men who have sex with men? 
Transgender people? 
Sex workers? 
People who inject drugs? 
People who live in prisons or other closed settings? 
• Adolescents and young people? 
• People with TB? 
• Persons with disabilities? 
• Migrants? 
 
What is needed to drive political will to specifically address/intensify actions for those left 
behind (not one-size-fits-all)?  
● Where many people with an HIV diagnosis are not receiving HIV treatment, what 
strategies should be rapidly adopted to close the gap?  
How would those strategies differ from the ones that are needed to optimize rapid treatment 
initiation for people newly diagnosed with HIV? 
● What strategies and investments are needed to sharply reduce loss-to-follow-up and 
service discontinuation?  
What are the costs of not acting immediately to reduce these losses? 
● In settings and among populations where knowledge of HIV-positive status is a major 
barrier, what strategies are needed? 
How should programmes invest in different mixes of testing approaches based on which 
populations are disproportionately undiagnosed? What should be the role of universal test-
and-connect strategies? 
● How do we build political commitment and catalyze meaningful action to remove the 
financial, social and structural factors that impede service access and optimal 
outcomes for testing and treatment services? 
● How do we ensure that strategic data are collected, disaggregated, analysed and 
effectively used to reach testing and treatment goals? 
What technical support approaches are needed to help countries?  
o develop and effectively use testing and treatment cascades? 
o develop disaggregated cascades that focus on outcomes for key populations? 
o achieve more detailed understandings of treatment cascades and develop targeted 
interventions?  
o develop and effectively use disaggregated and population-specific treatment cascades to 
inform population-specific efforts to close cascade gaps?  
What are the political barriers to differentiated services (i.e. modified or intensified service 
packages for people who are not being reached effectively) and how do we overcome 
them?  
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● What strategic actions are needed to prioritize and widely use innovations and 
biomedical advances?  
How can national testing and treatment programmes and programme implementers be 
made sufficiently agile to expedite uptake of biomedical and service delivery innovations? 
What investments, incentives or actions are required to ensure a robust research-and-
development pipeline for new HIV treatment options, including long-acting regimens?  
What is the role of community HIV literacy in ensuring preparedness for future HIV 
vaccines? 
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Eliminating vertical HIV transmission and 
ensuring effective HIV treatment of 
children 
The world is unlikely to achieve the Fast-Track target of eliminating new HIV infections among 
children in 2020. It has to work harder to deliver on its commitments to address the HIV-related 
needs of children and young people: 
● HLM Target 2: Eliminate new HIV infections among children by 2020, while ensuring that 1.6 
million children have access to HIV treatment by 2018. 
● Strategy Result Area 1: Children, adolescents and adults living with HIV access testing, know 
their status and are immediately offered and sustained on affordable quality treatment. 
● Strategy Result Area 2: New HIV infections among children eliminated and their mother’s 
health and well-being is sustained. 
Preventing vertical transmission 
Status report 
New HIV infections among children decreased by more than half from 2010 to 2019, but 
progress in preventing children from becoming infected has slowed since 2016 (Figure 28). 
Three countries (Mozambique, Nigeria and South Africa) accounted for one third of the 150 000 
children who acquired HIV in 2019. Considerable gains have been made in preventing new 
infections among children in Mozambique and South Africa. But in Nigeria the number of newly 
infected children has increased since 2016, primarily because of a decrease in the proportion of 
women living with HIV who receive ART.  
Outside of sub-Saharan Africa, there are less reliable data about vertical transmission. Available 
data suggest that the proportion of pregnant women living with HIV who are members of key 
populations or partners of key populations is larger than in sub-Saharan Africa. 
Figure 28. Number of new HIV infections in children, global, 2000–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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Since 2002, the UN and partners have called for stepped-up action in four areas, which were 
highlighted again in the Global plan towards the elimination of new HIV infections among 
children by 2015 and keeping their mothers alive, and they remain essential to reach the 
elimination target: 
1. Prevent HIV among women of reproductive age; 
2. Provide appropriate counselling and support, and contraceptives, to women living with 
HIV to meet their unmet needs for family planning and spacing of births, and to optimize 
health outcomes for these women and their children; 
3. For pregnant women living with HIV, ensure HIV testing and counselling and access to 
the ARV drugs needed to prevent HIV infection from being passed on to their babies 
during pregnancy, delivery and breastfeeding; and 
4. Provide HIV care, treatment and support for women, children living with HIV and their 
families (40). 
 
What is working and needs to be sustained 
Some countries have achieved relatively high coverage of ART among pregnant women living 
with HIV. In 2019, 84% of pregnant women living with HIV accessed ART––less than the global 
target of 95% but nevertheless an important accomplishment (Figure 29). In eastern and 
southern Africa, 60% of women living with HIV were already on HIV treatment when they 
became pregnant. As a result of such high coverage, 2.2 million HIV infections among children 
were prevented globally between 2000 and 2019.  
Unfortunately, HIV treatment coverage among pregnant women living with HIV has increased 
only slightly since 2015. Although scaled-up HIV treatment among pregnant women is central to 
hopes for eliminating new HIV infections among children, high coverage is insufficient on its 
own, as substantial numbers of children continue to acquire HIV. This is primarily due to a 
failure to retain women living with HIV in treatment throughout pregnancy and breastfeeding, as 
well as substantial new acquisition of HIV by women during pregnancy or breastfeeding (Figure 
30).  
Figure 29. Coverage of pregnant women reached with antiretroviral therapy (and 2020 
global target) and new child HIV infections, global, 2010–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS preliminary 2020 estimates. 
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Figure 30. Estimated new HIV infections in children, by missed opportunity for 
preventing vertical transmission, global and sub-Saharan Africa, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
 
Global attention to the elimination agenda has continued, although dividends seem to have 
diminished. In 2016, UNAIDS, PEPFAR and other partners launched the Start Free Stay Free 
AIDS Free framework, which identified a series of Super Fast-Track targets to accelerate 
progress towards the elimination goal (41). The Organization of African First Ladies Against 
HIV/AIDS’s Free to Shine campaign to end AIDS among children, adolescents and young 
people brought additional attention to efforts to eliminate new infections among children.  
 
The process of Global Validation of Elimination of Mother-to-Child Transmission celebrates 
prevention success stories and encourages accelerated progress. Launched by WHO in 2012, 
the process has validated elimination in eight countries and five territories (Cuba, Thailand, 
Belarus, Armenia, Anguilla, Antigua & Barbuda, Bermuda, Cayman Islands, Montserrat, St Kitts 
& Nevis, Malaysia, Maldives and Sri Lanka). Those countries account for a small fraction of new 
infections among children globally (0.2% in 2014), but the validation process is ground-breaking 
and includes requirements on human rights, gender equality and community engagement (42). 
In many countries, the validation process has helped keep HIV on the agenda, which has 
benefited other aspects of the response, including attention to the needs of key populations. 
Validation as defined by the process is not feasible for countries with HIV prevalence of 5% or 
more, as they would need to ensure universal treatment initiation prior to conception in order to 
achieve the elimination target of fewer than 50 transmissions per 100 000 births. An alternative 
pathway to elimination has been developed to celebrate countries as they achieve key 
milestones in preventing new HIV infections among children. 
 
 
Where the response is falling short 
Even as global coverage remains relatively high, many pregnant and breastfeeding women are 
not receiving ART. Ninety-five per cent of pregnant women living with HIV in eastern and 
southern Africa received ART in 2019. High coverage was reached in countries such as Malawi, 
Namibia and South Africa, where HIV has been integrated in antenatal care and progress has 
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been made in reducing HIV-related stigma. By contrast, treatment coverage among pregnant 
women was only 58% in western and central Africa, with very low coverage in the Democratic 
Republic of the Congo and Nigeria, due in part to low coverage of antenatal care generally. 
Where pregnant and breastfeeding women are not accessing HIV treatment, recommended HIV 
testing approaches for women (such as family or index testing) have not been brought to scale 
and effectively integrated with other health screening initiatives (e.g., HIV, TB, COVID-19, 
malaria, family planning) in hotspots.       
 
Evidence points towards a range of effective ways to improve ART uptake among pregnant 
women—including male involvement, more convenient service hours and enhanced case-
finding strategies—but these have not been scaled up sufficiently in areas with low coverage. In 
some settings, enrolment in antenatal care services occurs late in pregnancy, at the time of 
delivery or after home birth. Many women face considerable hindrances when accessing 
antenatal care, including user fees, transport costs, loss of income, lack of childcare, stigma, 
discrimination and unpleasant attitudes of some health-care workers. Women from key 
populations and young mothers are especially affected.  
      
Women who test HIV-negative at their first antenatal visit should be counselled on remaining 
HIV-negative and provided access to appropriate combination HIV prevention interventions, 
including encouraging partner testing. Pre-exposure prophylaxis (PrEP) should be considered 
for women at high risk of HIV infection. HIV-negative women should also be offered repeat HIV 
testing throughout pregnancy and breastfeeding and commence ART as soon after 
seroconversion as possible. Specific challenges exist in low-prevalence countries. Women from 
key populations or who are partners of key population members are seldom explicitly engaged 
in antenatal settings, HIV testing is not routinely offered and screening methods are not 
available to identify pregnant women who need of HIV testing and treatment services. 
 
Table 3. Estimated retention on antiretroviral therapy among breastfeeding women living 
with HIV (adjusted to other clinics), combined with sub-Saharan Africa, Latin America 
and the Caribbean regions, 2014–2019 
 
Period Delivery 1–6 months 7–12 months 13–24 months 
Retention (%, 95% CI) 80% (72–87%) 81% (75–87%) 83% (75–90%) 70% (57–83%) 
Source: Dugdale C. Maternal engagement in care during pregnancy and breastfeeding in the era of lifelong ART. Presentation at 
UNAIDS Reference Group on Child HIV estimates, Montreux, Switzerland, October 2019. Methodology from: Doi SAR, Barendregt 
JJ, Khan S, Thalib L, Williams GM. Advances in the meta-analysis of heterogeneous clinical trials II: the quality effects model. 
Contempt Clin Trials. 2015;45(Pt A):123-9; MetaXL, Version 5.3. In: epigear.com [Internet]. EpiGear International; c2016 
(http://www.epigear.com/index_files/metaxl.html),  
Note: Postpartum retention reported for those women who were in care at delivery. 
Too many women are not retained on treatment and their viral load is not monitored throughout 
pregnancy and breastfeeding. Retention of pregnant women in HIV treatment services varies, 
with high retention reported in Kenya and Rwanda but much lower retention reported in Uganda, 
for example (43). Evidence indicates that peer mentoring (including mother-to-mother 
mentoring) and partner involvement promote retention of pregnant women living with HIV, but 
these approaches have not been scaled up in all settings (44), 45). Obstacles preventing robust 
retention include inadequate integration of HIV testing into sexual and reproductive health and 
rights services. Implementation barriers include inconvenient and time-consuming arrangements 
at clinics, such as requiring mothers to attend separate facilities for their new-borns or other 
children. These challenges especially affect mothers who are breadwinners in their households. 
It is unclear whether more frequent viral load testing is warranted during pregnancy and 
breastfeeding. Currently, there is no specific guidance on this matter. Inadequate HIV treatment 
and low HIV literacy among mothers and women of childbearing age generally can also hamper 
retention. Gender-related barriers—including unpaid care work responsibilities, economic 
dependency on partner or household, gender-based stigma and discrimination—limit women 
and girls’ access to and retention in vertical transmission services.  
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Figure 31. Numbers of pregnant women living with HIV and the gaps in prevention of 
vertical transmission, 21 focus countries, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
Note: The 21 focus countries Angola, Botswana, Burundi, Cameroon, Chad, Côte d’Ivoire, Democratic Republic of 
the Congo, Eswatini, Ethiopia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, 
Uganda, the United Republic of Tanzania, Zambia and Zimbabwe. 
 
Continued high HIV incidence among pregnant and breastfeeding women is contributing to new 
HIV infections among children. The substantial number of new HIV infections among pregnant 
and breastfeeding women underscores the need to understand which pregnant women are at 
higher risk of infection and to intensify prevention services as part of antenatal care and post-
natal care (Figure 31). Of the seroconversions that occurred among pregnant and breastfeeding 
women in the 21 focus countries in 2019, 43% were among young women aged 15–24 years. 
Those incident infections among young women resulted in an estimated 30 000 new infections 
among children. Most new HIV infections in children that stem from the mothers' seroconverting 
during pregnancy and breastfeeding occur in eastern and southern Africa. 
It is essential to improve young women’s access to combination HIV prevention to protect them 
from HIV infection and reduce the number of new infections among children (see section on 
Combination HIV Prevention: special focus on adolescent girls and young women, youth, and 
key populations). To reduce young women’s risk of HIV acquisition during pregnancy or 
breastfeeding, Kenya is rolling out PrEP services for this population. Other prevention strategies 
with proven effectiveness for young women include combination prevention services that target 
high-risk women and high-incidence settings. HIV self-testing is potentially useful for increasing 
timely HIV diagnosis among young women during pregnancy or breastfeeding.  
Unequal gender power relations can increase the risk of HIV acquisition among women and 
especially young women.  As well as specifically focusing on reducing HIV risks among young 
pregnant and breastfeeding women, intensified efforts are needed more broadly to increase 
access to combination prevention and reduce gender inequality for all women of reproductive 
age. Age-of-consent laws that impede young women's access to HIV testing and sexual and 
reproductive health services should be reformed (Figure 32).  
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Figure 32. Countries with laws requiring parental consent for adolescents to access 
sexual and reproductive health services, among 197 countries, 2018 
Source: UNAIDS Global AIDS Monitoring, 2019 (see https://aidsinfo.unaids.org/). 
Note: n = number of countries giving this reply. 
 
 
Future strategic directions: key questions for consideration 
●  What is needed to overcome barriers to women living with HIV accessing HIV 
treatment during pregnancy and breast-feeding? 
In settings where antenatal care service uptake is low or declining, what service models can 
be more effective for reaching women? What services or interventions are needed to ensure 
that women who are members of key populations are welcome and supported in these 
services? 
● What strategic actions are needed to increase coverage of ART among pregnant 
women in settings where coverage is low? 
What specific actions are needed to rapidly increase coverage in the Democratic Republic of 
the Congo, Nigeria and other parts of western and central Africa where coverage is low? 
What specific actions are needed to ensure that antenatal care settings in low-prevalence 
settings are using behavioural screening and HIV testing protocols to identify and address 
the needs of pregnant women who belong to key populations or are the partners of key 
population members? 
● What strategic actions are needed to support pregnant and breastfeeding women to 
remain engaged in HIV treatment services throughout and beyond those time 
periods? 
● What strategic actions are needed to reduce new HIV infections among women during 
pregnancy and breastfeeding? 
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● How can we best translate expressions of political commitment on the elimination 
agenda into the effective actions and investments that are needed to prevent vertical 
transmission? 
● How can we ensure access for women who belong to key populations to the 
comprehensive services and support they need to prevent vertical transmission and 
protect their own health? 
 
Paediatric treatment  
Status report 
HIV treatment coverage among children living with HIV (53% in 2019) has plateaued at a level 
well below coverage for adults (68%). The 950 000 children who were accessing ART in 2019 
was well below the 1.4 million Fast-Track target for 2020 (Figure 33). An estimated 850 000 
children living with HIV were not receiving ART in 2019. The five countries that account for the 
largest number of children living with HIV who are not receiving ART are (in order of magnitude) 
South Africa, Nigeria, Mozambique, the Democratic Republic of the Congo and Kenya. 
Current testing approaches miss many children, including those who acquire HIV during 
breastfeeding. Among children who do receive HIV treatment, outcomes are frequently worse 
compared to adults in the same country (Figure 34). Although children accounted for 5% of 
people living with HIV in 2019, they represented 14% of all AIDS-related deaths, with most of 
those deaths occurring in the first four years of life. Consequently, more than two-thirds (69%) of 
children living with HIV who were not receiving treatment are aged 5–14 years (Figure 35).  
 
Figure 33. Number of children (0–14 years) living with HIV (CLHIV) and receiving 
antiretroviral therapy (and 2020 target), global, 2010–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/).  
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Figure 34. Viral load suppression among adults (15 years and older), and children (aged 
0–14 years), selected focus countries, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/).  
 
 
Figure 35. Number of children (aged 0–14 years) living with HIV not on antiretroviral 
therapy, 21 focus countries, 2015–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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What is working and needs to be sustained 
The paediatric treatment agenda has attracted political attention. The Vatican hosted a series of 
meetings among key stakeholders, including clinicians, drug companies and humanitarian 
agencies, to strategize actions that can close the paediatric treatment gap. The third leg of the 
Start Free Stay Free AIDS Free initiative set an ambitious target of reaching 1.6 million children 
living with HIV with treatment by 2018. While these initiatives succeeded in raising the political 
profile of the paediatric HIV treatment agenda, they have not led to the transformative actions 
that are needed to close the treatment gap for children. 
The evidence base for paediatric HIV testing has strengthened. It is now clear that family testing 
is a highly effective means of identifying children who are living with HIV but not receiving HIV 
treatment (46). Among PEPFAR-supported programmes, a modest increase (from 9% to 12%) 
in the proportion of family testing among children’s HIV tests overall in 2018–2019 generated a 
marked increase in the proportion of newly diagnosed HIV testing identified through index 
testing (from 17% to 28%), underscoring the potential of family testing to close gaps in 
knowledge of HIV status among children (47). UNICEF and UNAIDS have developed guidance 
on family testing scale-up in western and central Africa.  
There has been some progress towards optimizing paediatric regimens. Under the umbrella of 
the Paediatric Antiretroviral Drug Optimization group, WHO has convened diverse stakeholders 
to strategize ways to expand the array of child-approach ARV formulations and to improve the 
effectiveness and durability of paediatric regimens. Tailored “four-in-one” regimens have been 
made available for children, and dolutegravir was recently approved for infants and children 
above four weeks of age and weighing more than 3 kg (48).  
Where the response is falling short 
Current testing approaches miss many children living with HIV. The excessive number of 
children living with HIV but not receiving treatment stems primarily from two testing gaps: (1) low 
coverage of early infant diagnostic (EID) services; and (2) the lack of testing options for older 
children who are missed by EID efforts, especially children who acquire HIV during 
breastfeeding. Had EID been available at scale in 2019, an additional 75 000 children (or 
roughly 10% of those who are living with HIV but not receiving treatment) would have been 
diagnosed (49). In Namibia, which prioritized early roll-out of EID, treatment coverage among 
children is similar to coverage among adults.  
Immediate steps are needed to ensure universal access to EID services. As experience with 
point-of-care EID in eight countries in sub-Saharan Africa has shown, these platforms can 
reduce turnaround time for testing results from a median of 55 days (for traditional EID) to less 
than one day (50). Swifter scale-up of point-of-care EID is needed. In 2020, five high-burden 
countries (Botswana, Burundi, Namibia, Nigeria and South Africa) had no policy in place for 
point-of-care EID.  
Family testing strategies need to be used more extensively to identify older children living with 
HIV. At the moment, the approach is being used most widely in Mozambique, the United 
Republic of Tanzania and Zambia. Countries with large treatment gaps among children, such as 
the Democratic Republic of the Congo and Nigeria, should use these strategies.  
Sub-optimal treatment options for children contribute to poor paediatric HIV outcomes. Many 
countries have yet to prioritize the transition to optimized treatment regimens and continue to 
use nevirapine-based regimens which are associated with high rates of loss-to-follow-up among 
paediatric HIV patients. Rapid introduction and scale-up of newly approved dolutegravir-based 
regimens is urgent. Among children infected during breastfeeding, missed by EID and 
subsequently diagnosed with HIV, retention in care is poor, due in part to continued reliance in 
many settings on sub-optimal lopinavir-based regimens (51). 
Stigma, discrimination and challenges faced by caregivers undermine high uptake of paediatric 
HIV treatment and strong retention in care. Caregivers and families require enhanced 
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psychosocial and practical support, as well as adequate knowledge about paediatric treatment. 
Children living with HIV must navigate multiple transitions, including the transition from 
paediatric to adolescent care and then from adolescent to adult services. There is a need for 
innovations and child-centred support to facilitate smooth transitions, ensure continuity of care 
and tailor support as children grow older and develop. 
 
Table 4. Policies for paediatric treatment, focus countries, 2019 
Country 
Dolutegravir 
first-line for 
children ≥20 kg 
Lopinavir first-
line for children 
<20 kg 
Multimonth 
dispensing, 3 or 
6 months 
Point-of-care 
early infant 
diagnosis policy 
Virological 
testing at nine 
months 
  
a not available 
Source: UNAIDS National Commitments and Policy Instrument, 2020 (see http://lawsandpolicies.unaids.org/) and supplemented 
with data submitted to the World Health Organization. 
 
Many obstacles separate adolescents (10–19 years) living with HIV from quality HIV treatment 
access and good HIV outcomes. Quantifying treatment coverage and gaps for adolescents 
living with HIV is challenging due to the lack of data for this age group. However, given the 
evidence that both children (aged 0–14 years) and young people (aged 15–24 years) have 
lower HIV treatment coverage than adults, it is clear that more must be done to ensure that 
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adolescents living with HIV (including those with perinatally acquired HIV and young people who 
acquire HIV during youth) have robust, equitable access to HIV treatment and support services. 
Testing and treatment barriers experienced by adolescents living with HIV include the 
comparatively lower health-seeking behaviours associated with youth, lack of awareness of HIV 
risk and fear of disclosure. For adolescents who are receiving treatment services, the shortage 
of youth-friendly treatment services, as well as life transitions during youth, can reduce retention 
in care and worsen health outcomes. Peer support groups and the routine inclusion of 
adolescents and young people living with HIV in decision-making on community-led service 
delivery can improve retention, adherence and viral suppression, but these approaches are not 
been used widely enough (52). 
Political will remains inadequate. Efforts to spotlight the paediatric HIV agenda are losing 
momentum, in part due to the mistaken assumption that gains in preventing vertical 
transmission would automatically also lead to gains in meeting children’s HIV-related needs. 
Given the enormity of the paediatric HIV treatment gap and the need for urgent action to close 
this gap, re-building and sustaining political commitment to address the needs of children living 
with HIV is a critical priority. 
 
 
Future strategic directions: Key questions for consideration 
● What strategic actions are needed to sharply elevate paediatric HIV treatment on the 
political agenda? 
Despite leadership by African First Ladies and major international organizations to generate 
stronger action from decision-makers, we are seeing insufficient results. Who else can help 
unblock political commitment on paediatric HIV treatment? What arguments—humanitarian, 
economic, health, development—would be most persuasive to draw greater attention to 
paediatric HIV treatment, and what data and advocacy approaches will be needed to make 
these arguments compelling? 
● What strategic actions are needed to close the paediatric HIV testing gap? 
How can the scale-up of point-of-care EID be accelerated? In settings where point-of-care 
EID is unavailable, how can turnaround time of centralized EID be improved to ensure that 
results are returned to the mother and baby pair for action within days rather than weeks or 
months? What actions are needed to catalyze rapid scale-up of family testing, especially in 
settings with large treatment gaps such as the Democratic Republic of the Congo and 
Nigeria? 
● What strategic actions are needed to expand the transition to better child-appropriate 
regimens and formulations and to optimize children’s HIV treatment options? 
How can rapid roll-out of dolutegravir-based regimens be achieved? What actions are 
needed to incentivize investments for the development of improved regimens and 
formulations for children living with HIV? 
● What strategic actions are needed to ensure that caregivers and families receive the 
psychosocial support and treatment literacy they need to support the best-possible 
HIV outcomes for children? 
● What strategic actions are needed to increase HIV treatment coverage and ensure 
good treatment outcomes for adolescents living with HIV? 
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Combination HIV prevention: special 
focus on adolescent girls and young 
women, youth and key populations 
 
Combining and strategically layering different prevention approaches will avert more new HIV 
infections and enable programmes to tailor approaches to the needs of individuals and 
communities. A failure to use effective prevention approaches on a wide-enough scale has left 
the world off-track to achieve the prevention targets for 2020 and is holding back progress 
towards ending the AIDS epidemic. 
● HLM Target 2: Ensure access to combination prevention options, including PrEP, voluntary 
medical male circumcision, harm reduction and condoms to at least 90% of people by 2020, 
especially young women and adolescent girls in high-prevalence countries and key 
populations––gay men and other men who have sex with men, transgender people, sex 
workers and their clients, people who inject drugs and prisoners. 
● Strategic Result Area 3: Young people, especially young women and adolescent girls, 
access combination prevention services and are empowered to protect themselves from 
HIV. 
● Strategic Result Area 4: Tailored HIV combination prevention services are accessible to key 
populations, including sex workers, men who have sex with men, people who inject drugs, 
transgender people and prisoners, as well as migrants. 
Status report 
An estimated 1.7 million [1.2 million – 2.2 million] people were newly infected with HIV in 2019—
a 23% decline compared to 2010, but more than three times higher than the global target of less 
than 500 000 new infections in 2020 (Figure 36).  
Progress in preventing new infections varies by region. The number of new infections 
decreased by 38% in eastern and southern Africa from 2010 to 2019 but by 25% in western and 
central Africa, and by 29% in the Caribbean, 12% in Asia and the Pacific, and 15% in western 
and central Europe and North America. Elsewhere, new infections have increased since 2010: 
by 72% in eastern Europe and central Asia, 22% in the Middle East and North Africa and 21% in 
Latin America. 
Women and girls accounted for 48% of new HIV infections globally in 2019 and for 59% of new 
infections in sub-Saharan Africa. The number of new HIV infections among women fell by 23% 
globally from 2010 to 2019 and by 30% in sub-Saharan Africa. 
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Figure 36. Number of new HIV infections, global, 1990–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
Figure 37. HIV incidence among adolescent girls and young women (15–24 years), 
subnational levels, sub-Saharan Africa, 2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). For methodology, see: Seizing the moment: 
tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 2020 
(https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
Note: HIV incidence estimated as new HIV infections per 1000 person-years at risk. 
Countries: For selected countries in sub-Saharan Africa that had the data required to produce subnational HIV estimates. 
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The estimated 280 000 young women (15–24 years) who newly acquired HIV in 2019 marked a 
34% decline since 2010, but that number was almost three times larger than the 2020 target of 
fewer than 100 000 per year by 2020. Across sub-Saharan Africa, HIV incidence rates tend to 
be highest among young women aged 20–24 years. In some settings, particularly those with 
extremely high HIV incidence, adolescent girls aged 15–19 years already experience very high 
incidence, and HIV incidence remains high among women aged 25–29 years, as well (Figure 
37). Adolescent girls and young women up to the age of 29 have to be prioritized in HIV 
prevention programmes within those epidemic settings. 
The epidemic’s disproportionate burden among key populations (including gay men and other 
men who have sex with men, people who inject drugs, sex workers, transgender people and 
prisoners) continues to grow (Figure 38). In 2019, these populations and their sex partners 
accounted for an estimated 62% of new HIV infections globally. Compared to the general 
population, the risk of acquiring HIV is on average about 26 times higher for gay men and other 
men who have sex with men, 29 times higher for people who inject drugs, 30 times higher for 
sex workers and 13 times higher for transgender people than for adults in the general public. 
Globally, HIV incidence among people who inject drugs, sex workers and transgender people 
since 2010 has remained high but relatively stable since 2010. New infections are on the rise 
among gay men and other men who have sex with men, who comprised 23% of new infections 
globally in 2019, including more than 40% of new infections in Asia and the Pacific and Latin 
America, and nearly two thirds (64%) of new infections in western and central Europe and North 
America. Marked increases in new infections among gay men and other men who have sex with 
men were reported in Brazil, Mexico, Pakistan and Philippines.  
Figure 38. Distribution of new HIV infections by gender and population, global, 2019 
 
*Data only included from Asia and the Pacific, the Caribbean, eastern Europe and central Asia, Latin America, and western and 
central Europe and North America.  
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS special analysis, 2020. For 
methodology, see: Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 2020 
(https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
Note: Epidemiologic data from transgender populations are available primarily from the Asia and the Pacific, Caribbean and Latin 
America regions. Fewer data are available from the western and central Europe and North America region. Limited programme data 
are available from western and central Africa and eastern and southern Africa. Furthermore, data are primarily for transwomen and 
tend to be for transwomen who sell sex. Only a few data points were available from transmen.  
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Figure 39. HIV incidence among key populations, global, 2010–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS special analysis, 2020.  
 
Figure 40. Changes in HIV incidence among key populations 2010–2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS special analysis, 2020.  
 
 
COVID-19 and HIV prevention 
 
The unprecedented disruptions caused by COVID-19 are affecting multiple HIV 
prevention services, including voluntary medical male circumcision, condom production 
and distribution, and access to PrEP and HIV treatment. Lockdowns and physical 
distancing requirements have also forced a shift from in-person peer outreach activities 
to virtual ones. Countries in sub-Saharan Africa, Asia and the Pacific, and the 
Caribbean are increasing their use of social media and messenger apps to deliver 
combination HIV prevention information and services. 
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What is working and needs to be sustained 
 
We have the tools to sharply reduce the number of new HIV infections, since evidence clearly 
demonstrates that combination prevention works. Evidence from both clinical trials and real-
world implementation of combination prevention shows the effectiveness of diverse, layered HIV 
prevention strategies and approaches. Case studies of high-burden countries that have sharply 
lowered HIV incidence underscore the importance of changing sexual risk behaviours and the 
added prevention benefits of increased coverage of ART. Studies in Kenya and South Africa 
indicate that prevention and treatment work best when brought to scale simultaneously (Figure 
41) (53–56).  
 
Modelling exercises have quantified the number of infections averted for key prevention 
interventions. It is estimated that voluntary medical male circumcision averted about 250 000 
new HIV infections by 2018 and could avert 1.6 million new infections by 2030, along with 
preventing other sexually transmitted infections, as well (57). It is estimated that condom use 
has averted nearly 50 million HIV infections since the beginning of the HIV response (58). 
 
Figure 41. Coverage of HIV services and HIV incidence, by sex, four locations in eastern 
and southern Africa, 2006–2017 
 
Sources: Grabowski MK, Serwadda DM, Gray RH, Nakigozi G, Kigozi G, Kagaayi J et al. HIV prevention efforts and incidence of 
HIV in Uganda. N Engl J Med, 2017;377:2154-66; Uganda Demographic and Health Surveys, 2006, 2011, 2016; Vandormael A, 
Akullian AN, Dobra A, de Oliveira T, Tanser F. Sharp decline in male HIV incidence in a rural South African population (2004–2015). 
Abstract 46. Conference on Retroviruses and Opportunistic Infections (CROI), Boston (MA), 4–7 March 2018; Personal 
communication with A. Vandormael, May 2018; South African National HIV Prevalence, HIV Incidence, Behaviour and 
Communication Survey, 2005, 2008; South African National HIV Prevalence, Incidence and Behaviour Survey, 2012; Nkambule R, 
Nuwagaba-Biribonwoha H, Mnisi Z, Ao TT, Ginindza C, Duong YT et al. Substantial progress in confronting the HIV epidemic in 
Swaziland: first evidence of national impact. International AIDS Society Conference, Paris, 23–26 July 2017. Abstract 
MOAX0204LB; Swaziland HIV Incidence Measurement Survey, descriptive data tables, 2014; Justman J, Reed JB, Bicego G, 
Donnell D, Li K, Bock N et al. Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet 
HIV. 2017 Feb;4(2):e83-92; Swaziland HIV Incidence Measurement Surveys, 2016, preliminary findings; Multiple Indicator Cluster 
Survey, 2010, 2014; Borgdorff MW, Kwaro D, Obor D, Otieno G, Kamire V, Odongo F et al. HIV incidence in western Kenya during 
scale-up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis. Lancet HIV. 
2018;5(5):e241-9; Kenya Demographic and Health Survey, 2008–2009 and 2014; National AIDS Control Council, Kenya HIV 
country profiles, 2016; Spectrum 2018. 
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Combination HIV prevention entails an expanding array of biomedical, behavioural and 
structural interventions. Studies have found that several interventions—including ART, PrEP, 
condoms and sterile injecting equipment—have a very high level of effectiveness (80–100%) if 
consistently used. Evidence also shows that voluntary medical male circumcision is an effective 
one-time procedure which reduces men's risk of acquiring HIV from female partners by 38–66% 
(59). Opioid substitution therapy can reduce the risk of acquiring HIV by up to 54% for people 
who inject drugs and has a range of additional health and social benefits (60). 
Comprehensive sexuality education has been shown to improve HIV-related knowledge and 
encourage safer sexual behaviours. It is also relatively inexpensive: one multicountry evaluation 
found that comprehensive sexuality education need avert only 4% of projected HIV infections to 
be cost-saving (61). Oher behavioural interventions also have positive outcomes in specific 
contexts. Short-term HIV prevention campaigns in schools have been found to be effective in 
reducing sexual relations with older higher-risk partners, as well as teenage pregnancies (62). 
Combined behavioural and structural interventions using gender-transformative HIV prevention 
approaches are effective in changing sexual behaviours and in preventing HIV in some settings 
(63, 64).  
Two studies have found that the dapivirine vaginal ring reduced women’s risk of acquiring 
HIV by more than a quarter (65, 66). The European Medicines Agency issued a positive opinion 
on the ring and the International Partnership on Microbicides will seek regulatory approval in 
sub-Saharan Africa, where women are disproportionately at risk of HIV infection. Recent trial 
results have shown injectable cabotegravir to be superior to oral PrEP among men and 
transgender women who have sex with men,  findings which might spark greater PrEP uptake 
(67). Findings from a similar study involving African cis-gender women are pending. 
The effectiveness of various structural approaches is also evident, including reforms to laws that 
criminalize drug use. Criminalization has been shown to undermine HIV prevention and 
treatment (68). It is estimated that decriminalization of sex work would reduce 33–46% of new 
HIV infections over a decade (69). Cash transfers have proven effective in some contexts in 
reducing HIV risks among young women (70, 71). 
 
Prevention programmes are being expanded and there is increasing uptake of several highly 
effective prevention approaches. The number of people reported to have received PrEP at least 
once in the previous year rose from fewer than 2000 in 2016 to more than 590 000 in 2019. In 
places where PrEP has been scaled up—e.g. Australia, Brazil and many countries in western 
and central Europe and North America—HIV incidence among gay men and men who have sex 
with men has declined. New data from the SEARCH trial indicates that scale-up of PrEP 
alongside intensified health services reduced HIV infections in 16 communities in Kenya and 
Uganda by 74% (72). 
 
Similarly, implementation of effective harm reduction has improved prevention outcomes in 
Ukraine, where participants of peer-led community outreach are now more likely to use sterile 
injecting equipment, condoms and opioid substitution therapy and are achieving better 
outcomes on all stages of the HIV treatment cascade (73).  
 
Strong demand persists for voluntary medical male circumcision, with more than 15 million men 
and boys in 15 priority countries having undergone this procedure since the beginning of 2016 
(Figure 42).  
 
In Zimbabwe, roll-out of the national Sisters programme, which offers clinical services and 
community engagement, has been associated with reductions in new HIV infections among 
female sex workers, although not in all age groups (74). 
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Figure 42. Cumulative number of males voluntarily medically circumcised, 15 priority 
countries, 2016–2019 
 
Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/). 
Note: The 15 priority countries are: Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South 
Africa, South Sudan, Uganda, the United Republic of Tanzania, Zambia and Zimbabwe. 
 
Figure 43. Cumulative effect of scale-up of combination HIV prevention, Zimbabwe, 1990–
2019 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS Global AIDS Monitoring, 2020 (see 
https://aidsinfo.unaids.org/); UNAIDS National Commitments and Policy Instrument, 2019–2020 (see 
http://lawsandpolicies.unaids.org/); Voluntary medical male circumcision. Progress brief. Geneva: UNAIDS, WHO; 2019; 
STATcompiler [database]. The DHS Program (www.statcompiler.com, accessed 29 July 2020); Halperin DT, Mugurungi O, Hallett 
TB, Muchini B, Campbell B, Magure T et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS 
Med. 2011;8(2):e1000414. 
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There is encouraging progress in the provision of comprehensive sexuality education, with 80% 
of countries surveyed reporting the existence of supportive policies or strategies. Most countries 
in Asia and the Pacific (21 of 25) have national HIV strategies that refer to the role of education, 
while most countries in western and central Asia have formal policies on life skills-based HIV 
sexuality education. Health ministers in Latin America and the Caribbean have committed to 
nationwide school-based sexuality and HIV education (75). Although policies on comprehensive 
sexuality education are increasingly aligned with national norms, the translation of these policies 
into actual programmes lags in many settings, which adds to young people’s vulnerability to 
HIV. 
A number of countries have had striking success in reducing HIV incidence through the support 
of scaled-up combination prevention programmes. In Cambodia, a combination of strong 
political leadership, outreach to key populations, robust condom programming and high levels of 
viral load suppression led to a 95% reduction in new HIV infections over two decades (76). 
Likewise, the scale-up of combination prevention in Zimbabwe was associated with a reduction 
in new HIV infections of at least 80% over 25 years (Figure 43) (77). In South Africa, where new 
HIV infections have decreased by 53% since 2010, reductions in HIV incidence between 2000 
and 2008 were partially attributed to increased condom use (78). Since 2010, South Africa has 
achieved one of the steepest declines in HIV incidence in the region, a feat that is attributed to 
the country’s simultaneous expansion of ART and voluntary medical male circumcision (79). 
There is new momentum towards strengthening HIV prevention efforts. The launch of the Global 
HIV Prevention Coalition in 2017 focused renewed attention and efforts on achieving global 
prevention targets. Although the Coalition has yet to catalyze the sea change in prevention 
access that is urgently needed, all 28 focus countries have developed national prevention 
targets in line with the Coalition’s Road Map, and they have acted to revitalize their HIV 
prevention and leadership structures. Focus countries report that the Coalition has strengthened 
accountability through the use of prevention scorecards, regular reporting and annual joint 
reviews among stakeholders. 
 
Where the response is falling short 
Political will on HIV prevention is still lacking. Despite the momentum which the Global HIV 
Prevention Coalition has brought to HIV prevention, political commitment for stepped-up action 
remains inadequate. This is especially true with respect to combination prevention and harm 
reduction programming for key populations, which remains heavily dependent on external 
financial and technical support. Many countries remain reluctant to support or implement proven 
prevention strategies for key populations, such as opioid substitution therapy and other 
components of harm reduction for people who inject drugs. In 14 countries that reported 
relevant data from 2015–2019, coverage of opioid substitution therapy was below 40% in every 
country except among men in Mauritius and Malaysia. In 10 countries, coverage was below 
20% for both men and women. 
Insufficient political commitment has also resulted in chronic under-funding of prevention efforts. 
International development assistance support for HIV prevention decreased by 44% between 
2012 and 2017 (80). Domestic investment in HIV prevention, in particular for key populations, 
remains insufficient. While attention to HIV prevention increased in proposals to the Global Fund 
in the first half of 2020, many countries face competing priorities and Global Fund allocations on 
their own will remain insufficient to close coverage gaps, which suggests that a combination of 
increasing domestic investment, prioritization and efficiency will be required. 
Essential prevention strategies have yet to be brought to scale. Although the expanding access 
to certain prevention interventions is encouraging, access to essential components of 
 56 
 
combination prevention varies considerably across settings. Key components of combination 
prevention have yet to be scaled up and there are signs that access to some prevention options 
is decreasing in some countries. These gaps likely reflect challenges on the supply (i.e. funding 
and implementation support for specific interventions) and demand (i.e. community demand for 
specific prevention services) sides. Prevention access gaps undermine combination prevention, 
which is most effective when multiple prevention and treatment efforts are simultaneously 
brought to scale and made accessible. 
Table 5. Major gaps towards HIV prevention coverage targets (28 Global Prevention 
Coalition countries, unless otherwise indicated), 2018–2019 
Pillar Indicator  
(date of assessment) 
Latest 
coverage 
2020 target 
HIV prevention among 
adolescent girls and young 
women 
% of high-incidence locations covered 
(2018) 
31%   90% 
Key populations % of key populations who reported 
receiving at least two prevention 
services in the past three months 
(2018) 
SW: 47% 
MSM: 33% 
PWID: 32% 
90% 
Condoms % of condom distribution need met 
(2018) 
55% 90% 
VMMC % of VMMC target achieved 
(2018) 
15 million 
VMMCs 
25 million 
VMMCs 
PrEP Number of people on PrEP (global data) 
(2019) 
590,000 3 million  
Source: Global HIV Prevention Coalition special analysis of Global AIDS Monitoring 2019 and 2020 (see 
https://aidsinfo.unaids.org/). 
The defunding of condom social marketing programmes has led to a drop in sales and use of 
male condoms in sub-Saharan Africa. In several high-burden countries, reported condom use at 
last sex has declined, leaving the world far short of the Fast-Track target of 90% condom use 
target. Although PrEP use is increasing, current uptake (590 000 in 2019) is far less than the 
global target of 3 million people receiving PrEP by the end of 2020. Similarly, current uptake 
trends indicate that the world will not meet its target of providing voluntary medical male 
circumcision to 25 million people by 2020.  
Prevention coverage is notably limited for key populations. In six of 13 countries that have 
conducted surveys since 2016 and reported those data to UNAIDS, less than half of 
transgender women stated that they were able to access at least two HIV prevention services in 
the previous three months, as did similar proportions of female sex workers (in 16 of 30 
countries), gay men and other men who have sex with men (in 26 of 38 countries) and men who 
inject drugs (in 10 of 14 countries). 
Countries often do not make sufficient use of data to expand prevention programmes and 
ensure programme quality. Countries are not achieving the desired uptake of effective 
prevention interventions. Many national HIV programmes are not agile enough to identify and 
respond to emerging epidemic dynamics, such as the growing burden of infections among key 
populations or the uneven declines in HIV incidence among men and women in parts of 
southern Africa following scale-up of combination prevention programmes. Although the 
importance of targeting specific locations is increasingly recognized, programming is often not 
sufficiently differentiated by setting. For example, where HIV and viral hepatitis transmission 
through injecting drug use is primarily concentrated in one or two settings, it might be 
appropriate to prioritize harm reduction services there rather than nationally. In light of UNAIDS 
estimate that 20% of districts in sub-Saharan Africa account for about two-thirds of new HIV 
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infections among adolescent girls and young women, accurate targeting is essential to 
maximize prevention impact and programme efficiency. Innovation has served as an especially 
critical driver for improved uptake and outcomes for treatment services, but the same 
commitment to use data to drive innovative problem-solving and gap-closing is not always 
apparent for prevention programming. 
Table 6. New HIV infections among young women (15–24 years), by location, 39 countries 
in sub-Saharan Africa, 2019 
  
Population  
(15-24 years) 
Number of new 
HIV infections 
% of new 
HIV 
infections 
Extremely high-incidence districts (>2.0%) 646 826 16 142 7% 
Very high-incidence districts (1.0-2.0%) 5 830 753 73 356 30% 
High-incidence districts (0.3-1.0%) 13 723 551 72 700 30% 
Medium-incidence districts (0.1-0.3%) 34 542 472 57 597 24% 
Low-incidence districts (<0.1%) 45 183 607 20 747 9% 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS special analysis. For methodology, see: Seizing the 
moment: tackling entrenched inequalities to end epidemics. Geneva: UNAIDS; 2020 
(https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf). 
 
Countries participating in the Global Prevention Coalition have made good progress against the 
ten 2020 Prevention Roadmap commitments, but some gaps remain, particularly in relation to 
key population programming and social contracting (Table 7). 
For several priority populations there are limited data to guide effective action, and serious gaps 
exist for key populations. Effective implementation—including quality assurance and 
improvement, the capacity for rapid shifts in response to emerging needs, granular location and 
population targeting and a commitment to innovation—requires the reliable collection of detailed 
data, along with adequate analytic capacity to interpret and use the data. However, data 
systems relevant to prevention programming are often weak and/or inadequately used. Many 
countries lack robust size estimations or HIV prevalence estimates for key populations. Even 
when estimates are available, methodologies can be unreliable. National laws and policies that 
criminalize key populations often make it difficult and sometimes impossible to collect accurate 
data to guide prevention programming. While service cascade analyses have been important for 
increasing uptake of and improving outcomes for HIV treatment and prevention of vertical 
transmission, they are used less frequently to guide and catalyze implementation of primary 
prevention services.  
Countries urgently need to intensify efforts to eliminate stigma and discrimination, which 
continue to undermine HIV prevention efforts. This is true generally and but especially salient for 
key populations. Recent systematic reviews and meta-analyses found that African countries 
with oppressive anti-LGBT laws have low levels of HIV testing and awareness among gay men 
and other men who have sex with men, and their size estimates for those populations are either 
absent or unrealistically low (81, 82). Gay men and other men who have sex with men who live 
in countries that criminalize same-sex relations are more than twice as likely to acquire HIV as 
their peers living in countries without such criminal penalties (Figure 44). Those living in 
countries with severe criminalization are almost five times as likely to acquire HIV as those living 
in countries without such criminal penalties (83).  
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Table 7. Progress against the 10 Roadmap actions in 28 Global Prevention Coalition, 
2017–2019 countries, 2017–2019 
 
Source: Global HIV Prevention Coalition special analysis.  
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Figure 44. HIV prevalence among gay men and other men who have sex with men 
and level of criminalization of same-sex relations in 10 countries in sub-Saharan 
Africa, 2011–2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Lyons C. Utilizing individual level data to assess the relationship between prevalent HIV infection and punitive same sex 
policies and legal barriers across 10 countries in sub-Saharan Africa. 23rd International AIDS Conference, 6–10 July 2020. Abstract 
OAF0403. 
Note: The 10 countries are Burkina Faso, Cameroon, Côte d'Ivoire, Gambia, Guinea‐Bissau, Nigeria, Senegal, Eswatini, Rwanda 
and Togo.  
 
HIV prevention efforts need to link with other sectors. To address the many factors that 
contribute to HIV vulnerability, combination prevention programmes should be integrated, 
multisectoral and intersectional in their approach. A much stronger evidence base is needed to 
guide coordinated efforts across the biomedical, behavioural, social and structural domains that 
affect risk and vulnerability. The multipartner, PEFPAR-led DREAMS initiative uses a 
multisectoral approach to prevent new infections among adolescent girls and young women. 
Despite promising results, this approach has yet to be brought to scale in most priority settings. 
Depending on the setting, greater attention for prevention efforts is needed with respect to such 
issues as poverty, race, ethnicity and indigenous communities. In light of the flattening of HIV 
financing, finding ways to encourage other sectors to make needed investments in structural 
approaches will be needed. 
Future strategic directions: key questions for consideration 
● How can much stronger political commitment to HIV prevention be built and 
sustained? 
How can the momentum towards greater political support for HIV prevention be translated 
into meaningful action at the country level, including through increased domestic allocations 
for the pillars of combination prevention, the dismantling of legal and policy barriers and the 
implementation of evidence- and rights-based programming for key populations? 
● What strategic actions are needed to overcome specific gaps in availability, access 
and demand for: 
o Condom programming? 
o PrEP (including roll-out of injectable PrEP)?  
o Voluntary medical male circumcision? 
o Harm reduction? 
o Combination prevention programming for sex workers? Gay men and other men who 
have sex with men? People who inject drugs? Transgender people? Prisoners?  
o Combination prevention programming for adolescent girls and young women (including 
young adult women aged 20–34 years)?  
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● What strategic actions must we take to address pertinent social and structural 
issues? 
What strategic actions are needed to strengthen the evidence base to inform and guide 
social/structural actions? How can sectors other than health be persuaded to make 
necessary social/structural investments (such as in girls’ education)? 
● What strategic actions are needed to build the capacity of communities to lead HIV 
prevention and drive demand for services and innovation? 
What financial and technical support is needed to build community capacity to deliver 
essential prevention services? Especially in the case of marginalized communities, what 
actions are needed to prevent their work from being hindered by government authorities 
(e.g. law enforcement) or by negative social attitudes? How best can communities contribute 
to building demand for prevention services? 
● What strategic actions are needed to ensure that countries collect and effectively use 
data to drive implementation and improve the quality of prevention programming? 
Should national AIDS structures be revived or strengthened in order to oversee and drive 
accelerated implementation of combination prevention? How can we bring the same 
commitment to focus, quality, scale and innovation seen in testing and treatment 
programming to the prevention arena? How can we close key data gaps? What actions are 
needed to build analytic and programmatic capacity at the national and subnational levels to 
target resources more effectively and improve the performance and impact of prevention 
efforts? 
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Gender equality  
 
Ensuring that HIV responses work for women and girls is crucial for their health and wellbeing, 
and for ending the AIDS epidemic. 
● HLM Target 4: Eliminate gender inequalities and end all forms of violence and discrimination 
against women and girls, people living with HIV and key populations by 2020. 
● Strategy Results Area 5: Women and men practice and promote healthy gender norms and 
work together to end gender-based, sexual and intimate partner violence to mitigate the risk 
and impact of HIV. 
Status report 
The epidemic continues to have a severe impact on women and girls, who in 2019 accounted 
for 48% of new HIV infections worldwide and 59% of new infections in sub-Saharan Africa. 
Although important gains have been made in linking women with HIV treatment services, AIDS 
remains a leading cause of death among women of reproductive age (84). 
 
HIV risks are especially pronounced for adolescent girls and young women (15-24 years) in 
sub-Saharan Africa. Although young women account for only 10% of the population of sub-
Saharan Africa, they comprise 24% of people in the region who were newly infected in 2019. 
The number of adolescent girls and young women who acquired HIV in 2019 (280 000) was 
nearly three times higher than the global target of less than the 2020 target of no more than 100 
000 new infections. Adolescent girls (15–19 years) in sub-Saharan Africa are 4.5 times more 
likely to acquire HIV than their male counterparts (Figures 45, 46). 
 
Figure 45. Trends in new HIV infections, by age and sex, global, 2000–2019  
  
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/).  
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Figure 46. Trends in new infections by age and sex, in and outside sub-Saharan 
Africa, 2000–2019 
 
 
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/). 
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Women who belong to key populations, and women who are partners of members of key 
populations, are also at very high risk of HIV infection and have insufficient access to services. 
Female sex workers are 30 times more likely to acquire HIV than women in the general 
population. In some settings, up to 40% of transgender women are living with HIV. Women who 
inject drugs often have higher rates of HIV than males who inject drugs because of the dual risk 
from unsafe injection practices and unprotected sex (85). 
Women and girls can face multiple, intersecting forms of stigma, discrimination and 
criminalization. Unequal gender power dynamics, harmful gender norms and masculinities, and 
violence against women and girls increase their risk of acquiring HIV and diminish their ability to 
access services and to take decisions that safeguard their health and wellbeing. Harmful 
masculinities also negatively affect men’s health-seeking and risk-taking behaviours, 
exacerbating risks for both men and women. 
 
COVID-19 and gender equality 
 
The COVID-19 pandemic is threatening many of the gains made in expanding service 
access for women and girls. Extended confinement measures and restrictions on 
movement, compounded by economic and social stress brought on by the pandemic, 
have coincided with reports of increased numbers of women and girls facing abuse in 
many countries. Experiences during the Ebola crisis showed that school closures can 
lead to increases in gender-based violence, teenage pregnancies, child marriage, 
exploitation and other forms of abuse against adolescent girls. Lockdowns associated 
with COVID-19 are also adding to the disproportionate caregiving burdens borne by 
women and girls. 
 
 
What is working and needs to be sustained 
There have been Important gains in increasing women and girls' access to HIV prevention and 
treatment. From 2010 to 2019, the number of new HIV infections among women globally 
declined by 23%, including a 13% decline since 2015. The declines have been steepest among 
young women. However, new HIV infections among women are increasing in eastern Europe 
and central Asia, the Middle East and North Africa and Latin America. Women’s access to HIV 
treatment has improved, with 73% of women living with HIV receiving ART in 2019. The decline 
in AIDS-related mortality since 2010 has been greater for women than for men. 
A broad array of proven strategies is available for empowering women and girls and addressing 
their HIV-related needs. There is growing momentum towards a comprehensive, multisectoral 
approach that reaches beyond the health sector, is gender-transformative and rights-based, and 
can address the social, economic and structural drivers that increase HIV risk and vulnerability 
for women and girls. Effective combination prevention for women and girls includes enabling 
girls to stay in school longer, incentives to delay sexual activity and pregnancy, comprehensive 
services that integrate HIV and sexual and reproductive health, prevention of gender-based 
violence, enhancing women’s economic participation and fair remuneration for work, engaging 
both men and women in addressing harmful gender norms, and improving the range of HIV 
prevention options available, including by expanding access to PrEP. The multipartner, 
PEPFAR-led DREAMS initiative, which aims to reduce new HIV infections among adolescent 
girls and young women in high-incidence areas of sub-Saharan Africa, uses a multisectoral 
approach that includes youth-friendly sexual and reproductive health services, education 
subsidies, social protection, parenting programmes and HIV services. 
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The evidence base for multisectoral approaches for women and girls is robust and expanding. 
Several studies—including the Sitakhela Likusasa study in Eswatini, which documented 
declines in HIV infection of up to 25% among participants—have found that cash transfers can 
be an effective method for enabling young people, particularly girls, to stay in school, improving 
their academic results, increasing their use of health services, delaying their sexual debut, 
reducing early marriage and teen pregnancy and promoting safer sexual behaviours (71, 86). In 
Botswana, each additional year of secondary schooling led to an 8.1% reduction in cumulative 
risk of HIV infection and an 11.6% reduction in HIV risk among young women (87). Several 
programmes—including SASA!, Stepping Stones, Program H and One Man Can—have found 
that community-wide interventions engaging both men and women can change harmful social 
norms, reduce gender-based violence and prevent HIV. Studies in Botswana, Cameroon, 
Kenya, Malawi, South Africa, United Republic of Tanzania, Uganda and the United States of 
America showed that integrated HIV and sexual and reproductive health services are 
associated with increased uptake of HIV testing and other services (88). In South Africa, 
incorporation of PrEP in routine family planning services has achieved PrEP retention rates of 
92% among women (89). The engagement of faith leaders in gender-transformative approaches 
in the Democratic Republic of the Congo and of men in reproductive and maternal health in 
Rwanda have been associated with reduced sexual violence, improved contraceptive use, 
enhanced women’s antenatal health and more equitable divisions of labour in households (45, 
90). 
Important, though still inadequate, investments have been made to empower, mobilize and build 
leadership capacity among women and girls. Notable among these are the contributions of 
PEPFAR and the Global Fund, as well as efforts by UN Women to support the meaningful 
engagement of women living with HIV and adolescent girls and young women in the design, 
implementation and monitoring of national HIV responses (91). In the Middle East and North 
Africa, evidence of the links between gender-based violence and HIV has encouraged greater 
emphasis on the involvement and empowerment of women in all their diversity in national 
programmes. A number of policy and legal reforms have been introduced in the past decade to 
uphold women’s human rights in line with the Beijing Platform for Action and the Convention on 
the Elimination of all Forms of Discrimination Against Women. One hundred and fifty-five 
countries have strengthened legislation to combat violence against women and girls, and more 
countries have integrated HIV into their national action plans on preventing violence against 
women (84). However, support for grassroots responses remain inadequate, with feminist 
organizations, key leaders in catalysing gender-responsive approaches, receiving only a very 
small share of donor funds. 
Where the response is falling short 
Stronger political will is needed to address the human rights and needs of women and girls. The 
epidemic’s continuing burden on women and girls and the persistence of unequal gender norms 
and practices reflect a disturbing absence of political commitment to responding to the needs of 
women and girls. Only 57 of the 97 countries with a national strategy or policy guiding their 
AIDS responses in 2019 reported that the policy included interventions for achieving gender 
equality, and only 37 countries had a dedicated budget for those activities (92). Notwithstanding 
the pledges made in the Beijing Platform for Action for transformative progress to advance 
women’s rights, progress against key indicators has lagged. In the past 20 years, progress on 
women’s access to paid work has slowed, with less than two thirds of women between the ages 
of 25 and 54 years active in the labour market. Women continue to shoulder the bulk of unpaid 
care and domestic work. Men still occupy about three-quarters of parliamentary seats. Twice as 
many girls as boys aged 15-19 years are out of school or out of work. Globally, about 132 
million girls were out of school prior to the COVID-19 pandemic, including 34.3 million girls of 
primary school age, 30 million of lower-secondary school age, and 67.4 million of upper-
secondary school age (93). COVID-19 has worsened those trends.  
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Figure 47. Percentage of women (aged 15–49 years) with comprehensive correct 
knowledge of HIV, by wealth quintile, countries with available data, 2013–2018 
 
Source: Demographic and Health Surveys, 2013–2018. 
Although a handful of countries have conducted gender analysis to understand the root causes 
of the HIV epidemic among women and girls, the analysis is seldom translated into appropriate 
actions and budgetary allocations. A review of 18 national HIV strategic plans in sub-Saharan 
Africa showed limited sex-disaggregated targets and an overriding focus on the prevention of 
gender-based violence and women’s access to family planning. By contrast, strategies to 
integrate sexual and reproductive health and HIV programmes, improve rights or access to 
resources for women and girls and increase school access and attendance by adolescent girls 
and young women were identified in fewer than 6 of the 18 strategic plans that were analysed 
(92). Data on costing and financing gender-transformative interventions in national HIV 
responses remain scarce. Further work is needed to integrate gender-responsive actions and 
indicators in national HIV programmes, strategies and plans and ensure that these actions are 
costed and adequately resourced. Additionally, in order to ensure adequate expenditure and 
effective gender related outcomes, meaningful engagement of women living with HIV and 
adolescent girls and young women in all their diversity must be institutionalized in design, 
implementation and monitoring of the HIV response.  
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Figure 48. Percentage of women aged 15–49 years who are currently married or in union 
who are currently using contraceptives and who make their own informed decisions 
regarding sexual relations, contraceptive use and own health care, countries with 
available data, 2014–2018 
 
Source: Population-based surveys, 2014–2018. 
Knowledge about HIV prevention among young women is alarmingly low, with only about one-
third of young women in sub-Saharan Africa having comprehensive knowledge about HIV (94). 
Between 2000–2004 and 2014–2018, several countries made encouraging progress in 
improving young women’s HIV knowledge, with accurate and comprehensive knowledge 
increasing in Uganda (from 28.5% to 45.7%), Rwanda (23.4% to 42.6%), Nigeria (14.5% to 
42.6%), Kenya (33.8% to 54.2%), Cameroon (27.4% to 40.6%) and Armenia (9.3% to 20.2%) 
(94). 
Studies indicate that comprehensive sexuality education which emphasizes gender relations 
and women's rights can reduce the rates of sexually transmitted infections and unintended 
pregnancy, as well as gender-based and intimate partner violence. It can also support young 
women’s self-efficacy and confidence, and help young people develop stronger, healthier 
relationships. In Estonia, where a mandatory programme of comprehensive sexuality education 
has been implemented, it was found that the programme would need to avert only 4% of new 
infections to be cost-saving (61). 
Sexual and reproductive health and rights are not upheld. Sexual and reproductive health and 
rights are central to empowering women and adolescent girls, fulfilling their human rights, 
ensuring their health and wellbeing, creating gender-equal societies and economies, and 
preventing HIV infections. In 57 countries, only 55% of married or in-union women (aged 15–49 
years) currently using contraception are able to make their own decisions regarding their sexual 
and reproductive health including to refuse unwanted sex (95). Moreover, there is little sign of 
improvements in women’s agency (Figure 48) (96). 
Women’s lack of freedom and agency to make decisions regarding their sexual and 
reproductive health results in inadequate uptake of essential interventions and tools. More than 
half of the estimated 38 million sexually active adolescent girls (aged 15–19 years) in 
developing regions in 2016 who needed contraceptives because they were married or were 
unmarried and sexually active and did not want a child for at least two years, were not using 
modern contraceptives. Each year, 21 million adolescent girls become pregnant and 
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approximately 12 million adolescent girls give birth, including 777 000 girls under the age of 15 
(97, 98). One in three women living with HIV in 19 countries report experiencing at least one 
form of discrimination related to their sexual and reproductive health in a health-care setting in 
the previous 12 months (e.g. being advised not to have children, being offered ART on condition 
they use certain forms of contraception, or being denied sexual and reproductive health 
services) (99).  
Policy barriers undermine HIV responses for adolescent girls. Laws and policies prevent many 
adolescent girls from making decisions about their own sexual and reproductive health or 
accessing essential health services, including for contraception and HIV-related services.  In 
2019, 105 of 142 countries with available data required that adolescents have parental or 
guardian consent to access HIV testing. In 86 of 138 reporting countries, they needed similar 
consent to access HIV treatment and care. A recent multicountry review in sub-Saharan Africa 
found that laws allowing young people younger than 16 years to access HIV testing without 
parental consent were associated with a 74% increased likelihood of HIV testing utilization 
among adolescents (100). Discriminatory criminalization laws linked to HIV can 
disproportionately affect women, as women are more likely than men to know their HIV status 
as a result of routine HIV screening in antenatal care.      
Violence against women and girls increases their vulnerability to HIV and impedes an effective 
HIV response. Nearly 1 in 3 women worldwide have experienced physical and/or sexual 
violence by an intimate partner, nonpartner sexual violence, or both in their lifetime (Figure 49) 
(101). Reports indicate that COVID-19 lockdowns may be increasing women’s risks of domestic 
violence. Globally, one in every five girls is married, or in union, before reaching age 18 (102).  
Figure 49. Percentage of ever-married or partnered women (aged 15–49 years) 
who experienced physical and/or sexual violence by an intimate partner in the 
previous 12 months, countries with available data and regional aggregates, 2014–
2018 
 
Source: Population-based surveys, 2014–2018. 
Note: Aggregates refer to the most recent data available from population-based surveys during the period 2014 to 2018. Data 
coverage of aggregates: total: 46 countries, 43% of 2018 population; Asia and the Pacific: 12 countries, 48% of 2018 population; 
Caribbean: 3 countries, 40% of 2018 population; eastern and southern Africa: 11 countries, 84% of 2018 population; Latin America: 
6 countries, 41% of 2018 population; western and central Africa: 10 countries, 85% of 2018 population. Aggregates for eastern 
Europe and central Asia, the Middle East and North Africa, and western Europe and North America are not shown, as data were 
available for few countries for the period 2014 to 2018. 
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Figure 50. Children (aged 13‒17 years) and young people (aged 18‒24 years) who 
experienced one or more types of violence in childhood, countries with available data, 
2014‒2017 
 
Source: Violence against children surveys, 2014‒2017. 
Women and girls who are on the move, including refugees, the internally displaced and those 
affected by conflict and other humanitarian crises, are particularly at risk of violence, and they 
are often less able to access appropriate services (103). Although the prevalence of violence 
among women is intolerably high, some countries have managed to reduce the prevalence of 
intimate partner violence, including Uganda (from 43% in 2006 to 30% in 2016), Zambia (42% in 
2007 to 25% in 2018), Mozambique (28% in 2011 to 16% in 2015) and the Democratic Republic 
of the Congo (59% in 2007 to 37% in 2013–2014) (104). 
 
For many women and girls, the experience of violence begins at an early age. In nine countries, 
substantial proportions of young women and men (aged 18–24 years) reported having 
experienced physical, sexual and/or emotional violence during childhood (Figure 50) (105). 
About 120 million girls are estimated to have suffered some form of forced sexual contact before 
age 20 years (106).  Violence in schools is also a grave concern. Early experience of violence 
increases the odds that women will experience violence later in their lives. For men, it also 
increases the odds that they themselves will perpetrate violence (45). 
 
In addition to affecting the physical and mental health of survivors, violence is closely linked with 
HIV vulnerability. The experience of intimate partner violence in high-prevalence settings 
increases women’s risk of acquiring HIV (101). Violence against women living with HIV is 
associated with reduced access and adherence to treatment, lower CD4 counts and higher viral 
load (107). 
 
The cycle of violence against women and girls is rooted in unequal gender power dynamics and 
norms. For women and girls living with HIV, their HIV status can also be a trigger for physical 
and/or emotional violence—including from partners, in the community and even in health 
facilities. Involuntary and coerced sterilization and forced abortion among women living with HIV 
has been reported in at least 14 countries worldwide (108). In the majority of 43 countries with 
recent data from population-based surveys, more than 40% of young women said that a 
husband is justified in hitting or beating his wife (Figure 51) (109). Gender-transformative 
approaches that address the causes of gender-based power imbalances and that work to 
transform harmful gender norms and relations have been shown to reduce violence and 
improve a range of health- and gender-related behavioural outcomes (110). However, 
investments in gender-transformative approaches are limited, with a recent review finding that 
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only 8% of programmes engaging men and boys in sexual and reproductive health and rights 
included gender-transformative components (111).  
 
Figure 51. Percentage of women and men aged 15–24 years who agree that a 
husband is justified in hitting or beating his wife for at least one specific reason, 
countries with available data, 2014–2018 
 
Source: Demographic and Health Surveys, 2014–2018. 
Women who belong to key populations are at particular risk of experiencing violence. Women 
who use drugs are up to five times more likely to experience violence than non-drug-using 
women. It is estimated that 45–75% of female sex workers are assaulted or abused at least 
once in their lifetime, although mechanisms for reporting abuse or accessing survivor services 
are often blocked due to the criminalization of sex work (112). Women belonging to ethnic and 
other minorities, transgender women and women with disabilities face higher risks of violence 
(103).  
Future strategic directions: key questions for consideration 
● Notwithstanding repeated high-level pledges, political commitment to uphold the 
human rights and meet the needs of women and girls in the context of HIV is not yet 
strong enough. What strategic actions are required to build and sustain powerful 
national actions to cost, finance, implement and monitor gender-transformative 
approaches that tackle gender discrimination and benefit women and girls in all their 
diversity? 
How can we build robust multisectoral collaborations and coalitions to drive changes in 
gender norms and practices, at the scale needed? How we can substantially increase 
financing for the networks of women living with HIV and organizations of adolescent girls 
and young women to sustain their advocacy work and community-level response? 
● What strategic actions are needed to address the vulnerabilities and needs of 
marginalized women and girls? 
How can we effectively adopt and implement an intersectional approach, with measurable 
metrics, to address the needs of those who are left behind? How can women most in need 
of comprehensive packages be prioritized and reached? What arguments, analyses, 
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advocacy approaches are required to uphold women’s rights, including to roll back punitive 
laws targeting women who belong to key populations or who are partners of members of key 
populations? How do we replicate successes in eliminating age of consent laws and barriers 
in more countries? What is needed to ensure that marginalized women and girls have safe 
spaces where they can seek and provide mutual support and obtain needed services?  
 
● How can we systematically engage, empower and address the needs of diverse 
gender identities/expression, sexual orientations and thereby also address gender-
based violence directed against LGBTI people? 
● What strategic actions are needed to drive programmatic progress in addressing the 
needs of women and girls? 
How can we further strengthen gender expertise in national AIDS coordinating bodies to 
conduct gender analysis and develop gender-responsive HIV strategies, plans and 
programmes? How do we galvanize genuine large-scale integration of holistic, multisectoral 
approaches to address the linked challenges of HIV, sexual and reproductive health and 
rights and gender-based violence? How do we identify and effectively use lessons from 
settings where the prevalence of gender-based violence or teenage pregnancy has declined 
or where HIV knowledge among young women has increased? What steps are needed to 
avoid regressing in the COVID-19 era with respect to women and girls? What steps are 
needed to use the experiences of women and community-led HIV responses that have been 
effective in transforming harmful gender norms and practices and improving HIV services for 
women and girls? How do we accelerate the repealing of discriminatory laws and practices 
that affect women and girls’ abilities to prevent HIV or to live dignified lives with HIV? 
● What strategic actions are required to catalyze the involvement, empowerment and 
leadership of women in all their diversity––specifically in national HIV responses but 
also in broader efforts to improve health, wellbeing, equity and justice for women and 
girls? 
● What strategic actions are needed to expand gender-transformative approaches that 
engage men and boys in confronting harmful masculinities and becoming agents of 
change, and that shift the burden of responsibility away from women for 
contraception, HIV testing and treatment? 
How can we ensure a life course approach to sexual and reproductive health and rights that 
includes men in childbirth and care, family health and support and that addresses harmful 
masculinities and femininities? What steps are needed to recognize and respond to the 
gender inequalities and dynamics within LGBTI communities? 
● What strategic actions are needed to improve the data for effective strategies for 
women and girls? 
What strategic actions are needed to improve the capacity to perform gender analysis and 
use it to guide actions, measurement metrics and budgetary allocations?  
● How do we do a better job of mainstreaming key elements of promoting gender 
equality and ending gender-based violence across other strategic directions of the 
next UNAIDS Strategy to increase accountability of the HIV response to gender 
equality and the empowerment of all women and girls?  
How do we improve the measurement of progress across the UNAIDS Strategy vis-à-vis 
promoting gender equality and ending gender-based violence? How do we enhance 
accountability for gender-responsive financial monitoring of allocations and expenditures on 
gender equality and ending gender-based violence in the next UNAIDS Strategy? 
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Stigma, discrimination, and punitive 
laws: towards enabling social and legal 
environments 
 
Since its early days, the HIV epidemic has been accompanied by a "social epidemic" of stigma, 
discrimination and social exclusion, which is often anchored in harmful, punitive, 
counterproductive and scientifically baseless laws and policies. Ending AIDS will require 
progress in the biomedical arena and towards eliminating the many forms of stigma and 
discrimination that deny people their rights and dignity, and that undermine HIV responses and 
national social and child protection systems. 
● HLM Commitment 9: Empower people living with, at risk of and affected by HIV to know their 
rights and to access justice and legal services to prevent and challenge violations of human 
rights. 
● HLM Commitment 6: Ensure that 75% of people living with, at risk of and affected by HIV 
benefit from HIV-sensitive social protection by 2020. 
● Strategy Result Area 6: Punitive laws, policies, practices, stigma and discrimination that 
block effective responses to HIV are removed. 
● Strategy Result Area 8: People-centred HIV and health services are integrated in the 
context of stronger systems for health. 
 
Status report 
 
Although HIV-related stigma, as measured by population-based surveys, appears to have 
declined in some countries, it persists at extremely high levels in many others. In 25 of 36 
countries with recent survey data on a composite index of discriminatory attitudes, more than 
50% of people aged 15-49 years displayed discriminatory attitudes towards people living with 
HIV (104). HIV-related discrimination continues to occur in health-care settings. Among the 13 
countries reporting these data, up to 21% of surveyed people living with HIV in Peru and 
Tajikistan said they had been denied health services at least once in the previous 12 months 
(113).  
 
Punitive laws remain commonplace. Nearly all countries criminalize or otherwise punish some 
aspect of sex work, and all but a handful of countries criminalize or otherwise punish drug use 
or possession (Figure 52). A majority of the 92 countries reporting these data to UNAIDS 
criminalize HIV transmission, non-disclosure or exposure. Sixty-nine countries criminalize same-
sex relations, and at least 32 countries either formally criminalize or have prosecuted 
transgender people because of their gender identity and/or expression.  
 
Key populations face stigmatizing attitudes and violence. In 8 of 36 countries with recently 
available data, at least half of sex workers reported that they had experienced physical violence 
(Figure 53). Similarly, in 4 of the 17 countries providing these data, more than 20% of gay men 
and other men who have sex with men reported experiencing sexual violence. High rates of 
violence against transgender people and people who inject drugs have also been reported in 
the limited number of countries with relevant data (114).  
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Figure 52. Countries with discriminatory and punitive laws, global, 2019 
 
Figure 53. Percentage of sex workers who reported experiencing physical and sexual 
violence, selected countries, 2014–2018 
 
 
Source: Literature review by UNAIDS and the Key Populations Program of the Center for Public Health and Human Rights, Johns 
Hopkins University. Full list of references available on request.  
Punitive laws undermine HIV responses and increase the vulnerability of marginalized 
populations. Gay men and other men who have sex with men who live in countries that 
criminalize same-sex relations are 2.2 times more likely to acquire HIV than their counterparts 
in countries without such legal restrictions. Severe criminal penalties for same-sex relations are 
associated with a 4.7 times higher risk of HIV infection, compared with settings lacking such 
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penalties (83). According to an analysis of 75 countries, the existence of anti-LGBT laws is also 
associated with substantially lower uptake of HIV testing services (81). Evidence-based 
modelling indicates that decriminalization of all aspects of sex work could avert 33–46% of new 
HIV infections among sex workers and their clients over 10 years (69). Another meta-analysis 
found that repressive policing of sex work increased the prevalence of HIV and other sexually 
transmitted infections by 87% and increased the risk of sexual or physical violence nearly 
three-fold (115). A 2020 study examining 10 countries in sub-Saharan Africa linked increasingly 
repressive laws regarding sex work with increased prevalence of HIV infection (116). According 
to a 2017 systematic review, more than 80% of pertinent studies have correlated criminalization 
of drug use with an increased risk of HIV (68), while a separate analysis found that repressive 
policing of drug use is associated with HIV infection, needle sharing and avoidance of harm 
reduction programmes (117). In some countries in eastern Europe and central Asia, laws 
require individuals seeking harm reduction services to register with authorities, a step that in 
turn makes the individual ineligible for a driver’s license. Although study evidence of the HIV-
related impact of punitive laws on transgender people is scarce, the harm associated with 
repressive policing of transgender people is well-documented. Approximately 40% of 
transgender correctional inmates have experienced sexual violence in the previous 12 months, 
compared to 4% of the general prison population (118).  
 
Access to justice remains restricted for many people living with HIV and members of key 
populations. Most countries (69 of 90) have reported the existence of legal aid systems 
that are capable of handling HIV-related case work (Figure 54). However, accessible legal 
services (in the form of legal clinics or pro bono services from private law firms) are much 
less common. Most countries report having in place training or capacity-building initiatives 
to assist people living with HIV and key populations to understand and exercise their rights 
in the context of HIV, although these are operating at a small scale in many settings. Most 
countries report that they do not have HIV-related legal rights training in place for key 
actors in the judicial system including law enforcement officers, the judiciary and 
legislators.  
Figure 54. Countries with mechanisms in place to promote access to affordable legal 
services, 2019 
 
Source: UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/). 
Note: Data correspond to reporting by national authorities from 90 countries and by civil society representatives from 89 countries. 
The National Commitments and Policy Instrument consists of two parts, the first completed by national authorities and the second 
by civil society and other nongovernmental partners engaged in the national response. 
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Table 8. Effective coverage of social protection benefits and HIV-sensitivity of social 
protection strategies, policies or frameworks in Fast-Track countries, 2019 and 2020 
 
Source: UNAIDS National Commitments and Policy Instrument, 2019 and 2020 (see http://lawsandpolicies.unaids.org/); SDG 
Indicators Global Database [Internet]. New York: United Nations Statistics Division; c2020 
(https://unstats.un.org/sdgs/indicators/database/, accessed 17 April 2020). 
*Social protection strategy is not being implemented. 
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Women’s access to property and inheritance rights can be vital for preventing HIV infection or 
mitigating its impact. Yet, customary laws and practices continue to inhibit women’s access to 
land in 90 countries, daughters do not have the same inheritance rights as sons in 34 countries, 
and widows lack inheritance rights in 36 countries (119). Women living with and affected by HIV 
often do not have the economic means to access legal aid and receive adequate justice. 
Only two countries (the Islamic Republic of Iran and Mozambique) reported that all HIV-
sensitive elements are reflected in a national social protection strategy that is currently being 
implemented (120). Across 25 reporting countries with high HIV burdens, the proportion of the 
population covered by at least one social protection benefit ranged from 1.6% in Myanmar to 
90% in the Russian Federation, with a median of 15%. Less than half of the population was 
covered by at least one social protection benefit in 19 of the 25 countries with available data 
(121). 
 
COVID-19 and social and legal barriers and enablers 
 
In some contexts, efforts aimed at controlling the spread of the coronavirus have 
penalized the most vulnerable in society, including women, the homeless, those living 
in poverty, or people who are already marginalized, stigmatized or criminalized. There 
have been alarming reports of police harassing, harming or arresting vulnerable and 
criminalized groups, such as sex workers, people who use drugs, people living with 
HIV and LGBTI people. Sex workers have reported increased discrimination and 
harassment, including punitive crackdowns resulting in raids on homes, compulsory 
COVID-19 testing, and arrests and threatened deportation of migrant sex workers. 
 
The COVID-19 pandemic has also reinforced the absolute importance of strong and 
comprehensive social protection, as well as how many people currently live without it. 
During COVID-19 people living with, at risk of, and affected by HIV, including key 
populations, young people, women, and girls, those living with disabilities, refugees, 
asylum seekers and migrants are especially vulnerable to economic, spatial and social 
inequalities and the disruptions in the provision of, and adequate access to, essential 
services and social assistance. Many are living in a state of food insecurity and 
malnourishment. Loss of income has also meant in some cases loss of their homes, 
while lack of health insurance or access to health care has created barriers to receiving 
COVID-19-related care. 
 
What is working and needs to be sustained 
 
Discriminatory attitudes towards people living with HIV have declined in some countries. In 19 
countries where people were surveyed about their attitudes about people living with HIV, 
stigmatizing attitudes have declined since the early 2000s (96). There has been striking 
progress in reducing stigmatizing attitudes in eastern and southern Africa. However, stigma and 
discrimination remain powerful barriers to HIV services. In high-burden countries, people who 
perceive comparatively higher levels of HIV-related stigma are twice as likely to present late 
with HIV infection than individuals who perceive low stigma (122).  
 
There are encouraging examples of countries that have rolled back punitive laws and policies. 
Since 2016, Chile, Pakistan and Uruguay have shown leadership by formally recognizing 
gender identity and by introducing legal protections for transgender people. The Caribbean 
Court of Justice invalidated a law banning cross-dressing in public, and several countries (e.g. 
Belgium, Chile, France, Greece, Iceland, Luxembourg, Portugal and Uruguay) established 
avenues for legal changes to gender markers and names, although some still require surgery 
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before allowing people to change their gender markers. Globally, the number of countries and 
territories that have HIV-related restrictions in place for entry, stay or residence has decreased 
to 48 in 2019 (123). Since 2016, the Constitutional Court of Colombia has removed some 
restrictions on the personal consumption of drugs; courts in South Africa and Mexico held that 
laws criminalizing possession or cultivation of marijuana were unconstitutional; legislative 
bodies in Antigua and Barbuda, Belize and some states in the USA decriminalized possession 
of marijuana. A number of countries have removed the death penalty as either a mandatory or 
discretionary option for certain (but not all) drug offences (including the Islamic Republic of Iran, 
Malaysia, Thailand, Singapore and Viet Nam). In Malawi, the High Court found that laws which 
criminalize profiting from sex work were not intended to target sex workers. The number of 
countries criminalizing same-sex relations has continued to decline in recent years (Figure 55), 
with Botswana and India removing longstanding prohibitions. Since 2016, Colombia and Mexico 
removed their HIV criminalization laws, while Belarus, Canada and the Democratic Republic of 
the Congo narrowed the situations in which people living with HIV may be prosecuted or 
convicted, and Malawi opted not to include criminalization provisions in its new HIV laws.  
 
Figure 55. Number of countries that criminalize consensual same-sex sexual 
relations, global, 1969–2018 
 
 
Those examples are heartening evidence that punitive and counterproductive laws and policies 
can be changed or removed. However, punitive and discriminatory legal and policy frameworks 
remain the norm in much of the world, and they are holding back HIV responses.  
The evidence base for removing punitive laws and policies has expanded. Numerous studies 
and meta-analyses on the impact of punitive laws on HIV responses (summarized in the status 
report above) provide evidence that bolsters the efforts of advocates and public health experts 
to remove such counterproductive laws. The publication of a consensus statement on the 
science of HIV in the context of criminal law has strengthened litigants' and advocates' 
arguments that HIV criminalization laws are not grounded in science (124). The 2018 release of 
a supplement to the previous report of the Global Commission on HIV and the Law underscored 
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the consensus of public health experts that punitive laws undermine HIV responses, cause 
needless suffering and should be removed (125). 
Encouraging initiatives have increased support for human rights programming. The Global 
Fund’s Breaking Down Barriers Initiative allocated more than US$ 78 million in 2017–2019 to 
support efforts in 20 countries to reduce human rights barriers to HIV, TB and malaria services 
(126). Those countries have completed baseline human rights assessments, and 8 of them 
have adopted (as of June 2020) strategic national plans to reduce human rights barriers to 
services.  
UNAIDS, UN Women, UNDP and the Global Network of People Living with HIV (GNP+) are co-
convening the Global Partnership for Action to Eliminate All Forms of HIV-related Stigma and 
Discrimination to accelerate achievement of the Zero Discrimination agenda. Sixteen countries 
have joined the partnership, committing to address HIV-related stigma across six domains: 
health care, education, workplace, justice, individuals and communities and emergency and 
humanitarian settings. 
UNAIDS and partners have mobilized stronger political support for HIV-sensitive social 
protection in the past five years. The Joint Programme’s advocacy and data on social protection 
and HIV, such as the impact of cash transfers, has been especially important, reflecting the 
work of the UNAIDS Interagency Task Team on HIV and Social Protection, hosted by UNAIDS, 
co-led by UNICEF and the World Bank, and including ILO, UNDP, WHO and WFP. The Task 
Team led the generation of evidence and publicized the impact of social protection (including 
cash transfers) on HIV prevention, treatment, care and support. The Task Team includes 
governments, civil society and academics working on HIV, TB and social protection.  
Social protection assessments led by governments in 16 countries have provided a platform for 
building and strengthening linkages between governments, donors and communities of people 
living with HIV. These linkages have promoted the inclusion of people living with HIV in existing 
social protection programmes. The assessments are informing the development of a new social 
protection policy in the United Republic of Tanzania and the inclusion of social protection 
elements in Global Fund proposals d in Liberia, Namibia, Sierra Leone and Zambia. 
UNICEF, WFP, UNAIDS, the World Bank and partners have collaborated on cash-based 
transfer programmes, including the “Cash Plus” approach for adolescents in eastern and 
southern African countries, and the Village Saving Loan Association in Cameroon (which 
reaches nearly 1000 people living with HIV). UN Women reached over 30 000 HIV-vulnerable 
women and 6500 women living with HIV with income generation support in 14 countries. UNDP 
supported 38 countries in HIV-sensitive social protection. Following a UNDP-supported study in 
Sudan, technical support to government and civil society increased social protection measures 
to reach more than 4000 people living with HIV with health insurance cards.  
 
 
Where the response is falling short 
While discriminatory attitudes have declined in some settings, they remain common and 
continue to constitute a major barrier to an effective response. Regionally, the prevalence of 
stigmatizing attitudes towards people living with HIV ranges from 32% in eastern and southern 
Africa to 66% in the Middle East and north Africa (127). In 34 of 36 reporting countries, over 
25% of people (aged 15–49 years) reported discriminatory attitudes and those attitudes are 
becoming more common in some countries. 
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Notwithstanding progress in some countries, punitive laws and policies remain commonplace, 
and the legal and policy environment has deteriorated recently in some settings. Punitive, 
scientifically unsound and harmful laws and policies remain the norm globally with respect to 
most key populations. The ability of people living with HIV to travel remains limited or foreclosed 
altogether in 48 countries and territories. While a few countries have moved towards 
decriminalizing personal drug use/possession, the changes apply mainly to marijuana use only. 
For sex work the trend has been increased criminalization. Since 2016, the legal situation for 
key populations has worsened in several respects. A number of countries, including France and 
Iceland, have introduced end-demand or end-user criminal laws for sex work.  
While the judicial invalidation of India’s law criminalizing same-sex relations reduced the 
proportion of the world’s population covered by such laws, at least 69 countries retain laws that 
criminalize same-sex sexual relations. At least two countries, Chad and Gabon, recently 
criminalized same-sex consensual relations, though Gabon removed the law in 2020, and high-
level efforts were initiated in Brunei and Liberia to do the same. Some countries, including in 
Eastern Europe, have introduced, or attempted to introduce, “anti-propaganda” laws that stifle 
LGBTI communities and their organizations, and in some cases, prevent the distribution of 
information on sexual and reproductive health rights and HIV transmission under the pretext of 
“protecting minors”. Poland in 2020 introduced stronger penalties for HIV exposure and 
transmission, while Hungary enacted legislation that would prevent transgender people from 
being able to legally change their gender markers, while Oman intensified penalties for “cross-
dressing.” 
Data gaps undermine our ability to understand, assess and effectively respond to the human 
rights situations. Greater efforts are needed to collect and make full use of additional and new 
data, e.g. by including stigma, shame and harassment modules in biobehavioural surveys, 
collecting data on human rights issues (which the Global Fund now requires), and supporting 
community-led HIV monitoring. Much stronger data on the experiences of key populations are 
needed, and pertinent data should be disaggregated by age, race and gender. Information on 
discrimination in health-care settings needs to be captured systematically. Existing data 
systems provide little information on harassment. The impact of punitive laws on transgender 
people should be investigated more methodically.  
Linking important women’s rights monitoring mechanisms, such as CEDAW, to the HIV 
response is vital for monitoring, identifying and addressing specific human rights violations 
against women living with and affected by HIV. At the same time, new digital technologies for 
surveillance and service delivery may pose human rights risks for stigmatized and criminalized 
populations. 
The pace, scale and investments in efforts to address HIV-related stigma and discrimination 
remain insufficient. Although the inclusion of the zero-discrimination goal in the UNAIDS 
Strategy drew attention to the persistent barriers associated with stigma and discrimination, the 
necessary resources and programmatic efforts for tackling social and legal barriers have not yet 
materialized. Stronger efforts are required to address the root causes and consequences of 
stigma, discrimination, gender inequality, violence against women, and other social and 
structural dynamics.  
Fifty-five per cent of the world’s population lacks social protection. In many countries, social 
protection programmes do not explicitly include people living with HIV and some countries 
exclude sex workers or people who use drugs from social protection programmes. Only two 
countries report that all HIV-sensitive elements are reflected in their social protection strategies.  
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Future strategic directions: key questions for consideration 
● Given the limited success to date in “moving the needle” on reforming or removing 
punitive and discriminatory laws and creating enabling legal environments, what are 
the key elements of a new strategy to accelerate human rights progress in the HIV 
response? 
For example, do we need different targets? How do we use international mechanisms and 
actors to drive change? What types of investments and incentives would help? 
● How do we better share lessons and strategies across countries to bring about 
desired changes in policies and laws? 
Is it possible to distil and effectively use lessons from successful efforts to accelerate social 
change? Is a deeper dive warranted to identify lessons from successful law or policy 
changes (e.g. the longitudinal studies in Argentina and Portugal on the process for changing 
laws on gender and drug policy, respectively)? 
● Recognizing that decriminalization is a key outcome of a process of social change, 
does the next UNAIDS Strategy need a broader set of targets with respect to stigma, 
discrimination and punitive laws? 
Are additional targets needed to track important precursors to law and policy change? 
Should steps be taken to improve synergies between human rights and critical enabler 
targets? 
● How do we use the available evidence to drive change? What strategic actions are 
needed to close the remaining data gaps in the human rights response to HIV?  
How do we make use of important data developments and surveillance mechanisms (e.g. 
biobehavioural surveys, Global Fund mandates for reporting, community-led monitoring) to 
collect the evidence that can help drive action on stigma, discrimination and punitive laws? 
How do we support countries and communities to own their data collection processes and 
become better at capturing the experiences of key populations and women and girls, 
documenting health-care discrimination, monitoring police harassment, enhancing data 
disaggregation within populations and effectively documenting the impact of punitive policies 
(including on transgender people)? How can we engage more researchers from the global 
South in key population research? 
● Recognizing that evidence alone is insufficient to persuade decision-makers to 
remove punitive laws, what changes in advocacy approaches are needed to 
accelerate progress? 
Should we focus more on principles of human rights, equality and non-discrimination rather 
than love and affection when advocating for the removal of punitive laws that target sexual 
minorities? Is it possible to take advantage of important societal changes (e.g. growing 
concern regarding police brutality) to drive changes in law enforcement practices and 
legal/policy frameworks? 
● What strategic actions are needed to optimally leverage the Global Partnership for 
Action to eliminate all forms of HIV-related stigma and discrimination to promote 
stronger action against stigma, discrimination and punitive laws? 
How do we effectively engage and persuade key actors (e.g. police, judiciary, education 
sector, workplace) to advance progress on human rights issues? How can we contribute 
further to sensitizing health-care providers? Should we expand our focus on stigma and 
discrimination into areas besides HIV? How do we build the political for strong action in 
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countries that have joined the Partnership? How do we use other processes, such as Fast-
Track Cities, to bypass national barriers or the lack of progress with local policies and 
programmes? How can we institutionalize human rights funding as a core part of HIV and 
health work, capitalizing on the Global Funds investments while also moving to a diversity of 
human rights funders at the international and national levels? How can we effectively 
address stigma and discrimination in the Partnership’s six core settings? How do new digital 
technologies fit in to this? 
● How can the global HIV response help strengthen the basic functioning of social 
protection programmes to better respond to the needs of people living with, at-risk of 
and affected by HIV? 
How do we effectively work with countries to link and layer their programmes? How do we 
make sure adolescent girls and young women are able to access the full benefits of social 
protection schemes to achieve gender equality and reduce HIV infection rates? How can the 
global HIV response strengthen civil society organizations' active engagement  on HIV and 
social protection to reach populations who are being left behind? How can the HIV response 
prioritize countries, geographic areas and populations for interventions that can enhance 
access to HIV and social protection benefits? 
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Communities and the HIV response 
 
Communities are the conscience and the engine of the HIV response.  
• HLM Target 7: Ensure that at least 30% of all service delivery is community-led by 2020. 
• Strategy Result Area 7: AIDS response is fully funded and efficiently implemented based on 
reliable strategic information. 
Status report 
Responses led by communities living with and affected by HIV have been the backbone of the 
HIV response since the beginning of the epidemic. Since 2016, communities have expanded 
their activities and partnerships to become essential actors in HIV responses and health 
systems in many parts of the world. Although the evidence of the central and growing role of 
communities in the HIV response is overwhelming, measuring the evolution of community-led 
responses has proved challenging, due partly to the lack of agreed metrics in the current 
UNAIDS Strategy. To address this issue, civil society and governments are working within the 
UNAIDS PCB to produce recommendations on the use of definitions for community-led 
responses to HIV.  
 
COVID-19, communities and the HIV response 
 
In 2020, as the COVID-19 pandemic disrupted primary health-care access across the 
world, the importance of community-led service delivery became more apparent than 
ever, with community systems providing lifelines for vulnerable people. Communities 
have stepped up to lead local COVID-19 responses, challenge misinformation and 
stigmatization, deliver essential services and organize local support systems. But those 
community-led efforts are also threatened by the pandemic. They face grave funding 
uncertainty, while lockdowns and other restrictions on movement and social interaction 
make it difficult for them to reach and serve their communities. According to a recent 
survey of 160 civil society organizations by the Civil Society Institute for HIV & Health 
West and Central Africa, almost three-quarters of (72%) HIV-focused organizations are 
already working to raise COVID-19 awareness in the general population, even though 
little or no funding has been made available for that work (128). Meanwhile, another 
recent assessment showed that formal participation of civil society in national COVID-
response governance has been largely absent (129). 
 
 
What is working and needs to be sustained 
Communities have increased the rigor, depth and breadth of data collected for the HIV response 
as well as for TB, gender-based violence and access to sexual and reproductive health 
services. An updated People Living with HIV Stigma Index questionnaire (Stigma Index 2.0) was 
launched in January 2018. Twelve countries have completed the Stigma Index 2.0 process and 
35 others are currently implementing the survey. A more rigorous methodology, designed to 
collect comparable data across countries, is being piloted in 2020. Like its predecessor, the 
Stigma Index 2.0 is implemented by national networks of people living with HIV, with the support 
of the International PLHIV Stigma Index partnership (consisting of GNP+, the International 
Community of Women Living with HIV, and UNAIDS). Systematic community-led monitoring of 
 82 
 
HIV responses has been implemented in diverse regions. The International Treatment 
Preparedness Coalition established a regional community treatment observatory for the 90–90–
90 targets in 11 countries in western and central Africa. It is documenting service access 
(including barriers) and quality for pregnant women, young people, gay men and other men who 
have sex with men, people who inject drugs and sex workers (130). The Ritshidze Project, 
developed by people living with HIV and their activist partners, aims to hold PEPFAR and the 
South African Government accountable for improving HIV and TB services through routine 
monitoring of more than 400 high-burden clinics in South Africa (131). The community 
monitoring approach developed by REAct, the first-ever system to monitor, record and assist in 
responses to human rights issues faced by key populations, has been used by community-
based organizations in more than 22 countries in Asia and the Pacific, sub-Saharan Africa and 
the Middle East and North Africa (132). AVAC, the ATHENA Network, and Salamander Trust 
have documented gender-related barriers and facilitators for women’s access to treatment and 
adherence, using guidance from a global reference group of women living with HIV from 11 
countries. The results were published in the Health and Human Rights Journal (133). 
Key decision-makers have increased their use of strategic data generated through community-
led monitoring. Community monitoring has influenced the development of PEPFAR’s Country 
Operational Plans, including in Côte d’Ivoire (where communities provided data on the extent 
and impact of out-of-pocket spending on health services) and South Africa (where community 
monitoring documented the need for scale-up of community-led outreach and services to 
address service barriers). The Global Fund now includes questions from the People Living with 
HIV Stigma Index among its core list of HIV indicators. Heeding the call of civil society and UN 
organizations, the UNAIDS PCB reviewed available evidence on the effects of discrimination in 
health-care settings. That led to the launch of the Global Partnership for Action to eliminate all 
forms of HIV-related stigma and discrimination. The involvement of women living with HIV in the 
design of Zimbabwe’s funding requests to the Global Fund for 2018–2020 and 2021–2023 led to 
the prioritization of and budgeting for programming to address the needs of adolescent girls and 
young women, including support for community-led monitoring by adolescent girls and young 
women of service provision in four priority districts.  
As a result of community leadership, the depth and breadth of information available on key gaps 
in the response have increased. The Global State of Harm Reduction, published since 2006, is 
the only independent, civil society-led project monitoring global responses to HIV and hepatitis 
C epidemics among people who inject drugs. Its 2018 edition reflected the work of more than 
100 harm reduction practitioners, academics, advocates and activists across the world and and 
has served as an authoritative reference on the availability and accessibility of harm reduction 
services (37). Presentation of results from the Kazakhstan People Living with HIV Stigma Index 
in 2015–2016 led to the adoption of a national plan against stigma and discrimination and to 
community monitoring of its implementation. #uproot, an audit and accountability tool developed 
by PACT, a coalition of more than 80 youth organizations, uses scorecards to collect and 
summarize quantitative and qualitative information on key aspects of responses for young 
people, including global commitments on HIV (134). Across Asia and the Pacific, youth-led 
scorecards have galvanized action plans and strategic activities across the region. 
Community-led monitoring and advocacy in norm-setting spaces, such as with UN Treaty 
Bodies, has also driven human rights-based changes. An alternative CEDAW report by women 
living with HIV in Kazakhstan led to community participation in the second national plan for 
CEDAW implementation, which prioritizes steps to end stigma and discrimination against 
women living with HIV and enhance their access to sexual and reproductive health and services 
(135). A similar shadow CEDAW report in Ukraine summarized results from a survey of 4000 
women living with HIV and led to formal calls to accelerate HIV prevention among women and 
girls and improve access to services for gender-based violence (136). In 2017, Eurasian Harm 
Reduction Association and Estonian network of people who use drugs (LUNEST) submitted a 
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shadow report to the UN Committee on Economic, Social and Cultural Rights, based on the 
results of a community-led study of rights violations against women who use drugs in Estonia. 
The report prompted the UN Committee to recommend actions that can reduce social stigma 
against people who use drugs and to investigate and act on cases of police abuse and 
harassment, as well as deprivation of parental rights of people who use drugs .  
Community influence on health governance and decision-making has expanded in some 
settings. In addition to bringing to decision-making fora the perspectives of people living with 
and affected by HIV, community engagement in national AIDS commissions, country 
coordinating mechanisms and multilateral governing bodies also identifies important issues and 
gaps which might be ignored otherwise (137). In 2018–2019, 10 000 women living with HIV in 
30 countries strengthened their leadership and advocacy skills, increased their participation in 
HIV-related decision-making spaces and improved access to HIV services, with support from 
UN Women. The South African National AIDS Council facilitated the participation of women 
living with HIV via its dedicated women’s sector, while the Ukrainian National Council on 
Combating AIDS and Tuberculosis reserved a seat for a woman living with HIV. In Uganda, a 
community-led mentorship programme for adolescent girls and young women living with HIV is 
strengthening the leadership capacity of a new generation of women living with HIV. EANASSO, 
a regional network of national networks of civil society organizations and community-based 
organizations in seven eastern African countries, has enabled community organizations and 
networks to access technical assistance for Global Fund grants. Women living with HIV have 
influenced the International AIDS Conferences, catalyzing the creation of Women’s Networking 
Zones, which encourage cross-community exchanges among community members, 
researchers, donors and policy makers. 
Communities have expanded the reach, scale, quality and innovation of health services. The 
2018 Astana Declaration reaffirmed the 1978 Alma-Ata Declaration, noting the critical 
importance of the involvement of individuals, families, community and civil society in the 
development and implementation of health-related policies and plans (138).  
Community-led clinics and outreach programmes have accelerated uptake of HIV prevention, 
treatment and adherence support as well as integration of HIV, TB and sexual and reproductive 
health services. Community-led organizations have translated their lived expertise into more 
effective programming that responds to the needs of communities on their terms, such as in the 
case of HOYMAS, a clinic by and for sex workers in Kenya, or the emergence of the 
community-generated "U=U" and "You Can’t Pass It On" campaigns. In 2017, networks of 
women living with HIV worked with WHO to develop the first consolidated guidelines on the 
sexual and reproductive health and rights of women living with HIV, which promote a woman-
centred approach that is grounded in human rights and gender equality (139). 
Community-led responses have proved to be vital for ensuring the preservation and continuity of 
HIV services in conflict, humanitarian or other difficult conditions. In the Central African 
Republic, the network of people living with HIV delivers ART in conflict-affected areas, while 
SOS Sida has delivered care services for people affected by gender-based violence in the 
Democratic Republic of the Congo. COVID-19-related lockdowns have led to wider use of 
multimonth dispensing and community service delivery. In countries in Asia and other regions, 
people living with HIV have benefited from community delivery of medicines (140). In eastern 
Europe and central Asia, 330 people living with HIV maintained access to antiretroviral therapy 
due to the joint efforts of three community-led initiatives (141). 
Community partnerships with health systems and biomedical researchers have achieved 
transformative results. In Kyrgyzstan, peer consultants work as integral members of 
multidisciplinary care teams, helping people living with HIV remain engaged in care and adhere 
to prescribed regimens. In Burkina Faso, Cameroon, Mali and Togo, the involvement of 
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communities in operational PrEP-related research is helping ensure that projects respect 
research ethics while promoting PrEP uptake. 
Communities have demonstrated expertise and had success in addressing human rights 
violations and structural drivers of HIV, and in increasing social justice and equity. Community-
led organizations are often the first to become aware of violations and have played crucial roles 
in expanding human rights protections for the most vulnerable. In partnership with human rights 
organizations, communities have markedly increased legal literacy and galvanized substantially 
stronger efforts to roll back criminalization, including through training and placement of street 
paralegals and know-your-rights clinics and assembling broad-based coalitions for 
decriminalization and strategic litigation. "Support. Don’t Punish", a global grassroots-centred 
initiative promoting harm reduction and drug policies that prioritize public health and human 
rights, mobilized in at least 200 cities in 86 countries in 2020, even during the COVID-19 
pandemic (142). Innovative regional coalitions have been created to share skills and information 
and coordinate activities and funding. They include the Civil Society Institute for HIV and Health 
in western and central Africa (which brings together 80 organizations and countries), the 
Eurasian Network for Women for AIDS (which involves women living with HIV and women from 
key populations in 12 countries in eastern Europe and central Asia), MENA Rosa (the first 
regional network dedicated to women affected by HIV in the Middle East and north Africa) and 
the key population-led MENA H Coalition (which incorporates eight thematic regional networks).  
In December 2017, in response to the call of the PCB NGO delegation and UN organizations, 
the Global Partnership for action to eliminate all forms of HIV-related stigma and discrimination 
was formed by GNP+, the PCB NGO Delegation, UNAIDS, UN Women and UNDP. Throughout 
2019, GNP+ and the PCB NGO delegation organized global and national community planning 
meetings, forming joint UN-civil society technical working groups and facilitating the 
engagement of HIV communities in those processes. In 2020, the Global Partnership started 
country implementation, partnering with governments and communities at national level to take 
evidence-based action against stigma and discrimination in key settings. 
Communities are collaborating to ensure that responses are inclusive and people-centred. As 
organizations governed explicitly by and for people who are living with and affected by HIV 
and/or TB, GNP+ and TBpeople have joined forces to establish a more collaborative and 
formalized relationship to promote stronger and more unified global and regional TB and HIV 
community-led advocacy responses (143). The #StaySafe campaign’s Teenergizer team is 
focusing on psychological support for adolescents in eastern Europe and central Asia during the 
COVID-19 crisis (144). UNAIDS, UNDP and the Global Fund are supporting consultative 
processes on social contracting in HIV, TB and malaria responses, and will conduct analyses 
and document best practice examples of sustained community systems and responses.  
Faith-based organizations have also increased their engagement in the HIV response. Fifty 
organizations gathered in a workshop at the 2019 International Conference on AIDS and STIs in 
Africa to strengthen their collaboration around HIV and migration. Faith-based groups also came 
together for a satellite event to explore ways that faith-based groups could support the delivery 
of HIV testing services for vulnerable populations. In diverse regions, faith-based organizations 
continue to play a key role in combatting HIV-related stigma (145).  
Where the response is falling short 
Funding for community-led responses needs to be rapidly increased. Although reliable and up-
to-date data on funding for community-led organizations is lacking, there are indications that 
funding for community-led responses is insufficient. Funders continue to allocate the bulk of HIV 
funding to governments and international NGOs, with limited “trickle-down” to community 
groups. Funding shortfalls are especially acute for key population-led networks and 
organizations, particularly those that focus on women and young people from key populations. 
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In numerous instances, declines in funding have prompted community organizations to shut 
down or retrench staff. For example, ECOM, the only regional network of gay men and other 
men who have sex with men and transgender people in eastern Europe and central Asia, 
reduced its staff by half in 2020 due to a sharp decline in financial support. The Global Fund’s 
decision to terminate funding for regional projects in western and central Africa, including for 
community-led monitoring, has had a severe effect on the viability of community-led responses 
in that region. Funding gaps for community-led responses are occurring at the same time as 
overall HIV funding has flattened and as programmes for key populations remain badly under-
prioritized in the broader response (with programming for key populations accounting for only 
12% of overall philanthropic HIV spending in 2018) (146). The impact of the COVID-19 crisis on 
donor funding and government budgetary priorities is likely to diminish funding for community-
led responses even further.  
Even when funding is available for community-led responses, funding mechanisms are often 
complex and difficult for community organizations to access. This is a longstanding problem 
despite the advocacy efforts to simplify and streamline funding processes for civil society. 
Community-led organizations often do not have access to core funding, with most grants 
focusing on project implementation rather than organizational strengthening.iii Structural biases 
deeply rooted in gender inequality mean that funding for women’s organizations is especially 
scarce. Community organizations and individual workers in organizations are often expected to 
volunteer or to work for scant remuneration. Advocacy work, which is essential for creating 
enabling environments, is often unpaid. These practices are unfair and disrespectful, and they 
impede community-led responses.  
Social contracting, whereby governments procure services from civil society, is a potentially 
powerful option for supporting and sustaining community responses. However, while support for 
community-led services is essential, it is equally important to ensure that community 
organizations preserve their ability to function as independent advocates and accountability 
"watchdogs". The shift away from advocacy to service delivery could undermine that function, 
with important consequences for activities related to key populations. 
Efforts to address funding gaps for community-led responses are undermined by a lack of 
reliable, up-to-date data on funding, coverage and demand for community-led responses. 
Methodological challenges complicate efforts to obtain robust size estimates for key populations 
and impede efforts to assess and promote the demand for services among key populations. 
Data collected by communities need to be routinely integrated in HIV response planning. Data 
collected by communities through community-led monitoring and participatory research are 
rarely included in national or local data systems, which deprives decisionmakers of important 
information. When community-led monitoring data is available to decision-makers, significant 
progress often follows. For example, in the PEPFAR 2019 Country Operational Plan in Cote 
d’Ivoire, when community-led monitoring data highlighted how out-of-pocket expenses blocked 
uptake of HIV services, the Government committed to remove user fees for health services 
(147). 
Community-led responses should be integrated into local and national health systems more 
effectively. Given the pivotal role that community-led organizations and their staff play in HIV 
service delivery, especially during the COVID-19 crisis, community-led organizations should be 
considered integral components of modern systems for health, and they should receive funding 
and be included in coordination planning. In some cases, this requires reviewing national 
policies or regulations that prevent communities from providing certain health and outreach 
services––such as for differentiated service delivery for prevention, testing, provision of ART 
 
iii Notable exceptions are grants provided through the Robert Carr Fund and a few private donors. 
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and other medicines, and nutritional, social and adherence support. For some activities, national 
accreditation, training and funding processes are needed. 
The space for civil society is shrinking in many countries and needs to be protected. In the 
transition from donor-led to domestic financing for HIV underway in many countries, 
communities of people living with or affected by HIV are losing their presence and influence in 
HIV governance and resource allocation platforms. Global Fund Country Coordinating 
Mechanisms have served as a vital platform to enable communities to influence HIV responses. 
However, the withdrawal of Global Fund support in several countries has reduced the 
institutional opportunities for communities to shape and guide national HIV efforts (148). In 
Mexico, the withdrawal of Global Fund support initially led to the government implementing 
social contracting approaches that served as a lifeline for civil society organizations. However, a 
later government decision to end such funding disrupted community-led responses and 
highlighted the heavy reliance of community responses on external support (149). 
In many countries, the ability of communities to be fully engaged in HIV responses is also being 
undermined by growing conservatism, restrictions on freedom of speech and organizing, and 
laws and policies that restrict the ability of community groups to accept external support (in 
some countries limiting the amount of foreign funding an NGO can accept, or limiting the 
operations or imposing additional administrative requirements on organisations that receive 
foreign support). Laws and procedures in many countries make it difficult for community-led 
organizations and other civil society groups to register, access government funding, perform key 
services (especially biomedical interventions) and remain competitive with the private sector. 
The COVID-19 pandemic has aggravated those trends. Emergency decrees (e.g. restrictions on 
gatherings in Indonesia or the closure of bars where key services were delivered in Philippines) 
have restricted the ability of civil society organizations to operate.  
The criminalization of key populations greatly hinders the work and survival of organizations of 
key populations, and the persistent under-prioritization of youth engagement and involvement 
undermines the right of young people to participate in HIV-related decision-making. The lack of 
universal metrics to measure the meaningful engagement of people living with HIV highlights 
the need for improved data collection and monitoring tools for community-led responses.  
Social, legal and policy reforms are needed to reduce the stigma, discrimination, criminalization 
and violence that impede community-led responses. In 2020, for example, in western and 
central Africa, LGBTI people have been arrested in Mauritania, community-based violence has 
targeted an LGBTI network providing HIV prevention services in Burkina Faso, police raided an 
LGBTI network providing HIV services in Cameroon, and sex workers in the Democratic 
Republic of the Congo have confronted police abuse. Countries also often ignore the social and 
economic rights of communities living with or affected by HIV, including rights to employment, 
proper nutrition and access to social protection.  
Emerging challenges require well-resourced, well-planned community responses. As the 
number of people affected by humanitarian crises continues to rise, communities of migrants, 
refugees and other displaced peoples increasingly include people living with HIV and key 
populations. In the context of the COVID-19 pandemic and the ongoing climate crisis, those 
trends are likely to intensify. Communities will need increased funding and support to develop 
creative, adaptable strategies to provide care and services to people on the move. At present, 
funding and support for emergency planning for communities to respond to these humanitarian 
situations is inadequate. One successful example of cross-movement coordination and coalition 
building is the work of UNDP and WHO with the Stanley Foundation and Wellcome Trust to 
convene youth leaders and representatives from civil society working on HIV, environment and 
climate to strengthen coherent efforts and joint advocacy for investments. 
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Future strategic directions: key questions for consideration 
• Should the next UNAIDS Strategy include a pillar for community-led responses? How 
can we ensure that community-led approaches and activism are prioritized across all 
pillars of the new strategy? 
• What strategic actions are needed to ensure that communities and community-led 
responses are adequately resourced? 
How can data on funding for community-led responses be improved to inform and guide 
decision-making on the financing of community-led activities? What actions are needed to 
diversify funding for community-led responses and avoid having funding dictate the 
structure and focus of community-led responses? 
• What strategic actions are needed to preserve and strengthen community systems 
and activism that the HIV response has galvanized? 
What steps are needed to prevent the weakening of community-led responses (especially 
with respect to key populations) as responses transition from donor to domestic financing? 
More broadly, what actions are needed to prevent the achievements and momentum of the 
HIV response from being lost in an increasingly crowded and complicated global health and 
development agenda? 
• What are the responsibilities of governments, donors, the UN and other actors to 
ensure that communities have the means contribute fully to ending the AIDS 
epidemic?  
What frameworks, capacities and skills do key actors and stakeholders need to better 
support communities and community-led responses? 
• How can the deterioration in the human rights climate and the shrinking of space for 
civil society be reversed, and what role can the HIV response play? 
• How can national governments and health systems be encouraged to include 
community-led responses as integral partners in the HIV and broader health 
responses, while maintaining their necessary autonomy? 
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Financing, efficiencies and integration 
Under the Millennium Development Goals, the global HIV response benefited from a major 
surge on health funding. Substantial additional financing resources will be required to end the 
AIDS epidemic: 
● HLM Target 8: Ensure that HIV investments increase to US$ 26 billion by 2020, including a 
quarter for HIV prevention and 6% for social enablers. 
● HLM Target 10: Commit to taking AIDS out of isolation through people-centred systems to 
improve universal health coverage, including treatment for TB, cervical cancer and hepatitis 
B and C. 
● Strategy Result Area 7: AIDS response is fully funded and efficiently implemented, based on 
reliable strategic information. 
● Strategy Result Area 8: People-centred HIV and health services are integrated in the 
context of stronger systems for health and HIV-sensitive universal health coverage schemes 
implemented. 
Status report 
UNAIDS financial estimates show that financing for HIV responses in low- and middle-income 
countries is well short of the amounts needed to Fast-Track the response. Funding gaps for the 
HIV response were increasing even before the COVID-19 pandemic. 
Figure 56. Resource availability and key funding sources for HIV in low- and middle-
income countries, 2000–2019, with 2020 target resource needs 
Source: UNAIDS financial estimates, July 2020 (see http://hivfinancial.unaids.org/hivfinancialdashboards.html). 
Note: Constant 2016 US dollars. 
Total HIV resources increased by 20% from 2010 to 2015, but only by 3% from 2015 to 2019. 
Substantial gaps are evident in western and central Africa and in several regions with 
concentrated epidemics (e.g. Asia and the Pacific, eastern Europe and central Asia, the 
Caribbean and the Middle East and North Africa). Resources gaps are much smaller in eastern 
and southern Africa and in Latin America. 
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Figure 57. Total HIV resource availability per person living with HIV, HIV incidence and 
AIDS-related mortality rates in low- and middle-income countries, by region, 2010–2019 
and 2020 target 
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Source UNAIDS financial estimates, 2020 (see http://hivfinancial.unaids.org/hivfinancialdashboards.html). 
Source UNAIDS financial estimates, 2020 (see http://hivfinancial.unaids.org/hivfinancialdashboards.html). 
Note: Resource availability per person living with HIV and resource needs are in constant 2016 US dollars. 
 
Funding shortfalls are having demonstrable, negative effects on HIV responses. This is 
especially notable in western and central Africa, where acute gaps between available resources 
and actual needs are associated with modest declines in HIV incidence and AIDS-related 
mortality. By contrast, more fully funded responses in eastern and southern Africa have 
generated steady improvements in key HIV indicators in recent years. Preliminary analysis also 
indicates that the cost of HIV commodities in western and central Africa is higher than in eastern 
and southern Africa, indicating the potential to reduce the unit costs of service. 
Regional expenditure trends are often heavily influenced by one or two countries. For example, 
in Latin America, Brazil’s comparatively large investments in HIV programmes mask under-
investment in some other countries in the region. At the same time, Brazil’s experience also 
illustrates that greater investments do not always translate into successful programming and 
optimal health outcomes. New HIV infections in Brazil have increased since 2010, from an 
estimated 41 000 [19 000–60 000] to 48 000 [23 000–71 000] in 2019. Meanwhile, AIDS-related 
mortality has remained relatively stable (declining from 15 000 [6700–23 000] in 2010 to 14 000 
[6300–21 000] in 2019. Continued reliance on out-of-pocket expenditures, e.g. via user fees for 
health services, is a major barrier to equitable HIV service access, especially in western and 
central Africa (150–153). 
Efforts to integrate HIV more closely with other health and development programmes present a 
mixed picture. As described in greater detail below, a number of countries have taken steps to 
enhance the technical and allocative efficiency of their HIV response, although these 
approaches have yet to be comprehensively mainstreamed in all countries. 
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COVID-19 and the future of HIV financing 
 
Although it is too soon to accurately quantify the total effect of the COVID-19 pandemic on 
HIV financing, it is likely to be considerable. The multifaceted shocks associated with the 
COVID-19 pandemic can be expected to have negative effects on HIV resource 
mobilization, especially as previous global crises (e.g. the 2007–2009 global financial crisis, 
the 2012–2013 Euro zone debt crisis and the 2013–2014 migration response in Europe) 
led to reductions in HIV financing in many countries (Figures 58, 59) (154). The pandemic 
is likely to have a range of effects on funding availability for HIV in the coming years.  
Figure 58. Percent change in gross domestic product (GDP) and general 
government revenue (all donors except United States), 2007–2018 
 
 
Source: World economic outlook: the great lockdown. Washington (DC): IMF; 2020.  
 
 
Figure 59. Percent change in total official development assistance (ODA), total health 
ODA and HIV ODA (all donors except United States), 2007–2018 
 
Source:  UNAIDS financial estimates 2020 (see http://hivfinancial.unaids.org/hivfinancialdashboards.html);  
OECD Creditor Reporting System [database]. OECD; c2020 
(https://stats.oecd.org/Index.aspx?DataSetCode=crs1, last accessed June 2020). 
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A recent analysis indicated that the decline in economic growth associated with the COVID-
19 pandemic in countries belonging to the Southern African Development Community 
(SADC) is likely to be comparable to the decline caused by the 2007–2009 financial crisis 
(155). For most low- and middle-income countries, health and HIV domestic expenditures 
are expected to be decrease significantly, and contributions from donor countries are also 
expected to diminish. However, the severity and duration of the shock will likely vary across 
countries. While some countries may be able to return to more robust domestic financing 
within one 1 to 5 years, responses in low-income countries with a high HIV burden and a 
heavy dependence on donor financing could be set back by 5 to 10 years, as HIV 
resources are reallocated to cover other health and social development needs. In a worst-
case scenario, COVID-19 could result in a permanent, structural readjustment in fiscal 
revenue and expenditure allocations, to the long-term detriment of the HIV response and of 
health and social spending generally. 
 
In countries with the potential to return to pre-COVID spending levels in 1 to 5 years, the 
Joint Programme and other partners will need to work with governments to increase the 
proportion of government spending that is devoted to health, in order to shorten the 
recovery period. In countries where recovery within 5 years cannot reasonably be 
expected, UNAIDS will need to work with governments to focus on protecting health and 
HIV spending as part of a more structural fiscal rebalancing effort and on promoting equity 
in access to HIV services in HIV outcomes. 
  
All countries are likely to experience severe economic and budgetary disruptions due to the 
COVID-19 pandemic. UNAIDS should prioritize efforts to ensure that poorer households 
receive unconditional cash support to enable them to cover indirect service access costs. 
UNAIDS and other global entities should advocate against efforts to offload health and HIV 
service costs on to households as a counterproductive budget-balancing measure. It 
should intensify its advocacy to increase the share of domestic budgets dedicated to health 
and HIV, coupled with an aggressive reform programme to maximize the efficiency and 
effectiveness of health and HIV spending. At the global level, the international community 
should work to maintain official development assistance for health and HIV at the highest 
possible level and ensure that assistance is targeted towards countries that are least able 
to absorb the fiscal shocks associated with COVID-19.  
 
 
What is working and needs to be sustained 
Some countries have increased domestic HIV investments, although earlier increases in 
domestic HIV financing earlier have not been sustained in recent years. In 2015–2019, a 
number of countries increased domestic HIV investments, with domestic public expenditure as a 
share of total HIV investments rising by 231% in India, 225% in Philippines, 127% in South 
Sudan, 34% in both Colombia and Indonesia, 32% in Costa Rica and 25% in Nigeria.  At the 
same time, several countries reduced their domestic public investments in HIV, with 
expenditures falling by 88% in Uzbekistan, 78% in Malawi, 72% in Cambodia, 53% in Malaysia, 
27% in both Burkina Faso and Kenya, and 16% in Brazil. Regionally, domestic investments 
have declined in recent years in both eastern and southern Africa and western and central 
Africa, but domestic financing overall has increased in Asia and the Pacific and Latin America. 
Nigeria, home to 6.2% of all people newly infected with HIV in 2019, increased domestic 
expenditures from US$ 79.5 million in 2016 to US$ 91.5 million in 2018. The domestic funding 
share increased from 15% to 17% during this period. The national government has implemented 
a national initiative to raise revenue for HIV and other health services, with the support of 16 
state governments, and Lagos State committed to assume counterpart funding for a Global 
Fund grant, enabling an additional 50 000 people to start HIV treatment.  
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In several countries, social contracting has emerged as a means of preserving, sustaining and 
strengthening effective community-led service delivery. For example, in four provinces in Viet 
Nam, community-based services supported through social contracting averting nearly twice the 
number of disability-adjusted life years compared to facility-based services (156). 
 
Figure 60. Change in prices of key antiretroviral medicines, 2016–2019 
 
Source: UNAIDS special analysis (details available on request).  
The major pillars of international HIV financing have shown encouraging resilience. Investments 
in PEPFAR remain robust, with PEPFAR-related disbursements rising from US$ 3.7 billion in 
2010 to US$ 5.0 billion in 2015 and US$ 5.7 billion in 2019 (157). The successful replenishment 
of the Global Fund in 2019 also reflects promising, continued investment in this key source of 
HIV financing. 
UNAIDS has provided important support to optimize the impact of donor investments. 
Supporting the Global Fund partnership, UNAIDS provided technical support to more than 40 
countries to develop technically sound funding requests and it served as Principal Recipient in 
at least 20 countries during the review period. In Malawi, for example, UNAIDS provided 
comprehensive assistance to put Global Fund investments to work and ensure attention to key 
issues, including community systems strengthening and scale-up of differentiated service 
delivery (158, 159). In such countries as Kenya, Uganda and the United Republic of Tanzania, 
UNAIDS has supported PEPFAR investments by convening community partners.  
The evidence base for capturing efficiencies has increased, and a number of countries have 
taken important steps to enhance technical and allocative efficiencies. Since 2015, at least 54 
countries have conducted HIV investment cases to identify ways to maximize the efficiency of 
their national responses and the returns on their HIV investments. At least 20 of those countries 
have conducted more than one round of investment cases. In terms of impact, a desk review of 
 96 
 
13 investment frameworks in eastern and southern Africa concluded that the optimization and 
broad stakeholder consensus processes informed national HIV strategic plans, the preparation 
of Global Fund Concept Notes which provide the basis for country funding requests, and 
PEPFAR’s Country Operational Plans (160). In Belarus, an HIV allocative efficiency analysis led 
to improved allocations of resources for HIV prevention in 2016–2020. Guyana has acted to 
enhance efficiency by funding civil society organizations to reach key populations with 
prevention and testing services and by reducing the costs of ARV medicines through the use of 
pooled international procurement mechanisms. Informed by an investment case analysis, 
Botswana rapidly lowered ARV medicine prices by shifting to generic drugs, which paved the 
way for a successful transition to dolutegravir-based regimens and adoption of a national policy 
providing treatment access to non-citizens. In Uganda, the "One Dollar" initiative is engaging the 
private sector to mobilize additional HIV investments.  
Several trends have helped improve the efficiency of national responses. The shift to 
dolutegravir-based regimens and the increased use of optimized procurement strategies in 
many countries have lowered drug costs per person living with HIV. At the same time, many 
countries have moved to implement differentiated service delivery, with the transition complete 
in most PEPFAR-supported countries. Especially in PEPFAR programmes, improved targeting 
of testing programmes has increased diagnostic yield and possibly enhanced programmatic 
efficiencies, although evidence on the impact on total testing costs is lacking. Substantial 
efficiency gains are likely to have resulted from improved targeting of key interventions (e.g. 
community mobilization, condom promotion, voluntary medical male circumcision, PrEP, 
programmes for young people), especially in PEPFAR-supported programmes. 
Some countries have taken steps to improve the reach, impact and efficiency of HIV spending 
through enhanced service integration. In Zimbabwe, efforts to integrate HIV and sexual and 
reproductive health services reduced service delivery costs, increased uptake of HIV and sexual 
and reproductive health services and achieved higher levels of client satisfaction while 
maintaining service quality (161). 
Efforts have focused on building the evidence base for cofinancing of HIV-sensitive social and 
structural approaches. In 2018–2019, UNDP and the London School of Hygiene and Tropical 
Medicine-supported STRIVE Research Consortium supported four countries to model, cost and 
plan cross-sectoral cofinancing approaches for HIV and the SDGs. South Africa included its 
modelling to expand cash plus care for adolescent girls in KwaZulu-Natal in its Global Fund HIV 
request. 
Where the response is falling short 
Concerted efforts are needed to sustain or increase domestic financing in the face of multiple 
challenges. Prospects for generating increased domestic investments for HIV are uncertain. In 
addition to the anticipated impact of the COVID-19 pandemic, rising public debt in many low- 
and middle-income countries (especially among the so-called “risky middle”) is likely to limit the 
capacity of countries to allocate additional domestic financing for HIV activities. Insufficient 
domestic investments increase dependence on external donors. In Lesotho and Zimbabwe, for 
example, interventions for key populations and for adolescent girls and young women are 
almost wholly donor-financed. 
Donor HIV disbursements declined in 2019 and remain heavily reliant on continued investments 
by the United States. Although the Fast-Track strategy envisaged a 30% increase in donor 
financing for HIV, donor support has levelled again after a one-year increase in 2017. The 
United States remains the pillar of international HIV financing, supplying nearly 73% of all donor 
government’s official assistance for HIV in 2019. Especially since 2014–2015, many European 
donors have reduced HIV-related official development assistance (even though they have 
maintained or, in some cases, increased overall total official development assistance and health 
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funding) (Figure 61). The COVID-19 pandemic is likely to restrict the fiscal space in many donor 
countries, potentially encouraging further reductions in HIV assistance. In 2010–2019, 
significant reallocations of funding to regions with the highest needs and lowest income per 
capita resulted in reductions in HIV assistance from both the United States' bilateral channel 
and the Global Fund in several regions, especially those with concentrated HIV epidemics.  
Figure 61. Change in official development assistance and macroeconomic variables of 
donor countries (excluding the United States), 2006–2018 
 
Source: OECD Creditor Reporting System [database]. OECD; c2020 (https://stats.oecd.org/Index.aspx?DataSetCode=crs1, 
accessed May 2020); World economic outlook: the great lockdown. Washington (DC): IMF; 2020; World Bank Open Data 
[database]. Washington (DC): World Bank; c2020 (data.worldbank.org); UNAIDS financial estimates, 2020 (see 
http://hivfinancial.unaids.org/hivfinancialdashboards.html). 
Note: The graph shows official development assistance from all donors, excluding the United States of America. The Y axis uses a 
logarithmic scale, which allows large differences to be shown on the same graph. Between two points on the y axis, there is a 
tenfold difference: the difference between the first two points on the y axis is US$ 9, between the next two points it is US$ 90, and 
between the top two points it is US$ 90 million. 
 
 
Countries must address persistent inefficiencies that diminish the return on HIV investments. 
Although uptake of efficiency-enhancing interventions and service delivery innovations is 
encouraging, major efficiency gaps remain. Many settings have yet to shift to optimal 
dolutegravir-based regimens or fully implement differentiated service delivery strategies (see the 
section on testing and treatment). Undifferentiated, poorly targeted approaches to HIV testing 
persist in many countries. While some countries have reduced commodity costs through 
smarter procurement, parallel systems for procurement and supply management continue in 
many settings. Prices for ARV medicines remain high in many countries, especially in eastern 
Europe and central Asia, Latin America and the Caribbean. In Mexico, discontinuation of social 
contracting mechanisms has undermined efforts to sustain essential community-based services 
and maximize the efficiency of HIV spending. Changes to procurement practices for ARVs also 
heightened the risk of stock-outs in Mexico, which previously minimized such complications 
(149). 
Many countries have failed to realize key allocative efficiencies. Primary prevention 
programmes are chronically underfunded, and finite prevention funding is often allocated to 
prevention approaches that are less cost-effective than the five prevention pillars identified in 
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the 2020 Prevention Road Map (162). For example, Zimbabwe spends a substantial portion of 
its HIV budget on comparatively less cost-effective approaches such as mass media 
campaigns. Important efficiency-promoting interventions, such as opioid substitution therapy 
and cash transfers, have yet to be brought to scale.  
Inadequate strategic data undermine our ability to monitor and influence financing flows and 
expenditure allocations. Countries are conducting National AIDS Spending Assessments less 
frequently than they before, and many use methodologies which involve “short cuts” that 
compromise the monitoring of investments. This undermines the systematic production of inputs 
for efficiency, sustainability and other monitoring functions. Existing health systems tools and 
frameworks have been unable to offer alternative methods for adequately monitoring HIV 
expenditures, identify strategies for sustainable financing, or monitor programmatic efficiencies. 
A lack of reliable data on unit costs makes it difficult to assess efficiency gains for services for 
key populations. Efforts to include and cost gender-responsive interventions in efficiency models 
should be further strengthened and expanded. 
Fragmented service delivery is reducing the impact and efficiency of health spending, with 
poorly functioning health systems causing an estimated 8.6 million avoidable deaths, including 
300 000 among people living with HIV (163). Although service integration is common for HIV 
and maternal and child health, other potential efficiencies through service integration have not 
been realized effectively. Only 4 of 35 countries with relevant data have fully integrated HIV and 
cervical cancer screening; 10% of programmes in low- and middle-income countries have fully 
integrated HIV services and human papilloma virus vaccination); 2 of 14 countries have met 
integration targets for HIV and harm reduction; and coverage of harm reduction services in 
prison settings remains extremely low.  
 
 
Future strategic directions: key questions for consideration 
● What strategic actions would increase the efficiency of HIV spending? 
What actions are needed to ensure actual implementation of efficiency-enhancing measures 
that are identified in HIV investment cases? How can countries be persuaded or encouraged 
to increase spending on the five pillars of combination prevention, use the best-possible 
procurement approaches, or align national programmes with WHO guidelines for optimized 
regimens and differentiated service delivery? What strategic actions are needed to 
incentivize countries and programme implementers to integrate services where integration is 
appropriate? What steps are needed to increase the evidence base for decision-making on 
when and how service integration is appropriate and efficiency-promoting? How can we 
enhance collaboration with other components of health systems to encourage integration? 
● How do we generate political support for national and subnational governments to 
increase domestic investments in HIV, health and social enablers? 
How can we build (or in some cases, rebuild) stronger political support for HIV investments? 
How can we strengthen domestic resource mobilization for social enablers? What is the 
future of the HIV investment case approach? Can we make a stronger case (including to 
finance ministries) for the fiscal, economic, development and health benefits of HIV 
spending? Is it possible to navigate the political economy of HIV financing more effectively 
(effectively managing and balancing political/advocacy and technical support)? Are there 
potential sources of influence at national and subnational levels that have not been tapped 
effectively to encourage increased domestic investments? How can we use lessons learned 
from countries that have increased domestic investments (e.g. India, Nigeria, South Sudan) 
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to encourage similar action in other countries? What is a fair share for domestic investment 
in the response to HIV? How can we fully fund the HIV responses in resource-scarce settings 
where multiple competing needs have to be met? How can we ensure fully-funded human 
rights and other services for key populations in volatile political environments? What 
strategies are available to address the fiscal space limitations associated with national debt 
loads?  
• What macroeconomic actions or reforms are needed to expand domestic fiscal space 
in different country contexts? 
What policies would support revenue generation for increased investments in health, HIV 
and social enablers? 
● How do we build the political will and take the strategic actions that are needed to 
minimize disruptions to HIV financing associated with the COVID-19 pandemic and 
avert worst-case scenarios of a permanent reduction in HIV investments? 
How can UNAIDS work proactively with governments to encourage focused investments in 
health and HIV to shorten the recovery period? How can UNAIDS help ensure that cash 
transfers are provided to help poorer households can protect their wellbeing and health? 
What steps are needed to prevent or minimize the impact on vulnerable households by the 
potential substitution of out-of-pocket spending for domestic public sector investments? 
Should the Global Fund be encouraged to allocate additional resources towards livelihood 
support in response to economic dislocations associated with COVID-19? 
● How do we revive and sustain donor investments in the HIV response? 
Is it possible to increase the evidence base for advocacy to sustain official development 
assistance for health and HIV at current levels? What opportunities exist to re-engage donor 
governments which have reduced HIV investments while increasing investments in health? 
How do we manage and overcome the political changes that may lead to the defunding of 
HIV programmes while increasing investments for other areas? What would constitute a "fair 
share" of support from donor governments to countries for HIV and other priorities, health or 
otherwise? What steps are needed to diversify donors to the HIV response? How might 
UNAIDS further strengthen its support to PEPFAR and Global Fund to “make the money 
work”? 
● What role does innovative financing methods have in closing the HIV resource gap? 
What actions are needed to translate the work that UNAIDS and partners have been doing 
in developing innovative financing mechanisms into concrete progress? Is it possible to tap 
the growing market for social impact investments? What is the potential for national or 
regional AIDS bonds to help close the HIV resource gap? Is it possible (and advisable) to 
mobilize substantial resources for health and HIV through private equity funds? What steps 
are needed to strengthen social contracting to support community-led responses? What 
mechanisms are needed to assess the potential and equity impact of taxes on health-
harming products as an additional funding source for HIV and other health programmes? 
● What steps are needed to strengthen strategic information to monitor HIV expenditure 
an to guide investment decisions? 
Agreed and coordinated technical support needs to deploy the right tools for the right policy 
questions. What is the right tool for each programmatic policy question and for the 
harmonious operation within the health system or other social development sectors? How 
detailed should the monitoring of programmatic implementation be? How to institutionalize 
the application of the regular resource tracking assessments? How can innovations in 
finance data management and other logistics and management information systems be used 
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to generate data for action? What data should be produced routinely to inform the 
development of efficiency analyses? Which programmatic financing data are needed for 
National Strategic Plans or sustainability plans? 
● How can UNAIDS and the broader HIV response be best-positioned to leverage 
progress towards Universal Health Coverage to include HIV services? 
Which are the HIV services that need to be integrated with other health services? Which 
principles and guidelines should guide the selection of optimal packages of integrated 
services? Which practices are best suited for planning and financing the integration of HIV 
services in the broader health system? How can non-health components be included most 
effectively as part of the broad HIV response? How can we ensure that the system, service 
and social enablers are properly addressed to optimize effectiveness? How do we ensure that 
the critical components of the health service package are included in the health insurance 
benefit package, including appropriate services for key populations and community-led 
responses? Are we missing opportunities for enhancing the sustainability and efficiency of HIV 
responses?  
● How can social enablers (including improvements in the legal environment and access 
to social justice, elimination of stigma and discrimination and gender equality) be 
strengthened even though cost-effectiveness analyses may not necessarily be 
applicable to those activities? 
Which are the best ways to achieve joint and coordinated actions with other social 
components of the SDGs (e.g. inequality, poverty, education, housing and nutrition)? How can 
we coordinate the response with other programmes and actors which take the lead in 
implementing social actions, but without losing relevance in the HIV arena and in each one of 
the other priorities? 
● What would a sustainable HIV response in 2030 look like in: (i) a lower-income country 
with high HIV prevalence; (ii) a lower-income country with lower HIV prevalence; (iii) a 
middle-income country with high HIV prevalence; and (iv) a middle-income country 
with lower HIV prevalence? 
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United Nations (UN) Member States agreed at the UN General Assembly in 2016 that achieving the three zeros 
and ending AIDS as a public health threat by 
2030 required an accelerated expansion of 
HIV services alongside rights-affirming and 
enabling environments for those services. 
The resulting United Nations Political 
Declaration on Ending AIDS contains 10 
core commitments—Fast-Track Targets to 
be achieved by 2020. Progress against those 
targets has been decidedly mixed. 
Countries in a diverse range of geographic, 
economic and epidemic settings are on track 
or nearly on track to achieve many of these 
commitments, proving that bold targets can 
be met with sufficient political will, financial 
resources and community engagement. 
However, there are many more countries 
where high ambition has not been matched 
with Fast-Track actions; and in some countries, 
HIV epidemics have been allowed to continue 
expanding, causing entirely avoidable 
morbidity and mortality.
—
DATA
POINTS
2020 
COMMITMENTS
4 IN 5 
PEOPLE LIVING WITH HIV KNOW THEIR HIV 
STATUS. 2 IN 3 ARE ON TREATMENT, AND  
59% HAVE SUPPRESSED VIRAL LOADS
ONLY 53% OF CHILDREN 
LIVING WITH HIV ARE ON TREATMENT
IN 6 OF 13 REPORTING COUNTRIES,  
LESS THAN HALF OF  
TRANSGENDER WOMEN ARE ABLE 
TO ACCESS AT LEAST 
2 HIV PREVENTION 
SERVICES
4.2 MILLION
MEN AND BOYS 
ACROSS 15 PRIORITY COUNTRIES HAD BEEN 
VOLUNTARILY AND MEDICALLY CIRCUMCISED 
IN 2019
FUNDING FOR HIV RESPONSES IN LOW-  
AND MIDDLE-INCOME COUNTRIES 
DECREASED BY 7% 
BETWEEN 2017 AND 2019
MORE PEOPLE LIVING WITH HIV 
THAN EVER BEFORE KNOW THEIR 
HIV STATUS, ARE ACCESSING 
ANTIRETROVIRAL THERAPY AND ARE 
VIRALLY SUPPRESSED, REFLECTING 
STRONG PROGRESS TOWARDS THE 
90–90–90 TARGETS.
Credit: UNAIDS
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FAST-TRACK 
COMMITMENT 
1 
ENSURE THAT 30 MILLION PEOPLE LIVING WITH HIV HAVE ACCESS TO TREATMENT THROUGH 
MEETING THE 90–90–90 TARGETS BY 2020. 
Gains in HIV testing and treatment
More people living with HIV than ever before know 
their HIV status, are accessing antiretroviral therapy 
and are virally suppressed, reflecting strong 
progress towards the 90–90–90 targets:  
    90% of people living with HIV know their  
HIV status.
    90% of people who know their HIV-positive 
status are accessing treatment.
    90% of people on treatment have 
suppressed viral loads.
When all three 90s are achieved, 73% of all people 
living with HIV have suppressed viral loads. An 
estimated 25.4 million [24.5 million–25.6 million] of 
the 38.0 million [31.6 million–44.5 million] people 
living with HIV worldwide were on antiretroviral 
therapy in 2019, a number that has more than tripled 
since 2010 (Figure 2.1). In spite of this impressive 
increase, the world may not achieve its target of 30 
million on treatment by the end of 2020. 
There have been gains across the HIV testing 
and treatment cascade. At the end of 2019, 81% 
[68–95%] of people living with HIV knew their 
HIV status, more than two thirds (67% [54–79%]) 
were on treatment, and almost 59% [49–69%] 
had suppressed viral loads (Figure 2.2). Gains in 
treatment effectiveness, as well as increases in the 
number of people who know their status and are 
on treatment, are reflected in the fact that rates of 
viral load suppression among all people living with 
HIV have risen by 44% (or 18 percentage points) 
between 2015 and 2019 (Figure 2.3). 
Once people living with HIV start treatment, most 
are able to stay on treatment and achieve viral 
suppression, reflecting improvements in both 
FIGURE 2.1
Number of people living with HIV accessing antiretroviral therapy, global, 2000–2019 
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Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/).
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antiretrovial medicines and differentiated care. 
Progress towards the third 90 within the 90–90–90 
targets—the percentage of people on treatment 
who have durable viral suppression—stood at 
88% [71–100%] in 2019 (Figure 2.4). Progress has 
also been made towards the second 90, with 82% 
[66–97%] of people who know their HIV status on 
treatment. However, gaps across the testing and 
treatment cascade add up to 15.7 million people 
living with HIV globally who have an unsuppressed 
viral load, which endangers their health and 
facilitates the further spread of HIV.
 
 
FIGURE 2.2
HIV testing and treatment cascade, global, 2019
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FIGURE 2.3
HIV testing and treatment cascade, global, 2015–2019
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FIGURE 2.4
Progress towards 90–90–90 targets, global, 2019
Source: UNAIDS special analysis, 2020 (see annex on methods).
People living with HIV who 
know their status
People living with HIV who know  
their status and are on treatment
People on treatment who 
are virally suppressed 
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Globally, and in nearly all regions, greater 
percentages of women are accessing antiretroviral 
therapy than men. In 2019, treatment coverage 
globally was 12 percentage points lower among 
men living with HIV than women living with HIV. 
This gap was largest in western and central Africa 
(67% treatment coverage among women and 49% 
treatment coverage among men), while treatment 
coverage among both sexes in western and central 
Europe and North America was equal at 81% 
(Figure 2.5). 
FIGURE 2.5
Coverage of antiretroviral therapy by sex, men and women (aged 15 years and older), 
regional, 2019 
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HIV testing and status awareness 
among key populations
There are significant gaps in HIV testing among key 
populations at higher risk of HIV infection. Analysis 
of data from special surveys show that, on average, 
about two thirds of sex workers and gay men and 
other men who have sex with men globally either 
had taken an HIV test and received the results 
within the past 12 months or had previously tested 
positive for HIV—meaning that about one third 
did not know their HIV status.1 This testing gap was 
even larger for people who inject drugs (Figure 
2.6).
FIGURE 2.6
Average HIV testing and status awareness among key populations, global, 2016–2019 
Note: N = number of countries reporting. Data shown come from surveys, which are typically conducted in areas that have services available and thus may not be nationally 
representative. Data include members of key populations who have been tested in the past 12 months and know that their results are negative, and ever-tested members of 
key populations who know that they are living with HIV.
Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/).
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1 This testing gap does not include key populations living with HIV who know their HIV status.
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Region and country progress
Progress across the HIV testing and treatment 
cascade varies by region. Eastern and southern 
Africa has made remarkable progress, second only 
to western and central Europe and North America 
(Figure 2.7). Meanwhile, several regions are 
significantly off-track. There is a huge testing gap 
in the Middle East and North Africa, where just 
52% [36–86%] of people living with HIV know their 
HIV status, 38% [25–63%] were on treatment and 
32% [22–52%] were virally suppressed. In eastern 
Europe and central Asia, where 70% [61–79%] of 
people living HIV know their status, there is a large 
gap between testing and treatment initiation: just 
63% [52–71%] of people living with HIV who know 
their HIV status in the region are on treatment 
(Figure 2.8), leaving just 41% [34–46%] of all people 
living with HIV in the region virally suppressed. 
Achieving each of the three 90s results in a 
minimum of 73% of people living with HIV having 
durably suppressed viral loads. At the end of 2019, 
14 countries across three regions had achieved 
the 73% target—Australia, Botswana, Cambodia, 
Eswatini, Ireland, Namibia, the Netherlands, 
Rwanda, Spain, Switzerland, Thailand, Uganda, 
Zambia and Zimbabwe. Two of these countries, 
Eswatini and Switzerland, have made the 
remarkable achievement of surpassing the 2030 
target of 95–95–95, which equates to a minimum of 
86% of people living with HIV having suppressed 
viral loads. Notably, Eswatini has achieved each 
of the 2030 targets: 95% of people living with HIV 
know their HIV status, 95% of people living with HIV 
who know their HIV-positive status are accessing 
treatment and 95% of people on treatment have 
suppressed viral loads. An additional five countries 
across five regions are within reach of achieving 
the 90–90–90 targets by the December 2020 
deadline, and dozens more have achieved or 
nearly achieved one or more of the 90s (Table 2.1). 
What is particularly noteworthy is the diverse range 
of income levels, HIV epidemics and geography 
among these stand-out countries—proving 
that ambitious HIV targets are achievable when 
sufficient political will, financial resources and an 
enabling environment are all in place.
Credit: UNAIDS
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FIGURE 2.7
HIV testing and treatment cascade, by region, 2019
120   —
100   —
80   —
60   —
40   —
20   —
0   —
Source: UNAIDS special analysis, 2020 (see annex on methods).
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FIGURE 2.8
Progress towards the 90–90–90 targets, by region, 2019
Source: UNAIDS special analysis, 2020 (see annex on methods).
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TABLE 2.1
Progress towards 90–90–90 targets, by country, among those with treatment coverage 
equal to or greater than the annual global average, 2019*
People living with 
HIV who know 
their status
People living with 
HIV who know their 
status and are on 
treatment
People on 
treatment who  
are virally 
suppressed
Viral load suppression 
among people living 
with HIV
ACHIEVED 
2030 TARGET
(95%)
Eswatini Burundi Australia
ACHIEVED 
2030 TARGET
(86%)
Eswatini
Namibia Cambodia Botswana Switzerland
Denmark Cambodia
Eswatini Eswatini
Haiti Germany
Rwanda Ireland
Senegal Japan
Switzerland Myanmar
Zambia Netherlands
Switzerland
Thailand
Viet Nam
ACHIEVED 
2020 TARGET
(90%)
Australia Australia Brazil
ACHIEVED 
2020 TARGET 
(73%)
Australia
Botswana Burkina Faso Chile Botswana
Chile Ethiopia Kenya Cambodia
Guyana Germany Malawi Ireland
Ireland Morocco Morocco Namibia
Kenya Namibia Namibia Netherlands
Malawi Netherlands Rwanda Rwanda
Netherlands Singapore Singapore Spain
South Africa Spain South Africa Thailand
Switzerland Uganda Spain Uganda
Zambia
Zimbabwe
United Republic of 
Tanzania
Trinidad and 
Tobago
Zambia
Zimbabwe
Zimbabwe Uganda
United Republic of 
Tanzania
Zambia
NEARLY 
ACHIEVED 2020 
TARGET 
(85–89%)
Brazil Algeria Ethiopia
NEARLY 
ACHIEVED 2020 
TARGET
(68–72%)
Burundi Botswana Guyana
Cuba Cuba Italy
Italy Ireland Luxembourg
Romania Italy Portugal
Rwanda Luxembourg Zimbabwe
Spain Malawi
Uganda Peru
United States of 
America
Portugal
Slovakia
*Countries are eligible for inclusion in the table if HIV treatment coverage is equal to or greater than global HIV treatment coverage in the year they last reported data (global treatment 
coverage: 49% in 2015, 54% in 2016, 59% in 2017, 62% in 2018 and 67% in 2019). In addition, countries must also have published estimates of people living with HIV to be included in the columns 
describing progress towards people living with HIV who know their status and viral load suppression among people living with HIV. Estimates are for 2019, except as follows: for 2015: Japan; for 
2016: Denmark, Italy, Portugal and Spain; for 2017: Germany, Peru and Slovakia; and for 2018: Australia, Ireland, the Netherlands, Singapore and the United States. Eswatini, in bold italics, has 
reached all three of the 2030 95–95–95 target. Australia, Namibia, the Netherlands, Switzerland and Zambia, written in bold, have reported reaching each of the 2020 90–90–90 targets.
Estimates were not available at the time of publication for: Andorra, Argentina, Austria, the Bahamas, Bahrain, Bangladesh, Belgium, Bhutan, Brunei Darussalam, Canada, China, the Cook 
Islands, Cyprus, Czechia, Finland, France, Greece, Iceland, India, Indonesia, Iraq, Israel, Jordan, Kiribati, Kuwait, Latvia, Liechtenstein, Maldives, Malta, the Marshall Islands, Micronesia (Federated 
States of), Nauru, New Zealand, Niue, Norway, Palau, Panama, Paraguay, Poland, Qatar, the Republic of Korea, Sao Tome and Principe, Saudi Arabia, Serbia, Slovenia, Somalia, Sweden, the 
Syrian Arab Republic, Tonga, Turkey, Tuvalu, the United Arab Emirates, the United Kingdom of Great Britain and Northern Ireland, Uzbekistan and Vanuatu.
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/).
Italy
Kenya
Malawi
Myanmar
United Republic 
of Tanzania
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/).
FAST-TRACK 
COMMITMENT 
2 
ELIMINATE NEW HIV INFECTIONS AMONG CHILDREN BY 2020 WHILE ENSURING THAT 1.6 MILLION 
CHILDREN HAVE ACCESS TO HIV TREATMENT BY 2018 AND 1.4 MILLION BY 2020.
The number of new child infections resulting from 
the vertical transmission of HIV from mother-
to-child has more than halved in less than two 
decades, progress that in large part reflects 
concerted efforts to increase the provision of 
antiretroviral therapy to pregnant women living 
with HIV. However, this decline falls far short of the 
targets set for 2018 and 2020. Globally, there were 
an estimated 150 000 [94 000–240 000] new HIV 
infections among children (aged 0 to 14 years) in 
2019, compared to 310 000 [200 000–500 000] in 
2010 (Figure 2.9). 
Gaps in services to prevent vertical  
transmission—including uneven treatment 
coverage, women exposed to HIV during 
pregnancy and breastfeeding, and mothers 
living with HIV losing access to their antiretroviral 
therapy during breastfeeding—undermine further 
progress towards the target of eliminating new HIV 
infections among children.
Although the number of children living with HIV 
who are accessing treatment has more than 
doubled since 2010, all of the paediatric targets 
set in 2016 have been missed. In 2019, there were 
950 000 [910 000–960 000] children living with HIV 
(aged 0 to 14 years) globally who were accessing 
antiretroviral therapy (Figure 2.10). Treatment 
coverage among children living with HIV in 2019 
was 53% [36–64%]. The gap between that rate 
and adult treatment coverage (68% [54–80%]) 
represents nothing less than a global failure to 
provide life-sustaining care to the most vulnerable 
within our communities (see Chapter 5 for analysis 
of the challenges facing children living with HIV).
FIGURE 2.9
Number of new child infections, global, 2000–2019
800 000   —
700 000   —
600 000   —
500 000   —
400 000   —
300 000   —
200 000   —
100 000   —
0   —
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
20
16
20
17
20
18
20
19
20
20
2020 target
2018 target
2020 commitments      77
78      GLOBAL AIDS UPDATE 2020
FIGURE 2.10
Number of children (aged 0–14 years) accessing antiretroviral therapy, global, 
2000–2019 and 2018 and 2020 targets
Source: UNAIDS epidemiological estimates, 2020 (see https://aidsinfo.unaids.org/); UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/).
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FAST-TRACK 
COMMITMENT 
3 
ENSURE ACCESS TO COMBINATION PREVENTION OPTIONS, INCLUDING PRE-EXPOSURE 
PROPHYLAXIS, VOLUNTARY MEDICAL MALE CIRCUMCISION, HARM REDUCTION AND CONDOMS, 
TO AT LEAST 90% OF PEOPLE BY 2020, ESPECIALLY YOUNG WOMEN AND ADOLESCENT GIRLS IN 
HIGH-PREVALENCE COUNTRIES AND KEY POPULATIONS—GAY MEN AND OTHER MEN WHO HAVE 
SEX WITH MEN, TRANSGENDER PEOPLE, SEX WORKERS AND THEIR CLIENTS, PEOPLE WHO INJECT 
DRUGS AND PRISONERS. 
A combination approach to HIV prevention that 
includes behavioural, biomedical and structural 
approaches and is tailored to those in greatest 
need can lead to steep reductions in HIV 
infections. The launch of the Global HIV Prevention 
Coalition in 2017 sparked renewed focus among 
participating countries towards achieving global 
prevention targets. However, major gaps remain. 
Declines in condom use  
among young women
The defunding of condom social marketing 
programmes and decline in sales of socially 
marketed condoms in sub-Saharan Africa (Figure 
2.11) is emblematic of a decreased focus on 
condom demand generation, reduced emphasis 
on condoms in family planning services and weak 
stewardship of condom programmes since 2010, 
leaving the world far off the 90% target for condom 
use. A new generation of sexually active young 
people has not been exposed to the intense 
condom promotion that was in place a decade ago. 
Condom use at last higher risk sex reported by 
young women (aged 15 to 24 years) declined in five 
countries in western and central Africa and three 
countries in eastern and southern Africa (Figure 
2.12). Condom use at higher risk sex among men 
(aged 15 to 49 years) also declined in five out of 
nine countries (compared to the previous survey).
FIGURE 2.11
Male condom sales through social marketing, by region, 1991–2018  
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Source: Contraceptive social marketing statistics, 1991–Present. In: DKT International [Internet]. Washington (DC): DKT International;  
c2020 (https://www.dktinternational.org/contraceptive-social-marketing-statistics/, accessed 2 May 2020). 
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Western and central Africa
Eastern and southern Africa
FIGURE 2.12
Condom use at last higher risk sex, women (aged 15–24 years), by region, 2000–2018
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Note: Condom use at last higher risk sex is defined as the percentage of respondents who say they used a condom the last 
time they had sex with a nonmarital, noncohabiting partner among those who did have sex with such a partner in the last 
12 months. 
Source: Population-based surveys, 2000–2018.
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Combination prevention  
for key populations
Key population access to combination HIV 
prevention options varies greatly among countries, 
and it remains insufficient globally. In six of 13 
countries that have conducted surveys since 2016 
and reported those data to UNAIDS, less than half 
of transgender women stated that they were able 
to access at least two HIV prevention services in 
the past three months (Figure 2.13). The same is 
true for female sex workers in 16 of 30 reporting 
countries (Figure 2.14), for gay men and other 
men who have sex with men in 26 of 38 reporting 
countries (Figure 2.15) and for men who inject 
drugs in 10 of 14 reporting countries (Figure 2.16).
FIGURE 2.13
Transgender women who reported receiving at least two prevention services in the past 
three months, countries with available data, 2016–2019
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/). 
Note: The use of an asterisk (*) indicates that data for marked countries come from programme data (which tend to show higher values) and not from a survey. 
Possible prevention services received: condoms and lubricant, counselling on condom use and safe sex, and testing for sexually transmitted infections. 
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FIGURE 2.14
Female sex workers who reported receiving at least two prevention services in the past 
three months, countries with available data, 2016–2019
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/). 
Note: The use of an asterisk (*) indicates that data for marked countries come from programme data (which tend to show higher values) and not from a survey. 
Possible prevention services received: condoms and lubricant, counselling on condom use and safe sex, and testing for sexually transmitted infections. 
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FIGURE 2.15
Gay men and other men who have sex with men who reported receiving at least two 
prevention services in the past three months, countries with available data, 2016–2019
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/). 
Note: The use of an asterisk (*) indicates that data for marked countries come from programme data (which tend to show higher values) and not from a survey. 
Possible prevention services received: condoms and lubricant, counselling on condom use and safe sex, and testing for sexually transmitted infections. 
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Credit: UNAIDS
FIGURE 2.16
Men who inject drugs who reported receiving at least two prevention services in the 
past three months, countries with available data, 2016–2019
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/). 
Note: The use of an asterisk (*) indicates that data for marked countries come from programme data (which tend to show higher values) and not from a survey. 
Possible prevention services received: condoms and lubricant, counselling on condom use and safe sex, and sterile injecting equipment. 
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Pre-exposure prophylaxis
The number of people reported to have received 
PrEP at least once in the previous year has 
increased dramatically in recent years, from fewer 
than 2000 in 2016 to more than 590 000 in 2019 
(Figure 2.17). In several cities in North America, 
Europe and Australia where PrEP is widely 
Voluntary medical male circumcision 
Voluntary medical male circumcision (VMMC) 
provides lifelong partial protection against female-
to-male HIV transmission, reducing heterosexual 
male vulnerability to HIV infection by approximately 
60% (1, 2). VMMC can also act as an entry point 
for providing men and boys with broader health 
packages to improve their health outcomes. When 
combined with high levels of treatment coverage 
and viral suppression, evidence shows that the 
impact of VMMC is particularly significant (3). 
By the end of 2019, more than 15 million men 
and boys across 15 priority countries had been 
voluntarily and medically circumcised since the 
available, this relatively new prevention tool has 
contributed to steep reductions in HIV infections 
among gay men and other men who have sex with 
men. Global coverage, however, is still far short 
of the 2020 target of 3 million receiving PrEP (see 
Chapter 5 for additional analysis).
beginning of 2016, 4.2 million of them in 2019 
alone (Figure 2.18). Among 12 priority countries 
that reported age-disaggregated data, about 40% 
of those who underwent VMMC were between the 
ages of 10 and 14.
Among the priority countries, the United Republic 
of Tanzania performed the most VMMCs (nearly 
800 000) in 2019. Annual circumcisions in the 15 
priority countries have remained relatively stable 
since 2017, falling short of the annual amounts 
needed to reach the 2020 target of 25 million 
additional circumcisions since the beginning of 
2016 (Figure 2.19). 
 
 
 
 
FIGURE 2.17
Number of people who received PrEP at least once during the reporting period, global,
2016–2019 
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Source: UNAIDS Global AIDS Monitoring, 2017–2020 (see https://aidsinfo.unaids.org/); Country Updates. In: PrEPWatch [Internet]. AVAC; c2020 (https://www.prepwatch.org/
in-practice/country-updates/); amfAR: PEPFAR Monitoring, Evaluation and Reporting Database [Internet]. amfAR; c2020 (https://mer.amfar.org/Manual/PrEP_NEW); Hayes R, 
Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P et al. Estimating the “PrEP Gap”: how implementation and access to PrEP differ between countries in Europe and 
central Asia in 2019. Eurosurveillance. 2019;24(41); and country documents and meeting reports (available on request). 
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FIGURE 2.19
Cumulative number of males voluntarily medically circumcised, 15 priority countries, 
2016–2019 
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/).
Note: The 15 priority countries are: Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, South Sudan, Uganda, the United 
Republic of Tanzania, Zambia and Zimbabwe.
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FIGURE 2.18
Annual number of males voluntarily circumcised in 15 priority countries, 2016–2019 
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KEY POPULATION ACCESS TO 
COMBINATION HIV PREVENTION 
OPTIONS VARIES GREATLY AMONG 
COUNTRIES, AND IT REMAINS 
INSUFFICIENT GLOBALLY. IN SIX OF 
13 COUNTRIES THAT HAVE REPORTED 
DATA TO UNAIDS SINCE 2016, LESS 
THAN HALF OF TRANSGENDER 
WOMEN STATED THAT THEY WERE 
ABLE TO ACCESS AT LEAST TWO HIV 
PREVENTION SERVICES IN THE PAST 
THREE MONTHS.
Credit: UNAIDS
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FAST-TRACK 
COMMITMENT 
4 
Gender inequality, stigma and discrimination, and 
violence continue to impact the lives of women and 
girls, people living with HIV and key populations in 
myriad negative ways (see Chapter 1 and Chapter 4 
for more details).  
National authorities and civil society 
representatives in dozens of countries reported 
to UNAIDS in 2019 that various provisions and 
services were in place to protect the health, safety 
and security of survivors of domestic and sexual 
violence (Figure 2.20). However, the degree to 
which policies and legislation are implemented 
and enforced—including their coverage and 
quality—varies widely. Prevention efforts are also 
lagging significantly, as evidenced by the high 
levels of intimate partner violence reported in 
surveys conducted around the world (Figure 2.22). 
Surveys conducted in 46 countries between 2014 
and 2018 show that 19.7% of ever-married or 
partnered women and adolescent girls (aged 15 
to 49 years) experienced physical and/or sexual 
violence by an intimate partner in the past 12 
months. National prevalence of recent intimate 
partner violence ranged from 3.5% of respondents 
in Armenia to 47.6% in Papua New Guinea (Figure 
2.22).
FIGURE 2.20
Countries with provisions related to domestic violence, countries with available data, 2019
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ELIMINATE GENDER INEQUALITIES AND END ALL FORMS OF VIOLENCE AND DISCRIMINATION 
AGAINST WOMEN AND GIRLS, PEOPLE LIVING WITH HIV AND KEY POPULATIONS BY 2020.
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FIGURE 2.21
Countries with service delivery points providing appropriate medical and psychological
care and support for women and men who have experienced sexual violence, countries
with available data, 2019
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FIGURE 2.22
Percentage of ever-married or partnered women aged 15 to 49 years who experienced 
physical and/or sexual violence by an intimate partner in the past 12 months, 
2014–2018
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Source: Population-based surveys, 2014–2018. 
Note: Aggregates refer to the most recent data available from population-based surveys during the period of 2014 to 2018. Data coverage of aggregates: total: 46 countries, 
43% of 2018 population; Asia and the Pacific: 12 countries, 48% of 2018 population; Caribbean: 3 countries, 40% of 2018 population; eastern and southern Africa: 11 
countries, 84% of 2018 population; Latin America: 6 countries, 41% of 2018 population; western and central Africa: 10 countries, 85% of 2018 population. Aggregates for 
eastern Europe and central Asia, the Middle East and North Africa, and western Europe and North America are not shown, as data were available for few countries for the 
period of 2014 to 2018.
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FAST-TRACK 
COMMITMENT 
5 
ENSURE THAT 90% OF YOUNG PEOPLE HAVE THE SKILLS, KNOWLEDGE AND CAPACITY TO PROTECT 
THEMSELVES FROM HIV AND HAVE ACCESS TO SEXUAL AND REPRODUCTIVE HEALTH SERVICES BY 
2020, IN ORDER TO REDUCE THE NUMBER OF NEW HIV INFECTIONS AMONG ADOLESCENT GIRLS 
AND YOUNG WOMEN TO BELOW 100 000 PER YEAR. 
A critical component of HIV responses is ensuring 
that young people know both how to prevent HIV 
infections and where they can safely access HIV 
prevention and sexual and reproductive health 
services. 
An analysis of population-based surveys conducted 
since 2000 suggests that comprehensive 
knowledge of HIV among young women and men 
in western and central Africa—and men in eastern 
and southern Africa—has steadily risen. However, 
there has been little progress in efforts to increase 
comprehensive knowledge of HIV among young 
women in eastern and southern Africa (Figure 2.23).
Recent surveys show that there is still significant 
work to be done. Among surveys conducted 
between 2011 and 2018, just 39% of young women 
(aged 15 to 24 years) in eastern and southern 
Africa—and 28% in western and central  
Africa—demonstrated comprehensive knowledge 
of HIV, compared to 46% and 31% of young men in 
the same age group, respectively. 
Source: Population-based surveys from countries with two or more such surveys, 2000–2018. 
FIGURE 2.23
Comprehensive knowledge of HIV among young people (aged 15–24 years), 
select countries in sub-Saharan Africa, 2000–2018
Males (aged 15–24 years) Males (aged 15–24 years) 
Females (aged 15–24 years) Females (aged 15–24 years)
50   —
45   —
40   —
35   —
30   —
25   —
20   —
15   —
10   —
5   —
0   —
50   —
45   —
40   —
35   —
30   —
25   —
20   —
15   —
10   —
5   —
0   —
Pe
r 
ce
nt
Pe
r 
ce
nt
2000–2010 2011–2018 2000–2010 2011–2018
Eastern and southern Africa Western and central Africa
2020 commitments      91
FAST-TRACK 
COMMITMENT 
6 
ENSURE THAT 75% OF PEOPLE LIVING WITH, AT RISK OF AND AFFECTED BY HIV BENEFIT FROM HIV-
SENSITIVE SOCIAL PROTECTION BY 2020.
The Sustainable Development Goals (SDGs) call 
for universal social protection and guaranteeing at 
least a basic level of social security for all. Increased 
efforts are needed to extend coverage: only 45% 
of the world’s population are effectively covered 
by at least one social protection benefit, while the 
remaining 55%—about 4 billion people—are left 
unprotected (4).
In countries with a high HIV burden, it is 
recommended that social protection schemes be 
made sensitive to the needs of people living with 
HIV, those at higher risk of HIV infection and others 
affected by the epidemic. Among 35 countries 
that account for nearly 90% of new HIV infections 
globally, 31 reported to UNAIDS in either 2019 or 
2020 that they had an approved social protection 
strategy, policy or framework (Table 2.2). Of those, 
26 reported that their strategies were being 
implemented. Among the approved strategies, 25 
refer to HIV, 22 refer to people living with HIV as 
key beneficiaries, and 13 refer to key populations 
at higher risk of HIV infection as key beneficiaries. 
Only two countries (the Islamic Republic of Iran 
and Mozambique) reported that all HIV-sensitive 
elements are reflected within a social protection 
strategy that is being implemented. 
Across 25 high HIV burden countries with available 
data, the proportion of the population covered 
by at least one social protection benefit ranged 
from 1.6% in Myanmar to 90.4% in the Russian 
Federation, with a median of 15.3%. Less than 
half of the population was covered by at least one 
social protection benefit in 19 of the 25 countries 
with available data (5). 
Among 21 high HIV burden countries that have 
strategies that refer to HIV and recognize people 
living with HIV as key beneficiaries, only five 
countries (Brazil, China, Indonesia, the Russian 
Federation and the United States of America) 
reported that at least half of the total population is 
covered by at least one social protection benefit. 
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TABLE 2.2
Effective coverage of social protection benefits and HIV-sensitivity of social protection strategies, 
policies or frameworks in Fast-Track countries, 2019 and 2020
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Angola 9.9 *
Botswana 15.4
Brazil 74.9
Cameroon 8.7
Chad Data not available
China 63
Côte d'Ivoire Data not available
Democratic Republic of the Congo 14.1
Eswatini Data not available
Ethiopia 11.6
Ghana 18.3
Haiti Data not available *
India 22
Indonesia 54
Iran (Islamic Republic of) Data not available
Jamaica Data not available
Kenya 10.4
Lesotho 9.2
Malawi 21.3 *
Mali Data not available
Mozambique 10.9
Myanmar 1.6
Namibia Data not available
Nigeria 11
Pakistan 8 *
South Africa 47.8
South Sudan Data not available *
Uganda 2.9
Ukraine 73
United Republic of Tanzania 4
Viet Nam 37.9
Zambia 15.3
Zimbabwe Data not available
Russian Federation 90.4
United States of America 76.1
Source: UNAIDS National Commitments and Policy Instrument, 2019 and 2020 (see http://lawsandpolicies.unaids.org/); SDG Indicators Global Database [Internet]. New York: United Nations 
Statistics Division; c2020 (https://unstats.un.org/sdgs/indicators/database/, accessed 17 April 2020). 
*Social protection strategy is not being implemented.
  Yes
  No
  Data not available
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FAST-TRACK 
COMMITMENT 
7 
Communities play a critical role in HIV responses, 
serving as leaders, advocates, service providers 
and monitors. UN Member States recognized the 
role that community organizations play by making 
a commitment on community-led service delivery. 
However, progress on that commitment has proved 
difficult to measure, in part because community-led 
service delivery was not well-defined. To address 
this issue, civil society and governments are 
working together within the UNAIDS Programme 
Coordinating Board to produce recommendations 
on the use of definitions for community-led 
responses to HIV. 
ENSURE THAT AT LEAST 30% OF ALL SERVICE DELIVERY IS COMMUNITY-LED BY 2020.
Credit: UNAIDS
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FAST-TRACK 
COMMITMENT 
8 
ENSURE THAT HIV INVESTMENTS INCREASE TO US$ 26 BILLION BY 2020, INCLUDING A QUARTER 
FOR HIV PREVENTION AND 6% FOR SOCIAL ENABLERS.  
 
The funding gap for HIV responses is widening. 
Momentum established following global 
agreement on the Millennium Development Goals 
(MDGs) in 2000 has been lost in the SDG era. 
Increases in resources for HIV responses in low- 
and middle-income countries halted in 2017, with 
funding decreasing by 7% between 2017 and 2019 
(to US$ 18.6 billion in constant 2016 US dollars) 
(Figure 2.24).2 The total funding available in 2019 
for HIV in these countries amounted to about 70% 
of the 2020 target set by the UN General Assembly.
Domestic investments in HIV responses in low- 
and middle-income countries have grown by 50% 
since 2010. This growth peaked in 2017 and then 
declined by 2% in the following two years (in real 
terms, adjusted for inflation).3  Financial support for 
these countries provided through the Global Fund 
to Fight AIDS, Tuberculosis and Malaria (Global 
Fund) increased by 26% between 2010 and 2017, 
but it then declined by 15% over the next two 
years, leaving a 7% total increase over the  
nine-year period. Bilateral funding provided  
to these countries by the United States 
Government—primarily through the United 
States President’s Emergency Plan for AIDS Relief 
(PEPFAR)—increased by 50% between 2010 and 
2017 before declining by 8% over the next two 
Source: UNAIDS financial estimates, July 2020 (see http://hivfinancial.unaids.org/hivfinancialdashboards.html).
Note: Constant 2016 US dollars. 
FIGURE 02.24
Resource availability and key funding sources for HIV in low- and middle-income 
countries, 2000–2019, with 2020 target resource needs
28   —
23   —
18   —
13   —
8   —
3   —
R
es
o
ur
ce
 a
va
ila
b
ili
ty
 (b
ill
io
n 
U
S 
d
o
lla
rs
)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
  Domestic (public and private)   United States (bilateral)   Global Fund   Other international   Resource needs target
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Assembly in the 2016 Political Declaration on Ending AIDS.
3 The nominal decrease (not adjusted for inflation) was 4%.
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years, leaving a 38% total increase since 2010 
(in constant 2016 US dollars). Contributions 
from other international sources have declined 
by 50% between 2010 and 2019. These trends 
reflect the fact that most bilateral donors have 
substantially reduced their contributions to 
the global HIV response in recent years. The 
United Kingdom of Great Britain and Northern 
Ireland, the second largest bilateral contributor 
of official development assistance for HIV, 
decreased its bilateral funding by 30% between 
2017 and 2018, and then maintained the 2018 
level of funding in 2019.
Further analysis of financial resource data 
shows how the mix of funding sources for 
HIV responses in low- and middle-income 
countries has changed significantly since 2010. 
The share of domestic resources grew from 
47% of total funding in 2010 to 57% in 2019 
(Figure 2.26). Bilateral funding from the United 
States increased from 23% to 26% over the 
same period, funding from the Global Fund 
decreased from 11% to 9%, and funding from 
other international donors dropped from 20% 
of total HIV resources in 2010 to only 8% in 
2019.
Over that same period (2010–2019), funding for 
HIV responses increased in all regions except 
western and central Africa, the Caribbean, 
and the Middle East and North Africa (see the 
region chapters for details). 
Note: All units in constant 2016 US dollars.
Source: UNAIDS financial estimates, July 2020 (see http://hivfinancial.unaids.org/
hivfinancialdashboards.html).
FIGURE 2.26
Changes in the HIV funding landscape,  
all sources, 2010–2019
Source: UNAIDS financial estimates, July 2020 (see http://hivfinancial.unaids.org/
hivfinancialdashboards.html).
FIGURE 02.25
Funding gap between 2019 resources 
and estimated need, 2020, by region
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In Latin America, where HIV responses are 
predominantly funded by domestic resources, total 
resource availability increased by 38% between 
2015 and 2019. Total HIV resources available in 
western and central Africa, by contrast, decreased 
by 14% in 2015–2019, reflecting both a steep 
drop (59%) in funding from international sources 
other than the United States and the Global Fund 
and an 18% decline in domestic HIV investments. 
Global Fund and bilateral United States support 
became increasingly focused on sub-Saharan 
Africa between 2010 and 2019 (see Chapter 5 for 
additional analysis). The regions with the largest 
shares of the overall resource gap in low- and 
middle-income countries in 2019 were western and 
central Africa (32%), Asia and the Pacific (26%), and 
eastern Europe and central Asia (17%) (Figure 2.25).
Large shares of HIV response spending in low- 
and middle-income countries go to HIV testing 
and antiretroviral therapy. UN Member States 
recognized in 2016 that HIV prevention efforts 
required greater attention, leading to a global 
commitment to spend a quarter of HIV response 
resources on prevention. The percentage of total 
spending needed for evidence-informed primary 
HIV prevention programmes varies from country 
to country, depending on the number of people 
living with HIV in the country, the per person cost 
of antiretroviral therapy and other variables.4 In 
Myanmar, spending on HIV prevention that focused 
on populations in greatest need accounted for 
most of the 24% of total HIV spending that went 
to primary prevention in 2017 (Figure 2.27). In 
South Africa, the country with the most people 
living with HIV on treatment, spending on primary 
HIV prevention in 2018 was about 9% of total HIV 
spending. In addition, some countries continue to 
spend significant proportions of their HIV funding 
on less effective forms of HIV prevention.
Note: Interventions included only when greater than 1% of prevention spending 
Source: Country reports to UNAIDS; UNAIDS Global AIDS Monitoring, 2019–2020 (see https://aidsinfo.unaids.org/). 
FIGURE 2.27
Country spending on prevention interventions as a proportion of total spending on  
HIV interventions, 2017 and 2018
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Myanmar spending on prevention as a 
proportion of all interventions, 2017
South Africa spending on prevention as a 
proportion of all interventions, 2018
4 Priority primary HIV prevention interventions are: (i) combination prevention for adolescent girls and young women and their male partners in high-prevalence locations, 
mainly in sub-Saharan Africa; (ii) combination prevention programmes for all key populations; (iii) strengthened national condom and related behaviour change programmes; 
(iv) voluntary medical male circumcision; and (v) PrEP. See: HIV prevention road map 2020: accelerating HIV prevention to reduce new infections by 75%. Geneva: UNAIDS; 
2016.
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FAST-TRACK 
COMMITMENT 
9 
EMPOWER PEOPLE LIVING WITH, AT RISK OF AND AFFECTED BY HIV TO KNOW THEIR RIGHTS AND 
TO ACCESS JUSTICE AND LEGAL SERVICES TO PREVENT AND CHALLENGE VIOLATIONS OF  
HUMAN RIGHTS.
 
Effective HIV responses require legal, policy and 
social environments that empower people living 
with HIV, those at higher risk of HIV infection and 
others affected by the epidemic to claim their 
rights and receive redress when those rights are 
violated.
National authorities from 90 countries reported 
to UNAIDS in 2019 on whether various rights 
protection mechanisms were in place. Most 
(69) reported the existence of legal aid systems 
applicable to HIV casework, while half (45) reported 
the availability of community paralegals. Much 
less commonly reported were pro bono legal 
services provided by private law firms (35) and 
legal services provided by legal clinics (30). Civil 
society representatives were less likely to report 
the existence of legal aid systems applicable to 
HIV casework, but they were more likely to report 
the existence of pro bono legal services and legal 
services provided by legal clinics (Figure 2.28). 
Credit: UNAIDS
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FIGURE 2.28
Countries with mechanisms in place to promote access to affordable legal services, 2019 
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Source: UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
Note: Data correspond to reporting by national authorities from 90 countries and by civil society representatives from 89 countries. The National Commitments and Policy 
Instrument consists of two parts, the first completed by national authorites and the second by civil society and other nongovernmental partners engaged in the national 
response. 
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FIGURE 2.29
Countries with training and/or capacity-building programmes for people living with HIV 
and key populations on their rights in the context of HIV, 2019 
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Reports from national authorities and civil society 
representatives were similar regarding whether 
training programmes for people living with HIV and 
key populations on their rights in the context of 
HIV were available in 2019, and at what level and 
scale (Figure 2.29). Country reporting to UNAIDS 
in 2019 show that training programmes on human 
rights and non-discrimination legal frameworks 
applicable to HIV are operating at scale at the 
national level for police and other law enforcement 
personnel in 40 out 102 reporting countries, for 
members of the judiciary in 36 out of 100 reporting 
countries, and for lawmakers and parliamentarians 
in 30 out of 97 reporting countries (Figure 2.30). 
Reporting from national authorities and civil 
society representatives suggests that complaints 
procedures and systems to protect patient 
confidentiality and privacy in health-care settings 
are often in place, but that barriers to accessing 
these mechanisms are common. This includes 
limited awareness or knowledge of how to use 
these mechanisms, poor functionality of the 
mechanisms, cost constraints and a lack of HIV-
sensitive approaches (Figure 2.31).
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Members of the judiciary (n = 100)
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 Yes, at scale at the subnational level
 Yes, at scale at the national level
  No
  Yes, at a small scale
FIGURE 2.30
Countries with training programmes on human rights and non-discrimination legal 
frameworks as applicable to HIV, 2019 
Source: UNAIDS National Commitments and Policy Instrument, 2019 
(see http://lawsandpolicies.unaids.org/).
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FIGURE 2.31
Countries with accountability mechanisms on discrimination and human rights violations 
in health-care settings and barriers to accessing these mechanisms, global, 2019
Source: UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
Note: The National Commitments and Policy Instrument consists of two parts, the first completed by national authorities and the second by civil society and other non-
governmental partners engaged in the national response.
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FAST-TRACK 
COMMITMENT 
0 
The risk of developing tuberculosis is 19 times 
higher (range, 15–22) for a person living with 
HIV than the rest of the world population. And 
tuberculosis remains the single largest cause of 
premature death among people living with HIV (6). 
Scale-up of antiretroviral therapy and 
improvements in the integrated delivery of HIV 
and tuberculosis services has reduced tuberculosis-
related deaths among people living with HIV by 
58% globally, from a 2005 peak of 590 000  
[470 000–730 000] to 250 000 [220 000–280 000] 
in 2018 (Figure 2.32). Among the 135 countries 
that reported data to UNAIDS and the World 
Health Organization (WHO) in 2019, 47.5% of the 
estimated 862 000 [776 000–952 000] people living 
with HIV who developed tuberculosis (incident 
cases) received treatment for both HIV and 
tuberculosis.
Since 2010, tuberculosis-related deaths among 
people living with HIV have declined in all 10 
countries that account for the majority of such 
deaths: the Democratic Republic of the Congo (33% 
decline), India (84% decline), Kenya (69% decline), 
Malawi (56% decline), Mozambique (49% decline), 
Nigeria (39% decline), South Africa (52% decline), 
Uganda (14% decline), the United Republic of 
Tanzania (60% decline) and Zambia (8% decline). 
FIGURE 2.32
Number of tuberculosis-related deaths among people living with HIV, global, 2004–2018 
and 2020 target
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Source: Global tuberculosis report. Geneva: WHO; 2019.
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The tuberculosis testing gap among people living 
with HIV is narrowing (Figure 2.33). However, the 
477 461 tuberculosis cases among people living 
with HIV that were notified in 2018 represented 
just 56% of the estimated number of incident 
tuberculosis cases among people living with HIV 
that year. Among people living with HIV who were 
notified tuberculosis cases, 86% were accessing 
antiretroviral therapy in 2018.
Additional information on the integration of HIV 
and tuberculosis responses, including the provision 
of preventive treatment for tuberculosis among 
people living with HIV, can be found in Chapter 5.
Hepatitis C coinfection with HIV is reported across 
all key populations at higher risk of HIV, especially 
among people who inject drugs. This is due to the 
ease with which both viruses are spread through 
the sharing of non-sterile drug preparation and 
injecting equipment (Figure 2.34). Additional 
information on the integration of HIV and viral 
hepatitis responses can be found in Chapter 5.
Cervical cancer is the most common cancer 
among women living with HIV, and the likelihood 
of a woman living with HIV developing invasive 
cervical cancer is up to five times greater than for 
a woman who is not living with HIV (7). Almost 
all cases of cervical cancer are caused by human 
papillomavirus (HPV), a common but preventable 
infection that women living with HIV have a higher 
risk of acquiring, with the risk increasing when CD4 
count is lower (8). Data and analysis on efforts to 
expand HPV vaccination can be found in Chapter 5.
Most countries with high rates of cervical cancer 
are in sub-Saharan Africa. Cervical screening 
programmes are slowly building in high-burden 
countries, with a total of 11 countries in sub-Saharan 
Africa reporting having either opportunistic or 
organized population-based screening programmes 
for cervical cancer in 2019. The estimated coverage 
of cervical cancer screening programmes in the 11 
countries varies, from less than 10% in Ethiopia, 
Guinea and Madagascar to 50–70% in Mozambique 
and South Africa (Table 2.3). 
FIGURE 2.33
Number of notified new and relapse tuberculosis cases known to be HIV-positive, number of HIV-
positive tuberculosis patients receiving antiretroviral therapy, and estimated number of incident 
tuberculosis cases among people living with HIV, 2004–2018
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Source: UNAIDS Global AIDS Monitoring, 2019 (see https://aidsinfo.unaids.org/); Global tuberculosis report. Geneva: WHO; 2019. 
FIGURE 2.34
Distribution of coinfection with hepatitis C and HIV, by key population, countries with available 
data, 2016–2019
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Source: UNAIDS Global AIDS Monitoring, 2020 (see https://aidsinfo.unaids.org/).
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TABLE 2.3
Sub-Saharan African countries reporting a cervical cancer screening programme, its characteristics 
and estimated coverage, 2019
Estimated coverage Country Type of screening
Most widely used  
screening method
50–70% Mozambique Opportunistic screening Visual inspection1
South Africa Opportunistic screening PAP smear
10–50% Burkina Faso Organized population-based screening Visual inspection1
Côte d'Ivoire Opportunistic screening Visual inspection1
Djibouti Organized population-based screening PAP smear
Kenya Opportunistic screening HPV test
Malawi Organized population-based screening Visual inspection1
Senegal Opportunistic screening Visual inspection1
<10% Ethiopia Opportunistic screening Visual inspection1
Guinea Opportunistic screening Visual inspection1
Madagascar Opportunistic screening Visual inspection1
Source: Coverage of national cervical cancer screening program (%). In: The Global Health Observatory [database]. Geneva: WHO; c2020 (https://www.who.int/data/gho/data/indicators/
indicator-details/GHO/coverage-of-national-cervical-cancer-screening-program-(-), accessed 2 June 2020). 
1 Visual inspection with acetic acid.
Note on coverage estimation methodology: WHO coverage recommendation is cervical cancer screening for all women over 30 years. Official country response to the WHO NCD Country 
Capacity Survey. Countries that indicated they had a national cervical cancer screening programme were asked to indicate its coverage: "less than 10%," "10% to 50%," "more than 50% but less 
than 70%" or "70% or more." 
Note on type of screening: Organized screening programmes are preferred to an ad-hoc, opportunistic approach to achieve high screening coverage.
104      GLOBAL AIDS UPDATE 2020
References
1. Galarraga O, Wamai RG, Sosa-Rubí SG, Mugo MG, Contreras-Loya D, Bautista-Arrodondo S et al. HIV prevention 
costs and their predictors: evidence from the ORPHEA Project in Kenya. Health Policy Plan. 2017;32(10):1407-16.
2. Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. 
PLoS Med. 2006;3(12):e517.
3. Borgdorff MW, Kwaro D, Obor D, Otieno G, Kamire V, Odongo F et al. HIV incidence in western Kenya during scale-
up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis. Lancet HIV. 
2018;5(5):e241-e249.
4. World social protection report 2017–19: universal social protection to achieve the Sustainable Development Goals. 
Geneva: ILO; 2017.
5. SDG Indicators Global Database [Internet]. New York: United Nations Statistics Division; c2020 (https://unstats.un.org/
sdgs/indicators/database/, accessed 17 April 2020).
6. Global tuberculosis report. Geneva: World Health Organization; 2019.
7. Denslow SA, Rositch AF, Firnhaber C, Ting J, Smith JS. Incidence and progression of cervical lesions in women with 
HIV: a systematic global review. Int J STD AIDS. 2014;25:163-77.
8. Liu G, Sharma M, Tan N, Barnabas R. HIV-positive women have higher risk of HPV infection, precancerous lesions, and 
cervical cancer: a systematic review and meta-analysis. AIDS. 2018 Mar 27;32(6):795-808. 
